NZ620610B2 - Heterocyclic derivative and pharmaceutical drug - Google Patents

Abstract

Disclosed herein are benzimidazole compounds of formula I where the substituents are as defined herein. The compounds of the invention or pharmaceutically acceptable salt thereof have high mPGES-1 inhibitory activity and can be used as a prophylactic agent or therapeutic agent for a variety of diseases involving mPGES-1, such as, rheumatoid arthritis, osteoarthritis, temporomandibular joint disease, low back pain, endometriosis, dysmenorrhea, overactive bladder, malignancy, or neurodegenerative disease. ses involving mPGES-1, such as, rheumatoid arthritis, osteoarthritis, temporomandibular joint disease, low back pain, endometriosis, dysmenorrhea, overactive bladder, malignancy, or neurodegenerative disease.

Description

HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL [Field of the Invention] The present invention relates to novel heterocyclic derivatives.

[Background Art] Prostaglandins (PG) are produced abundantly in the site of inflammation and involved in progress of inflammation.

Prostaglandin production is initiated with the release of arachidonic acid from membrane glycerophospholipid by phospholipase A2, and the arachidonic acid is then converted into prostaglandin H2 (PGH2) by cyclooxygenase (COX). PGH2 is converted into prostaglandins including prostaglandin E2 (PGE2), prostaglandin F2α (PGF2α), prostaglandin D2 (PGD2), prostaglandin I2 (PGI2), and thromboxane A2 (TXA2). These prostaglandins are known to have various physiological or pathophysiological activities, including inflammation inducing effect. Especially, PGE2 is known as an inflammatory inducer in acute and chronic inflammations and further known to induce pyrexia and hyperpathia. Non-steroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors have anti-inflammatory effect via reduced production of PGE2 based on their COX-1 and/or COX-2 inhibitory effect. PGE2 synthase (PGES) catalyzes the final step of the synthetic pathway of PGE2, which is an inflammatory mediator.

To date, three subtypes of PGES, microsomal prostaglandin E synthase-1 (mPGES-1) [for example, Non-Patent Document 1], mPGES-2 [for example, Non-Patent Document 2] and cytosolic prostaglandin synthase (cPGES) [for example, Non-Patent Document 3] are known. Among these, mPGES-1, in the same manner as COX-2, is primarily induced during inflammation and plays a major part in PGE2 production in inflammatory lesion. On the other hand, cPGES is constitutively expressed PGES and coupled to COX-1 to play a part in basal PGE2 production [for example, Non-Patent Document 4]. As to mPGES-2, it is a subject of controversy as there is a report that it can be coupled to both COX isoforms. The studies in mPGES-1 deficient mouse suggest that mPGES-1 contributes to pathological progress in various inflammation models, such as acetic acid writhing model (e.g., Non-Patent Document 5), arthritis model (e.g., Non-Patent Documents 5 and 6), multiple sclerosis model (e.g., Non-Patent Document 7), fever model (e.g., Non-Patent Document 8). Also, mPGES-1 inhibitors specifically inhibit COXdependent PGE2 production, and therefore, they are expected to reduce various side effects, compared with NSAIDs or COX-2 inhibitors. It is believed that elevated risk of cardiovascular events by COX-2 inhibitors is attributed to enhanced coagulation system and vasoconstriction via inhibited COXdependent PGI2 production (e.g., Non-Patent Document 9). In contrast, mPGES-1 inhibitors are believed not to increase the risk of cardiovascular events, which is a problem with COX-2 inhibitors, since they do not inhibit PGI2 production (e.g., Non-Patent Document 10). mPGES-1 inhibitors are expected to serve as a safe anti-inflammatory agent by inhibiting only PGE2 production, which participates in inflammation. Thus, a pharmaceutical agent which is able to inhibit mPGES-1, and reduce PGE2 production is useful in the treatment or prevention of a disease, such as an inflammatory disease in which mPGES-1 participates. mPGES-1 inhibitors have been disclosed in the patent applications by NovaSAID AB (Patent Documents 1 and 2) and Boehringer Ingelheim International GmbH (Patent Document 3).

[Prior Art Documents] [Patent Documents] [Patent Document 1] WO2009/103778 [Patent Document 2] US2010/0324086 [Patent Document 3] WO2011/048004 [Non-Patent Documents] [Non-Patent Document 1] Jakobsson et al., Proc. Natl. Acad.

Sci. USA, 1999, 96, 7220-7225 [Non-Patent Document 2] Tanikawa et al., Biochem. Biophys.

Res. Commun., 2002, 291, 884-889 [Non-Patent Document 3] Tanioka et al., J. Biol. Chem., 2000, 275, 32775-32782 [Non-Patent Document 4] Murakami et al., J. Biol. Chem., 2000, 275, 32783-32792 [Non-Patent Document 5] Kamei et al., J. Biol. Chem., 2004, 279, 33684-33695 [Non-Patent Document 6] Kojima et al., J. Immunol., 2008, 108, 3861-3868 [Non-Patent Document 7] Kimura et al., Proc. Natl. Acad. Sci.

USA, 2000, 106, 21807-21812 [Non-Patent Document 8] Engblom et al., Nat. Neurosci., 2003, 6, 1137-1138 [Non-Patent Document 9] Foudi et al., Cardiovasc. Res., 2009, 81, 269-277 [Non-Patent Document 10] Cheng et al., J. Clin. Invest., 2006, 116, 1391-1399 [Non-Patent Document 11] J. Biol. Chem., 2004, 279(13), 12647-12658 [Non-Patent Document 12] Biomed. Pharmacother., 2011, 65(1), 77-84 [Non-Patent Document 13] Acta. Med. Okayama, 2008, 62(6), 373-378 [Non-Patent Document 14] Proc. Natl. Acad. Sci. USA, 2009, 106, 21807-21812 [Non-Patent Document 15] J. Biol. Chem., 279(32), 33684-33695 [Non-Patent Document 16] J. Immunol., 2008, 180, 8361-8368 [Non-Patent Document 17] Glia, 2011, 59, 208-218 [Non-Patent Document 18] J. Burn. Care. Res., 2011, 32(1), 79-90 [Non-Patent Document 19] J. Biol. Chem., 2003, 278(21), 19396-19405 [Non-Patent Document 20] Oncogene, 2012, 31(24), 2943-2952 [Non-Patent Document 21] Cancer Res., 2008, 68(9), 3251-3259 [Non-Patent Document 22] Proc. Natl. Acad. Sci. USA, 2006, 103, 14507-14512 [Non-Patent Document 23] Proc. Natl. Acad. Sci. USA, 2006, 103(31), 11790-11795 [Non-Patent Document 24] J. Rheumatol., 2005, 32(5), 887-895 [Non-Patent Document 25] J. Pharmacol. Exp. Ther., 2008, 326, 754-763 [Non-Patent Document 26] Kidney Int., 2011, 79(1), 77-88 [Non-Patent Document 27] J. Immunol., 2012, 188, 4093-4102 [Non-Patent Document 28] Am. J. Physiol. Lung Cell Mol.

Physiol., 2004, 287, L981-L991 [Non-Patent Document 29] Am. J. Physiol. Lung Cell Mol.

Physiol., 2005, 288, L1010-L1016 [Non-Patent Document 30] J. Immunol., 2012, 188, 4093-4102 [Non-Patent Document 31] Oncogene, 2012, 31(24), 2943-2952 [Non-Patent Document 32] Arthritis Res. Ther., 2011, 13, R6 [Summary of the Invention] [Problem to be solved by the invention] The present invention provides a novel heterocycle derivative or a pharmaceutically acceptable salt thereof.

Also, the invention provides with a pharmaceutical composition containing such heterocycle derivative or a pharmaceutically acceptable salt thereof as an active ingredient.

[Means for solving the problem] The present invention is based on the inventors' discovery that the novel heterocycle derivative or a pharmaceutically acceptable salt thereof, as described below, has an excellent mPGES-1 inhibiting activity.

The present invention provides a heterocycle derivative represented by the general formula [1] or its tautomer (hereinafter referred to as "compound of the invention"), or a pharmaceutically acceptable salt thereof.

[Chemical Formula 1] O NH wherein ring A is a group represented by the general formulae [2], [3] or [4]: [Chemical Formula 2] wherein X is NH, N-alkyl, or O; A is hydrogen or alkyl; A is i) hydrogen; ii) halogen; iii) alkyl optionally substituted with one to three groups selected from the group consisting of halogen, amino, monoalkylamino, dialkylamino, carbamoyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, a saturated cyclic aminocarbonyl, alkoxy, alkoxyalkoxy and alkylcarbonyloxy; iv) cycloalkyl optionally substituted with alkyl optionally substituted with one to three halogens; v) alkoxy; vi) a saturated heterocycle group optionally substituted with alkyl, alkyloxycarbonyl, alkylcarbonyl or oxo; vii) alkylthio; viii) alkylsulfonyl; ix) alkylsulfinyl; x) a group represented by the general formula [5]: [Chemical Formula 3] wherein R and R are the same or different group selected from a) hydrogen, b) alkyl optionally substituted with a group selected from the group consisting of monoalkylamino, dialkylamino, a saturated cyclic amino optionally substituted with alkyl, a saturated heterocycle group optionally substituted with alkyl, alkoxy, hydroxycarbonyl, hydroxyl, alkyloxycarbonyl and alkylthio, or c) cycloalkyl; or xi) a saturated cyclic amino optionally substituted with alkyl, amino, monoalkylamino, dialkylamino, alkoxy or hydroxyl; R is phenyl, benzyl, naphthyl, cycloalkyl, cycloalkylmethyl, heteroaryl, heteroarylmethyl, 1,2,3,4-tetrahydronaphthalenyl, 1,2,3,4-tetrahydronaphthalenyl, 2,3-dihydro-1H-indenyl, 2,3-dihydro-1H-indenyl, 1,2-dihydrocyclobutabenzenyl, 1,2-dihydrocyclobutabenzenyl or alkyl, wherein said phenyl, benzyl, cycloalkyl, cycloalkylmethyl, heteroaryl and heteroarylmethyl is optionally substituted with one to three groups selected from the group consisting i) halogen, ii) alkyl optionally substituted with one to three groups selected from the group consisting of halogen, hydroxy and phenyl, iii) alkoxy, iv) hydroxy, and v) cyano; R is phenyl or pyridyl, wherein said phenyl and pyridyl is optionally substituted with one to three groups selected from the group consisting i) halogen, ii) alkylsulfonyl, iii) alkoxy optionally substituted with one to three halogens or alkoxy; iv) alkynyl optionally substituted with alkoxyalkyl or cycloalkyl, and v) alkyl optionally substituted with one to three groups selected from the group consisting of alkoxy, alkoxyalkoxy, cycloalkyl, phenyl and halogen.

A preferred embodiment of the invention is any one of the following (A) to (C), or a pharmaceutically acceptable salt thereof: (A) a compound of the invention or a pharmaceutically acceptable salt thereof, wherein the ring A is a group of formula [4] and X is NH; (B) a compound of the invention or a pharmaceutically acceptable salt thereof, wherein R is phenyl, 1,2,3,4-tetrahydronaphthalenyl, 1,2,3,4-tetrahydronaphthalenyl, 2,3-dihydro-1H-indenyl, 2,3-dihydro-1H-indenyl, 1,2-dihydrocyclobutabenzenyl, or 1,2-dihydrocyclobutabenzenyl, and said phenyl is optionally substituted with one to three groups selected from the group consisting of i) halogen, ii) alkyl optionally substituted with one to three halogens, iii) alkoxy, and iv) cyano ; or (C) a compound of the invention a pharmaceutically acceptable salt thereof, wherein R is phenyl and said phenyl is optionally substituted with one to three groups selected from the group consisting of i) halogen ii) alkylsulfonyl, iii) alkoxy optionally substituted with alkoxy, iv) alkynyl optionally substituted with alkoxyalkyl or cycloalkyl, and v) alkyl optionally substituted with one to three groups selected from the group consisting of halogen, alkoxy, alkoxyalkoxy, cycloalkyl and phenyl A more preferred embodiment of the invention is a compound of the invention or a pharmaceutically acceptable salt thereof, wherein the ring A is a group of formula [4], X is NH, A is i) hydrogen, ii) alkyl optionally substituted with a group selected from the group consisting of halogen, monoalkylamino, dialkylamino, monoalkylaminocarbonyl, dialkylaminocarbonyl, a saturated cyclic aminocarbonyl, alkoxy, alkoxyalkoxy and alkylcarbonyloxy, iii) cycloalkyl optionally substituted with alkyl optionally substituted with one to three halogens, iv) alkoxy, v) a saturated heterocyclic group optionally substituted with alkyl or alkyloxycarbonyl, vi) alkylthio, vii) alkylsulfonyl, viii) alkylsulfinyl, ix) amino substituted with alkyl wherein said alkyl is optionally substituted with a group selected from the group consisting of monoalkylamino, dialkylamino, a saturated cyclic amino optionally substituted with alkyl, tetrahydrofuryl, morpholino, alkoxy, hydroxycarbonyl, hydroxyl and alkylthio, x) amino substituted with cycloalkyl or xi) a saturated cyclic amino optionally substituted with alkyl, dialkylamino, alkoxy or hydroxyl, and R is i) phenyl optionally substituted with one to three groups selected from the group consisting of halogen, alkyl optionally substituted with one to three halogens, alkoxy and cyano, ii) 1,2,3,4-tetrahydronaphthalenyl, iii) 2,3-dihydro-1H-indenyl, iv) benzyl optionally substituted with halogen or alkyl optionally substituted with one to three halogens, v) cycloalkyl, vi) cycloalkylmethyl, vii) naphthyl, viii) pyridylmethyl optionally substituted with alkyl optionally substituted one to three halogens, ix) thienyl, x) thienylmethyl, xi) benzothiazolyl, xii) benzothiadiazolyl, xiii) indolyl or xiv) alkyl, and R is phenyl or pyridyl wherein said phenyl is optionally substituted with one to three groups selected from the group consisting of i) halogen, ii) alkylsulfonyl, iii) alkoxy optionally substituted with alkoxy, iv) alkynyl optionally substituted with alkoxyalkyl or cycloalkyl, and v) alkyl optionally substituted with one to three groups selected from the group consisting of halogen, alkoxy, alkoxyalkoxy, cycloalkyl and phenyl, and said pyridyl is optionally substituted with halogen A further more preferred embodiment of the invention is a compound of the invention or a pharmaceutically acceptable salt thereof, wherein the ring A is a group of formula [4], X is NH, A is alkyl substituted with alkoxy, dialkylamino, tetrahydrofuryl, tetrahydrofurylmethyl, alkoxyalkylamino, or cycloalkyl optionally substituted with alkyl optionally substituted with one to three halogens, R is phenyl substituted with one halogen and one methyl, and R is phenyl optionally substituted with one trifluoromethyl or two halogens A particularly preferred embodiment of the invention is any one of the following (1)-(239), or its tautomer or a pharmaceutically acceptable salt thereof: N-[2-(trifluoromethyl)benzyl]({[2-(trifluoromethyl)pheny l]carbonyl}amino)-1H-benzimidazolecarboxamide, N-cyclohexyl({[2-(trifluoromethyl)phenyl]carbonyl}amino) -1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl)({[2-(trifluoromethyl)phenyl] carbonyl}amino)-1H-benzimidazolecarboxamide, N-[(1-hydroxycyclohexyl)methyl]({[2-(trifluoromethyl)phe nyl]carbonyl}amino)-1H-benzimidazolecarboxamide, N-[2-(trifluoromethyl)benzyl]({[2-(trifluoromethyl)pheny l]carbonyl}amino}-2,3-dihydrobenzofurancarboxamide), N-cyclohexyl({[2-(trifluoromethyl)phenyl]carbonyl}amino) -2,3-dihydrobenzofurancarboxamide, N-(3-chloromethylphenyl)({[2-(trifluoromethyl)phenyl] carbonyl}amino)-2,3-dihydrobenzofurancarboxamide, N-cyclohexyl({[2-(trifluoromethyl)phenyl]carbonyl}amino) -1H-indazolecarboxamide, N-[2-(trifluoromethyl)benzyl]({[2-(trifluoromethyl)pheny l]carbonyl}amino)-1H-indazolecarboxamide, (10) N-(3-chloromethylphenyl)(methoxymethyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide, (11) 2-methyl-N-[2-(trifluoromethyl)benzyl]({[2-(trifluoromet hyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (12) N-cyclohexylmethyl({[2-(trifluoromethyl)phenyl]carbon yl}amino)-1H-benzimidazolecarboxamide, (13) N-(3-chloromethylphenyl)methyl({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (14) N-cyclopentylmethyl({[2-(trifluoromethyl)phenyl]carbo nyl}amino)-1H-benzimidazolecarboxamide, (15) N-cyclobutylmethyl({[2-(trifluoromethyl)phenyl]carbon yl}amino)-1H-benzimidazolecarboxamide, (16) N-(3-chloromethylphenyl)ethyl({[2-(trifluoromethyl )phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (17) N-cyclohexylethyl({[2-(trifluoromethyl)phenyl]carbony l}amino)-1H-benzimidazolecarboxamide, (18) 2-ethyl-N-[2-(trifluoromethyl)benzyl]({[2-(trifluorometh yl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (19) N-cyclohexyl(methoxymethyl)({[2-(trifluoromethyl)phen yl]carbonyl}amino)-1H-benzimidazolecarboxamide, (20) 2-(methoxymethyl)-N-[2-(trifluoromethyl)benzyl]({[2-(tri fluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarb oxamide, (21) 2-(methoxymethyl)-N-(2-methylphenyl)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (22) 2-(methoxymethyl)-N-(4-methylphenyl)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (23) N-(2-chlorobenzyl)(methoxymethyl)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (24) 2-(methoxymethyl)-N-(4-methylbenzyl)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (25) N-(4,4-difluorocyclohexyl)(methoxymethyl)({[2-(triflu oromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxa mide, (26) N-(4-tert-buthylphenyl)(methoxymethyl)({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamid (27) 2-(methoxymethyl)-N-[4-(trifluoromethyl)phenyl]({[2-(tri fluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarb oxamide, (28) N-(2,4-dimethylphenyl)(methoxymethyl)({[2-(trifluorom ethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide (29) N-(2-chloromethylphenyl)(methoxymethyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide, (30) N-(3,4-dimethylphenyl)(methoxymethyl)({[2-(trifluorom ethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide (31) N-(3-chloromethylphenyl)(methoxymethyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide, (32) N-(2,3-dihydro-1H-indenyl)(methoxymethyl)({[2-(tri fluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarb oxamide, (33) 2-(methoxymethyl)-N-(5,6,7,8-tetrahydronaphthalenyl)( {[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazol ecarboxamide, (34) N-(2-fluorophenyl)(methoxymethyl)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (35) 2-(methoxymethyl)-N-(2-methoxypheny)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (36) 2-(methoxymethyl)-N-(4-methoxypheny)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (37) N-(3-bromomethylphenyl)(methoxymethyl)({[2-(triflu oromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxa mide, (38) N-(3-chloromethylbenzyl)(methoxymethyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide, (39) N-(2,6-difluorophenyl)(methoxymethyl)({[2-(trifluorom ethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide (40) N-(3-cyanomethylphenyl)(methoxymethyl)({[2-(triflu oromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxa mide, (41) 2-(methoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-N-{[3-(trifluoromethyl)pyridinyl]methyl}-1H-benzim idazolecarboxamide, (42) N-(2-chloromethylphenyl)(methoxymethyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide, (43) 2-(2-aminooxoethyl)-N-(3-chloromethylphenyl)({[2-( trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolec arboxamide, (44) 2-(2-aminooxoethyl)-N-[2-(trifluoromethyl)benzyl]({[2 -(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4 -carboxamide, (45) N-(3-chloromethylphenyl)methyl({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (46) N-cyclohexylmethyl({[2-(trifluoromethyl)phenyl]carbon yl}amino)-1H-benzimidazolecarboxamide, (47) 1-methyl-N-[2-(trifluoromethyl)benzyl]({[2-(trifluoromet hyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (48) N-(3-chloromethylphenyl)ethyl({[2-(trifluoromethyl )phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (49) N-cyclohexylethyl({[2-(trifluoromethyl)phenyl]carbony l}amino)-1H-benzimidazolecarboxamide, (50) 1-ethyl-N-[2-(trifluoromethyl)benzyl]({[2-(trifluorometh yl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (51) N-(3-chloromethylphenyl)methyl({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1,3-benzoxazolecarboxamide, (52) 2-methyl-N-[2-(trifluoromethyl)benzyl]({[2-(trifluoromet hyl)phenyl]carbonyl}amino)-1,3-benzoxazolecarboxamide, (53) N-(3-chloromethylphenyl)ethyl({[2-(trifluoromethyl )phenyl]carbonyl}amino)-1,3-benzoxazolecarboxamide, (54) N-(3-chloromethylphenyl)ethoxy({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (55) 2-ethoxy-N-[2-(trifluoromethyl)benzyl]({[2-(trifluoromet hyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (56) N-(3-chloromethylphenyl)(1-chloromethylpropanyl )({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimi dazolecarboxamide, (57) N-(3-chloromethylphenyl)[(dimethylamino)methyl]({[ 2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole- 4-carboxamide, (58) N-(3-chloromethylphenyl)(2-methylpropyl)({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xamide, (59) 2-(2-methylpropyl)-N-[2-(trifluoromethyl)benzyl]({[2-(tr ifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecar boxamide, (60) tert-butyl 3-{4-[(3-chloromethylphenyl)carbamoyl]({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolyl}azetidin ecarboxylate, (61) N-(3-chloromethylphenyl)[(methylamino)methyl]({[2- (trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide, (62) {4-[(3-chloromethylphenyl)carbamoyl]({[2-(trifluorome thyl)phenyl]carbonyl}amino)-1H-benzimidazolyl}methyl acetate, (63) N-(3-chloromethylphenyl)[(2R)-tetrahydrofuranyl]-6 -({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidaz olecarboxamide, (64) 2-[[(2R)-tetrahydrofuranyl]-N-[2-(trifluoromethyl)benzyl ]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimi dazolecarboxamide, (65) N-(3-chloromethylphenyl)[(2S)-tetrahydrofuranyl]-6 -({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidaz olecarboxamide, (66) 2-[[(2S)-tetrahydrofuranyl]-N-[2-(trifluoromethyl)benzyl ]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimi dazolecarboxamide, (67) 2-(1-acetylazetidinyl)-N-(3-chloromethylphenyl)({[ 2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole- 4-carboxamide, (68) tert-butyl (2S){4-[(3-chloromethylphenyl)carbamoyl]({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolyl}pyr rolidinecarboxylate, (69) tert-butyl (2R){4-[(3-chloromethylphenyl)carbamoyl]({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolyl}pyr rolidinecarboxylate, (70) N-(3-chloromethylphenyl)[(2S)-pyrrolidinyl]({[2 -(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4 -carboxamide, (71) N-(3-chloromethylphenyl)[(2S)methylpyrrolidinyl ]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimi dazolecarboxamide, (72) 2-[(2S)acetylpyrrolidinyl]-N-(3-chloromethylphenyl )({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimi dazolecarboxamide, (73) N-(3-chloromethylphenyl)[(2-methoxyethoxy)methyl]( {[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazol ecarboxamide, (74) N-(3-chloromethylphenyl)(1-methoxymethylpropany l)({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzim idazolecarboxamide, (75) 2-tert-butyl-N-(3-chloromethylphenyl)({[2-(trifluorom ethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide (76) 2-tert-butyl({[2-(trifluoromethyl)phenyl]carbonyl}amino) -N-{[3-(trifluoromethyl)pyridinyl]methyl}-1H-benzimidazo lecarboxamide, (77) N-(3-chloromethylphenyl)(2-ethoxyethyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide, (78) N-(3-chloromethylphenyl)(ethoxymethyl)({[2-(triflu oromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxa mide, (79) 2-(ethoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}am ino)-N-{[3-(trifluoromethyl)pyridinyl]methyl}-1H-benzimi dazolecarboxamide, (80) N-(3-chloromethylphenyl)(2-methoxyethyl)({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xamide, (81) N-(3-chloromethylphenyl)(2,2-dimethylpropyl)({[2-( trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolec arboxamide, (82) N-(3-chloromethylphenyl)cyclopropyl({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamid (83) N-(3-chloromethylphenyl)(2-methylpentanyl)({[2- (trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide, (84) N-(3-chloromethylphenyl)(1-methylcyclopropyl)({[2- (trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide, (85) 2-tert-butyl-N-(3-chloromethylphenyl)({[2-(trifluorom ethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide (86) 2-tert-butyl-N-(3-chloromethylphenyl){[(2,5-dichlorop henyl)carbonyl]amino}-1H-benzimidazolecarboxamide, (87) 2-tert-butyl-N-(3-chloromethylphenyl){[(2,5-dichlorop henyl)carbonyl]amino}-1H-benzimidazolecarboxamide, (88) N-(3-chloromethylphenyl)[1-(trifluoromethyl)cycloprop yl]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzi midazolecarboxamide, (89) N-(3-chloromethylphenyl)(methoxymethyl)methyl({ [2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide, (90) N-(2-chlorobenzyl)(methoxymethyl)methyl({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide, (91) 6-{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)(methoxymethyl)-1H-benzimidazolecarboxam ide, (92) 6-{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)methoxymethyl-1H-benzimidazolecarboxamid (93) 6-{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)(methoxymethyl)-1H-benzimidazolecarboxam ide, (94) N-(3-chloromethylphenyl){[(2-chlorophenyl)carbonyl]am ino}(methoxymethyl)-1H-benzimidazolecarboxamide, (95) N-(3-chloromethylphenyl){[(2-chloropyridinyl)carbo nyl]amino}(methoxymethyl)-1H-benzimidazolecarboxamide (96) 6-{[(2-bromophenyl)carbonyl]amino}-N-(3-chloromethylphen yl)(methoxymethyl)-1H-benzimidazolecarboxamide, (97) N-(3-chloromethylphenyl){[(2,6-dichlorophenyl)carbony l]amino}(methoxymethyl)-1H-benzimidazolecarboxamide, (98) N-(3-chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}(methoxymethyl)-1H-benzimidazolecarboxamide, (99) 6-{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)(methoxymethyl)-1H-benzimidazolecarboxam ide, (100) 6-{[(2-chloro-3,6-difluorophenyl)carbonyl]amino}-N-(3-chlor omethylphenyl)(methoxymethyl)-1H-benzimidazolecarb oxamide, (101) 6-{[(2-bromochlorophenyl)carbonyl]amino}-N-(3-chlorom ethylphenyl)(methoxymethyl)-1H-benzimidazolecarboxami (102) 6-{[(2-bromofluorophenyl)carbonyl]amino}-N-(3-chlorom ethylphenyl)(methoxymethyl)-1H-benzimidazolecarboxami (103) N-(3-chloromethylphenyl){[(2-chloromethylphenyl)ca rbonyl]amino}(methoxymethyl)-1H-benzimidazolecarboxam ide, (104) N-(3-chloromethylphenyl){[(2-chloromethylphenyl)ca rbonyl]amino}(methoxymethyl)-1H-benzimidazolecarboxam ide, (105) 6-{[(5-bromochlorophenyl)carbonyl]amino}-N-(3-chlorom ethylphenyl)(methoxymethyl)-1H-benzimidazolecarboxami (106) 6-{[(2-bromochlorophenyl)carbonyl]amino}-N-(3-chlorom ethylphenyl)(methoxymethyl)-1H-benzimidazolecarboxami (107) N-(3-chloromethylphenyl){[(2-chloromethylphenyl)ca rbonyl]amino}(methoxymethyl)-1H-benzimidazolecarboxam ide, (108) N-(3-chloromethylphenyl)(methoxymethyl)({[5-methyl (trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide, (109) 6-({[2,5-bis(trifluoromethyl)phenyl]carbonyl}amino)-N-(3-ch loromethylphenyl)(methoxymethyl)-1H-benzimidazolec arboxamide, (110) 6-({[2,4-bis(trifluoromethyl)phenyl]carbonyl}amino)-N-(3-ch loromethylphenyl)(methoxymethyl)-1H-benzimidazolec arboxamide, (111) N-(3-chloromethylphenyl)({[5-fluoro(trifluoromethy l)phenyl]carbonyl}amino)(methoxymethyl)-1H-benzimidazole carboxamide, (112) N-(3-chloromethylphenyl)({[2-chloro(trifluoromethy l)phenyl]carbonyl}amino)(methoxymethyl)-1H-benzimidazole carboxamide, (113) N-(3-chloromethylphenyl)[({2-chloro[2-(propanyl oxy)ethoxy]phenyl}carbonyl)amino](methoxymethyl)-1H-benz imidazolecarboxamide, (114) 6-({[2-chloro(2-ethoxyethoxy)phenyl]carbonyl}amino)-N-(3 -chloromethylphenyl)(methoxymethyl)-1H-benzimidazole- 4-carboxamide, (115) 6-({[2-chloro(3-methoxypropyl)phenyl]carbonyl}amino)-N-( 3-chloromethylphenyl)(methoxymethyl)-1H-benzimidazole carboxamide, (116) 6-({[5-(3-tert-butoxypropynyl)chlorophenyl]carbony l}amino)-N-(3-chloromethylphenyl)(methoxymethyl)-1H-b enzimidazolecarboxamide, (117) 6-({[5-(3-tert-butoxypropyl)chlorophenyl]carbonyl}amino) -N-(3-chloromethylphenyl)(methoxymethyl)-1H-benzimida zolecarboxamide, (118) 6-({[2-chloro(3-hydroxymethylbutyl)phenyl]carbonyl}am ino)-N-(3-chloromethylphenyl)(methoxymethyl)-1H-benzi midazolecarboxamide, (119) 6-({[2-chloro(ethoxymethyl)phenyl]carbonyl}amino)-N-(3-c hloromethylphenyl)(methoxymethyl)-1H-benzimidazole carboxamide, (120) 6-[({2-chloro[(2-ethoxyethoxy)methyl]phenyl}carbonyl)ami no]-N-(3-chloromethylphenyl)(methoxymethyl)-1H-benzim idazolecarboxamide, (121) 6-({[2-chloro(2-cyclopropylethyl)phenyl]carbonyl}amino)- N-(3-chloromethylphenyl)(methoxymethyl)-1H-benzimidaz olecarboxamide, (122) N-(3-chloromethylphenyl)({[2-chloro(2-phenylethyl) phenyl]carbonyl}amino)(methoxymethyl)-1H-benzimidazole-4 -carboxamide, (123) N-(3-chloromethylphenyl)cyclopentyl({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamid (124) N-(3-chloromethylphenyl)cyclopentyl{[(2,5-dichloro phenyl)carbonyl]amino}-1H-benzimidazolecarboxamide, (125) 6-{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)cyclopentyl-1H-benzimidazolecarboxamide, (126) 6-[{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro-2 -methylphenyl)[(2R)-tetrahydrofuranyl]-1H-benzimidazo lecarboxamide, (127) N-(3-chloromethylphenyl){[(2,6-dichlorophenyl)carbony l]amino}[(2R)-tetrahydrofuranyl]-1H-benzimidazolec arboxamide, (128) N-(3-chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}[(2R)-tetrahydrofuranyl]-1H-benzimidazolec arboxamide, (129) N-(3-chloromethylphenyl)[(2S)oxopyrrolidinyl]-6 -({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidaz olecarboxamide, (130) N-(3-chloromethylphenyl)[(2R)oxopyrrolidinyl]-6 -({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidaz olecarboxamide, (131) N-(3-chloromethylphenyl)[2-oxo(pyrrolizinyl)eth yl]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzi midazolecarboxamide, (132) N-(3-chloromethylphenyl)[2-(dimethylamino)oxoethyl ]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimi dazolecarboxamide, (133) N-(3-chloromethylphenyl)[2-(methylamino)oxoethyl]- 6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimida zolecarboxamide, (134) 2-chloro-N-(3-chloromethylphenyl)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (135) N-(3-chloromethylphenyl)[(2-methoxyethyl)amino]({[ 2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole- 4-carboxamide, (136) N-(3-chloromethylphenyl)[(2-hydroxyethyl)amino]({[ 2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole- 4-carboxamide, (137) N-(3-chloromethylphenyl)(methylamino)({[2-(trifluo romethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxam ide, (138) N-(3-chloromethylphenyl)(ethylamino)({[2-(trifluor omethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxami (139) N-(3-chloromethylphenyl)[(2,2-dimethylpropyl)amino]-6 -({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidaz olecarboxamide, (140) N-(3-chloromethylphenyl)(cyclopentylamino)({[2-(tr ifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecar boxamide, (141) N-(3-chloromethylphenyl)(piperidinyl)({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xamide, (142) N-(3-chloromethylphenyl)(4-methylpiperazinyl)({ [2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide, (143) 2-[bis(2-hydroxyethyl)amino]-N-(3-chloromethylphenyl) ({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazo lecarboxamide, (144) N-(3-chloromethylphenyl)(dimethylamino)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide, (145) N-(3-chloromethylphenyl){[2-(morpholinyl)ethyl]ami no}({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzi midazolecarboxamide, (146) N-(3-chloromethylphenyl){[2-(dimethylamino)ethyl]amin o}({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzim idazolecarboxamide, (147) N-(3-chloromethylphenyl)(3-hydroxyazetidinyl)({ [2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide, (148) N-(3-chloromethylphenyl)[(3S)(dimethylamino)pyrrol izinyl]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1 H-benzimidazolecarboxamide, (149) N-(3-chloromethylphenyl)[(3S)hydroxypyrroliziny l]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzim idazolecarboxamide, (150) N-(3-chloromethylphenyl){[2-(diethylamino)ethyl]amino }({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimi dazolecarboxamide, (151) N-(3-chloromethylphenyl){[2-(pyrrolizinyl)ethyl]am ino}({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benz imidazolecarboxamide, (152) N-(3-chloromethylphenyl){[3-(dimethylamino)propyl]ami no}({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzi midazolecarboxamide, (153) N-(3-chloromethylphenyl){[3-(dimethylamino)-2,2-dimet hylpropyl]amino}({[2-(trifluoromethyl)phenyl]carbonyl}am ino)-1H-benzimidazolecarboxamide, (154) N-(3-chloromethylphenyl){[2-(dipropanylamino)ethyl ]amino}({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-b enzimidazolecarboxamide, (155) N-(3-chloromethylphenyl)(morpholinyl)({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xamide, (156) 2-amino-N-(3-chloromethylphenyl)({[2-(trifluoromethyl )phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (157) N-(3-chloromethylphenyl)[(3-hydroxy-2,2-dimethylpropy l)amino]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H- benzimidazolecarboxamide, (158) N-(3-chloromethylphenyl){[(3-methyloxetanyl)methyl ]amino}({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-b enzimidazolecarboxamide, (159) tert-butyl N-{4-[(3-chloromethylphenyl)carbamoyl]({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolyl}glycinat (160) N-{4-[(3-chloromethylphenyl)carbamoyl]({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolyl}glycine, (161) N-(3-chloromethylphenyl)[(3-hydroxy-2,2-dimethylpropy l)amino]methyl({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxamide, (162) N-(3-chloromethylphenyl)[(3-methoxy-2,2-dimethylpropy l)amino]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H- benzimidazolecarboxamide, (163) N-(3-chloromethylphenyl)(pyrrolizinyl)({[2-(tri fluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarb oxamide, (164) 2-(azetidinyl)-N-(3-chloromethylphenyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide, (165) N-(3-chloromethylphenyl)(3-methoxyazetidinyl)({ [2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide, (166) N-(3-chloromethylphenyl)[(2-hydroxymethylpropyl)am ino]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benz imidazolecarboxamide, (167) N-(3-chloromethylphenyl){[(2S)-tetrahydrofuranylme thyl]amino}({[2-(trifluoromethyl)phenyl]carbonyl}amino)- 1H-benzimidazolecarboxamide, (168) N-(3-chloromethylphenyl){[(2R)-tetrahydrofuranylme thyl]amino}({[2-(trifluoromethyl)phenyl]carbonyl}amino)- 1H-benzimidazolecarboxamide, (169) N-(3-chloromethylphenyl){[(2S)hydroxymethylbuta nyl]amino}({[2-(trifluoromethyl)phenyl]carbonyl}amino )-1H-benzimidazolecarboxamide, (170) N-(3-chloromethylphenyl){[(2R)hydroxymethylbuta nyl]amino}({[2-(trifluoromethyl)phenyl]carbonyl}amino )-1H-benzimidazolecarboxamide, (171) N-(3-chloromethylphenyl){[(2S)hydroxy-3,3-dimethyl butanyl]amino}({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxamide, (172) N-(3-chloromethylphenyl)[(3-methoxy-2,2-dimethylpropy l)(methyl)amino]({[2-(trifluoromethyl)phenyl]carbonyl}am ino)-1H-benzimidazolecarboxamide, (173) N-(3-chloromethylphenyl)[(3-methoxypropyl)amino]({ [2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide, (174) N-(3-chloromethylphenyl){[2-(propanyloxy)ethyl]ami no}({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzi midazolecarboxamide, (175) 2-[(2-tert-butoxyethyl)amino]-N-(3-chloromethylphenyl)-6 -({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidaz olecarboxamide, (176) N-(3-chloromethylphenyl)[(2-methoxymethylpropyl)am ino]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benz imidazolecarboxamide, (177) N-(3-chloromethylphenyl){[2-(methylsulfanyl)ethyl]ami no}({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzi midazolecarboxamide, (178) N-(3-chloromethylphenyl)(methylsulfanyl)({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xamide, (179) N-(3-chloromethylphenyl)(methylsulfonyl)({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xamide, (180) N-(3-chloromethylphenyl)(methylsulfinyl)({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xamide, (181) 6-{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)(dimethylamino)-1H-benzimidazolecarboxam ide, (182) N-(3-chloromethylphenyl){[(2,6-dichlorophenyl)carbony l]amino}(dimethylamino)-1H-benzimidazolecarboxamide, (183) N-(3-chloromethylphenyl){[(2,4-dichlorophenyl)carbony l]amino}(dimethylamino)-1H-benzimidazolecarboxamide, (184) N-(3-chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}(dimethylamino)-1H-benzimidazolecarboxamide, (185) 6-{[(2-bromofluorophenyl)carbonyl]amino}-N-(3-chlorom ethylphenyl)(dimethylamino)-1H-benzimidazolecarboxami (186) 6-{[(2-bromochlorophenyl)carbonyl]amino}-N-(3-chlorom ethylphenyl)(dimethylamino)-1H-benzimidazolecarboxami (187) 6-({[2-chloro(cyclopropylethynyl)phenyl]carbonyl}amino)- N-(3-chloromethylphenyl)(dimethylamino)-1H-benzimidaz olecarboxamide, (188) N-(3-chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}[(3-hydroxy-2,2-dimethylpropyl)amino]-1H-benzimi dazolecarboxamide, (189) N-(3-chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}[(3-methoxy-2,2-dimethylpropyl)amino]-1H-benzimi dazolecarboxamide, (190) N-(3-chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}[(2-hydroxymethylpropyl)amino]-1H-benzimidazo lecarboxamide, (191) N-(3-chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}[(2-methoxymethylpropyl)amino]-1H-benzimidazo lecarboxamide, (192) N-(3-chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}{[2-(propanyloxy)ethyl]amino}-1H-benzimidazol ecarboxamide, (193) 6-[{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro-2 -methylphenyl){[2-(propanyloxy)ethyl]amino}-1H-benzim idazolecarboxamide, (194) 2-[(2-tert-butoxyethyl)amino]{[(2-chlorofluorophenyl) carbonyl]amino}-N-(3-chloromethylphenyl)-1H-benzimidazol ecarboxamide, (195) 6-[{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro-2 -methylphenyl)[(3-methoxy-2,2-dimethylpropyl)amino]-1H-b enzimidazolecarboxamide, (196) 6-[{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro-2 -methylphenyl)[(2-methoxymethylpropyl)amino]-1H-benzi midazolecarboxamide, (197) 6-[{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro-2 -methylphenyl){[(2S)-tetrahydrofuranylmethyl]amino}-1 H-benzimidazolecarboxamide, (198) 6-[{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro-2 -methylphenyl){[(2R)-tetrahydrofuranylmethyl]amino}-1 H-benzimidazolecarboxamide, (199) 6-[{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro-2 -methylphenyl)[(3-hydroxy-2,2-dimethylpropyl)amino]-1H-b enzimidazolecarboxamide, (200) 6-[{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro-2 -methylphenyl){[(2S)hydroxymethylbutanyl]amino} -1H-benzimidazolecarboxamide, (201) N-(3-chloromethylphenyl)(dimethylamino)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide, (202) N-(4-tert-buthylphenyl)(dimethylamino)({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamid (203) N-(2,3-dihydro-1H-indenyl)(dimethylamino)({[2-(tri fluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarb oxamide, (204) 6-{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)(dimethylamino)-1H-benzimidazolecarboxam ide, (205) N-(3-chloromethylphenyl){[(2,6-dichlorophenyl)carbony l]amino}(dimethylamino)-1H-benzimidazolecarboxamide, (206) N-(3-chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}(dimethylamino)-1H-benzimidazolecarboxamide, (207) N-(3-chloromethylphenyl)cyclopropyl{[(2,5-dichloro phenyl)carbonyl]amino}-1H-benzimidazolecarboxamide, (208) N-(3-chloromethylphenyl)cyclopropyl{[(2,5-dichloro phenyl)carbonyl]amino}-1H-benzimidazolecarboxamide, (209) N-(3-chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}(1-methylcyclopropyl)-1H-benzimidazolecarboxa mide, (210) N-(3-chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}(1-methylcyclopropyl)-1H-benzimidazolecarboxa mide, (211) N-(3-chloromethylphenyl)(methoxymethyl)({[2-(methy lsulfonyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxa mide, (212) N-(3-chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}(2-methoxyethyl)-1H-benzimidazolecarboxamide, (213) 2-(methoxymethyl)-N-phenyl({[2-(trifluoromethyl)phenyl]c arbonyl}amino)-1H-benzimidazolecarboxamide, (214) 2-(methoxymethyl)-N-propyl({[2-(trifluoromethyl)phenyl]c arbonyl}amino)-1H-benzimidazolecarboxamide, (215) 2-(methoxymethyl)-N-(pyridinyl)({[2-(trifluoromethyl) phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (216) N-benzyl(methoxymethyl)({[2-(trifluoromethyl)phenyl]c arbonyl}amino)-1H-benzimidazolecarboxamide, (217) N-(cyclohexylmethyl)(methoxymethyl)({[2-(trifluoromet hyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (218) 2-(methoxymethyl)-N-(naphthalenyl)({[2-(trifluorometh yl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (219) 2-(methoxymethyl)-N-(thiophenyl)({[2-(trifluoromethyl )phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (220) N-(2,1,3-benzothiadiazolyl)(methoxymethyl)({[2-(tr ifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecar boxamide, (221) N-(1,1-dioxidebenzothiophenyl)(methoxymethyl)({ [2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide, (222) 2-(methoxymethyl)-N-(thiophenylmethyl)({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamid (223) N-(1H-indolyl)(methoxymethyl)({[2-(trifluoromethyl )phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (224) N-(1,3-benzothiazolyl)(methoxymethyl)({[2-(trifluo romethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxam ide, (225) N-(2,2-dimethylpropyl)(methoxymethyl)({[2-(trifluorom ethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide (226) 2-(methoxymethyl)-N-(thiophenyl)({[2-(trifluoromethyl )phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (227) N-(5-chloro-1,3-benzoxazolyl)(methoxymethyl)({[2-( trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolec arboxamide, (228) N-(2-benzylphenyl)(methoxymethyl)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (229) 2-(methoxymethyl)-N-(quinolinyl)({[2-(trifluoromethyl )phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (230) N-(cycloheptylmethyl)(methoxymethyl)({[2-(trifluorome thyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, (231) N-(1,3-benzoxazolyl)(methoxymethyl)({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamid (232) N-(6-chloro-1,3-benzoxazolyl)(methoxymethyl)({[2-( trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolec arboxamide, (233) N-[3-chloro(hydroxymethyl)phenyl](methoxymethyl)({ [2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide, (234) N-(3-chloromethylphenyl){[(3-fluoropyridinyl)carbo nyl]amino}(methoxymethyl)-1H-benzimidazolecarboxamide (235) N-(3-chloromethylphenyl){[(3-chloropyridinyl)carbo nyl]amino}(methoxymethyl)-1H-benzimidazolecarboxamide (236) N-(3-chloromethylphenyl){[(3,5-dichloropyridinyl)c arbonyl]amino}(methoxymethyl)-1H-benzimidazolecarboxa mide, (237) 6-{[(5-butoxychlorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)(methoxymethyl)-1H-benzimidazolecarboxam ide, (238) 6-({[2-chloro(2,2-difluoroethoxy)phenyl]carbonyl}amino)- N-(3-chloromethylphenyl)(methoxymethyl)-1H-benzimidaz olecarboxamide, (239) N-(3-chloromethylphenyl)({[2-chloro(4,4,4-trifluor obutoxy)phenyl]carbonyl}amino)(methoxymethyl)-1H-benzimi dazolecarboxamide.

DETAILED DESCRIPTION OF THE INVENTION Detail description of the terms used in the present specification is provided as follows.

Examples of "halogen" include fluorine, chlorine, bromine and iodine.

Examples of "alkyl" include straight or branched alkyl having 1 to 8 carbon atoms, such as, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, isohexyl, n-heptyl, isoheptyl, n-octyl. Among which alkyl having 1 to 6 carbon atoms is preferred, and alkyl having 1 to 3 carbon atoms is more preferred.

The alkyl moiety of "monoalkylamino", "dialkylamino", "monoalkyl aminocarbonyl", "dialkylaminocarbonyl", "alkylcarbonyloxy", "alkyloxycarbonyl", "alkylcarbonyl", "alkylthio", "alkylsulfonyl", "alkylsulfinyl", "alkoxyalkyl", "monohaloalkyl", "dihaloalkyl", "trihaloalkyl" and "alkoxyalkylamino" is as defined above for "alkyl".

Examples of "alkoxy" include straight or branched alkoxy having 1 to 8 carbon atoms, such as, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, t-butoxy, n-pentyloxy, n-hexyloxy, n-heptyloxy, n-octyloxy.

The alkoxy moiety of "alkoxyalkoxy", "alkoxyalkyl" and "alkoxyalkylamino" is as defined above for "alkoxy".

Examples of "heteroaryl" include monocyclic or bicyclic aromatic rings having 1 to 3 hetero atoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom.

Specific examples include furyl (e.g., 2-furyl, 3-furyl), thienyl (e.g., 2-thienyl, 3-thienyl), pyrrolyl (e.g., 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), imidazolyl (e.g., 1-imidazolyl, 2-imidazolyl, 4-imidazolyl), pyrazolyl (e.g., 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl), triazoryl (e.g., 1,2,4-triazolyl, 1,2,4-triazolyl, 1,2,4-triazolyl), tetrazolyl (e.g., 1-tetrazolyl, 2-tetrazolyl, 5-tetrazolyl), oxazolyl (e.g., 2-oxazolyl, 4-oxazolyl, 5-oxazolyl), isoxazolyl (e.g., 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl), oxadiazolyl (e.g., 1,3,4-oxadiazolyl), thiazolyl (e.g., 2-thiazolyl, 4-thiazolyl, 5-thiazolyl), thiadiazolyl (e.g., 1,3,4-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,3-thiadiazolyl), isothiazolyl (e.g., 3-isothiazolyl, 4-isothiazolyl, -isothiazolyl), pyridyl (e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl), pyridazinyl (e.g., 3-pyridazinyl, 4-pyridazinyl), pyrimidinyl (e.g., 2-pyrimidinyl, 4-pyrimidinyl, -pyrimidinyl), pyrazinyl (e.g., 2-pyrazinyl), benzothiadiazolyl (e.g., 1,2,3-benzothiadiazolyl, 1,2,3-benzothiadiazolyl, 2,1,3-benzothiadiazolyl, 2,1,3-benzothiadiazolyl), benzothiazolyl (e.g., benzothiazolyl, benzothiazolyl, benzothiazolyl, benzothiazolyl, benzothiazolyl), indolyl (e.g., indolyl and indolyl, indolyl, indolyl, indolyl), benzothiophenyl (e.g., 1-benzothiophenyl, 1-benzothiophenyl, 1-benzothiophenyl, 1-benzothiophenyl, 1-benzothiophenyl, 1-benzothiophenyl), 1,1-dioxobenzothiophenyl (e.g., 1,1-dioxobenzothiophenyl, 1,1-dioxobenzothiophenyl, 1,1-dioxobenzothiophenyl, 1,1-dioxobenzothiophenyl, 1,1-dioxobenzothiophenyl, 1,1-dioxobenzothiophenyl), quinolyl (quinolinyl, quinolinyl, quinolinyl, quinolinyl, quinolinyl, quinolinyl, quinolinyl) and 1,3-benzoxazolyl.

The heteroaryl moiety of "heteroarylmethyl" is as defined above for "heteroaryl".

Examples of "a saturated cyclic amino" include 4- to 7-membered saturated cyclic amino groups having one or two nitrogen atoms, said ring optionally having one oxygen or sulfur atom and optionally substituted with oxo. Specific examples include 1-azetidinyl, 1-pyrrolidinyl, 1-imidazolidinyl, piperidino, 1-piperazinyl, 1-tetrahydropyrimidinyl, 4-morpholino, 4-thiomorpholino, 1-homopiperazinyl, and 2-oxo-oxazolidinyl.

The saturated cyclic amino moiety of "a saturated cyclic aminocarbonyl" is as defined above for "a saturated cyclic amino".

Examples of "a saturated heterocycle group" include 4- to 6-membered saturated heterocycle group having one nitrogen or oxygen atom in the ring. Specific examples include 2-pyrrolidinyl, 3-pyrrolidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 2-oxetanyl, 3-oxetanyl, 2-tetrahydrofuranyl, and 3-tetrahydrofuranyl.

Examples of "cycloalkyl" include cycloalkyl having 3 to 8 carbon atoms. Specific examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

The cycloalkyl moiety of "cycloalkyl methyl" is as defined above for "cycloalkyl".

Examples of "naphthyl" include 1-naphthyl and 2-naphthyl.

Examples of "pyridyl" include 2-pyridyl, 3-pyridyl and 4-pyridyl.

Examples of "alkynyl" include straight or branched alkynyl having 2 to 6 carbon atoms. Specific examples include ethynyl, 1-propynyl, 1-butynyl, 1-pentynyl, 2-propynyl, 2-butynyl, 3-butynyl, 1-methylpropynyl, 2-pentynyl, 3-pentynyl and 4-pentynyl,.

[Mode for Carrying Out the Invention] The compound of the invention can be prepared according to the following procedures, working examples or procedures known in the art. If the starting material has a substituent group that may interfere with a reaction during the process, it may be protected with an appropriate protecting group according to known method before subjecting to the reaction.

The following abbreviations can be used herein to simplify the description. p-: para-, t-: tert-, s-: sec-, m-: meta-, THF: tetrahydrofuran, DMF: N,N-dimethylformamide, DMA: N,N-dimethylacetamide, HBTU: O-(benzotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, HATU: O-(7-azabenzotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, TFA: trifluoroacetic acid, DME: ethylene glycol dimethyl ether, NMP: N-methylpyrrolidone, DMSO: dimethyl sulfoxide, MeOH: methanol, EtOH: ethanol.

Process 1 [Formula 4] CO H R NH O NH wherein ring A, R and R are as defined above.

This reaction is the condensation of Compound [6] with Compound [7] and can be performed according to a method for condensation reaction known per se. A compound of the invention can be synthesized by the reaction of a carboxylic acid Compound or its reactive derivative with an amine derivative [7].

Examples of such reactive derivative of Compound [6] include those commonly used in an amide condensation formation, such as, for example, acid halides (e.g., acid chloride, acid bromide), mixed anhydrides, imidazolides, active amides. When using Compound [6], the reaction can be performed using a condensing agent at a temperature in the range from -20°C to 100°C in the presence or absence of a base. Examples of the condensing agent which may be used for this reaction include 1,1'-oxalyldiimidazole, 1-ethyl(3-dimethylaminopropyl)carbodiimide, dicyclohexylcarbodiimide, diethyl cyanophosphonate, HBTU, HATU, 1H-benzotriazolyl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate. Examples of the base which can be used for this reaction include organic bases such as triethylamine, N,N-diisopropylethylamine, N,N-dimethylaniline, pyridine, 1,8-diazabicyclo[5,4,0]undecene. Any solvent may be used so long as it does not interfere with the reaction, and examples of such solvent include ethers such as THF, 1,4-dioxane and diethyl ether, amides such as DMF and DMA, nitriles such as acetonitrile and propionitrile, hydrocarbons such as benzene and toluene, halogenated hydrocarbons such as chloroform and methylene chloride, and mixed solvents thereof. Also, an additive agent can be used if necessary. Examples of such additive agent which can be used include 1-hydroxybenzotriazol and 1-hydroxyaza-benzotriazol. Preferred reaction time is generally within the range from 10 minutes to 24 hours, but it should vary depending on the starting material, the reaction temperature, etc. Preferred amounts of Compound [7] and the condensing agent to be used are within the range from 1 to 3 moles for one mole of Compound [6]. Preferred amount of the base to be used is within the range from 1 Eq to 10 Eq, preferably from 1 Eq to 4 Eq, to Compound [6].

For example, Compound [6] can be prepared according to the process as described below.

[Formula 5] O OH A A A CO R CO R CO H [9A] [Step 1-A] [Step 2] NH O NH O NH [8A] CO R [9B] [Step 1-B] [8B] wherein ring A and R are as defined above, X represents halogen and R represents alkyl.

Step 1-A This reaction is a condensation reaction of Compound [8A] with Compound [9A] to synthesize Compound [10] according to Process 1 as described above.

Step 1-B The reaction is a coupling reaction of Compound [8B] with Compound [9B] using palladium catalyst, and the reaction is performed according to a method known per se. The solvent which can be used is not limited so long as it does not interfere with a reaction, and examples of such solvent include hydrocarbons such as toluene and xylene, ethers such as 1,4-dioxane and THF, amides such as DMF, DMA and NMP, and a mixed solvent thereof.

The reaction is performed in the presence of a base at a temperature in the range from 20°C to 200°C, optionally using microwave. Examples of the palladium catalyst which can be used include tris(dibenzylideneacetone)(chloroform)dipalladium (0), tris(dibenzylideneacetone)dipalladium (0) and palladium acetate (II). Suitable amount of such palladium catalyst is within the range from 0.001 mol to 0.3 mol, to 1 mol of aryl halide. Examples of the ligand for the palladium catalyst which can be used include 1,1'-bis(diphenylphosphino)ferrocene, 4,5-bis(diphenylphosphino)-9,9'-dimethylxanthene, 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl, (±)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, 2-(di-t-butylphosphino)biphenyl, bis[2-(diphenylphosphino)phenyl] ether, tri-t-butylphosphine, etc. Examples of the base which can be used include sodium t-butoxide, tripotassium phosphate and cesium carbonate. The amount of the base to be used is within the range from 1 Eq to Eq, preferably within the range from 1 Eq to 4 Eq, to Compound [8B]. Appropriate reaction time is generally within the range from 10 minutes to 24 hours, but it should vary depending on the starting material, the reaction temperature, etc.

Step 2 Compound [6] can be prepared by hydrolyzing Compound [10] according to a known method. The reaction is usually performed in the presence of acid or base in a suitable solvent. Examples of the acid used in the hydrolysis include inorganic acids such as hydrochloric acid and sulfuric acid, and examples of the base include inorganic bases such as sodium hydroxide and potassium hydroxide. Examples of reaction solvent include alcohols such as MeOH and EtOH, ethers such as THF and dioxane, water, and mixed solvents thereof. The reaction is performed at a temperature within the range from 0°C to 100°C, and the reaction time is usually within the range from 30 minutes to 24 hours.

For example, Compound [8A] can be prepared by the following process.

[Formula 6] A 5 A 5 CO R CO R NO NH [8A] wherein ring A and R are as defined above.

This reaction is a reduction reaction of Compound [11] to aromatic amine, and the reaction can be carried out with a conventional method. For example, the reaction is achieved by catalytic hydrogen reduction of Compound [11] using a catalyst such as Raney nickel, palladium, rhodium, platinum, etc., in a suitable solvent under hydrogen gas atmosphere, hydride reduction using lithium aluminum hydride, etc., iron reduction using reduced iron reagent and ammonium chloride etc., or zinc reduction using zinc dust and acetic acid, etc. In addition, there are also a method using sulfides such as hydrosulfite sodium and a reducing method by ammonium formate, hydrazine, etc. with a metal catalyst such as palladium on carbon.

Selection of the solvent depends on the kind of compound or reagent to be used, and the solvent may be used alone or as a mixture thereof. Examples of such solvent include toluene, THF, 1,4-dioxane, 1,2-dimethoxyethane, ethyl acetate, acetone, acetonitrile, DMF, or alcohols such as MeOH, EtOH and tert-butanol, and water. Although the reaction temperature depends on the kind of compound and reagent to be used, it is usually within the range from 0°C to 300°C, preferably within the range from 20°C to 150°C.

When the ring A of Compound [8A] is a group represented by the general formula [2] or [3], the compound can be prepared according to the method described in WO2008/65508. When the ring A of Compound [8A] is a group represented by the general formula [4], the compound can be prepared according to a method described in literature (e.g., EP2226315, J. Org. Chem., 1960, ,942, etc.). Also, the compound may be prepared according to the following process.

[Formula 7] CO R CO R 2 [13] [Step 1]

[14] X 5 5 CO R 2 CO R CO R [Step 2] [Step 3] [Step 4] NO NH

[16] [8A'] 1 5 2 2 wherein X , R and A are as defined above, and X represents NH or OH.

Step 1 This reaction is an acylation reaction of Compound [12] with Compound [13] or its reactive derivative and can be performed according to method known per se as acylation reaction.

Examples of the reactive derivative of Compound [13] include those generally used for acylation reaction and include acid halides (e.g., acid chloride, acid bromide), mixed acid anhydrides, imidazolides, active amides, etc. When using Compound [13], the reaction can be conducted using a condensing agent in the presence or absence of a base at temperature within a range from -20°C to 100°C. Examples of the condensing agent which can be used for this reaction include 1,1'-oxalyldiimidazole, 1-ethyl(3-dimethylaminopropyl)carbodiimide, dicyclohexylcarbodiimide, diethyl cyanophosphonate, HBTU, HATU and 1H-benzotriazolyloxytripyrrolidinophosphonium hexafluorophosphate. Examples of the base which can be used for this reaction include organic bases such as triethylamine, N,N-diisopropylethylamine, N,N-dimethylaniline, pyridine, 1,8-diazabicyclo[5,4,0]undecene. The solvent to be used is not limited so long as it does not interfere with a reaction, and examples of such solvent include ethers such as THF, 1,4-dioxane and diethyl ether, amides such as DMF and DMA, nitriles such as acetonitrile and propionitrile, hydrocarbons such as benzene and toluene, halogenated hydrocarbons such as chloroform and methylene chloride, and a mixed solvent thereof.

Also, an additive agent can be used if necessary. Examples of such additive agent which can be used include 1-hydroxybenzotriazol and 1-hydroxyaza-benzotriazol.

Preferred amount of the base to be used is within the range from 1 Eq to 10 Eq, preferably 1 Eq to 4 Eq, to Compound [13].

Preferred reaction time is generally within the range from 10 minutes to 24 hours, but it should vary depending on the starting material, the reaction temperature, etc. Preferred amounts of Compound [13] and the condensing agent to be used are within the range from 1 to 3 moles for one mole of Compound [12].

Step 2 This reaction is intramolecular cyclization of Compound using an acid catalyst and can be performed according to a method known per se. The reaction is performed in a suitable solvent or in the absence of a solvent, and examples of the acid which can be used include hydrochloric acid, p-toluenesulfonic acid, acetic acid, pyridinium p-toluenesulfonate, polyphosphoric acid, phosphoryl chloride, etc. The reaction can be carried out usually at a temperature within the range from 0°C to 200°C.

The solvent which can be used is not limited so long as it does not interfere with a reaction, and examples of such solvent includes hydrocarbons such as toluene and xylene, alcohols such as MeOH and EtOH, ethers such as 1,4-dioxane and THF, amides such as DMF and DMA, halogenated hydrocarbon such as chloroform and dichloromethane, acetonitrile, or a mixed solvent thereof.

The reaction time is generally within the range from 30 minutes to 48 hours although it should vary depending on the starting material and the reaction temperature.

Step 3 This reaction is a nitration reaction of Compound [15] and can be performed according to a known method. Generally, a nitrating agent, such as nitric acid, mixed acid, metal nitrate, acetyl nitrate, dinitrogen pentaoxide, nitronium salt (e.g., nitronium tetrafluoro borate, nitronium trifluoromethanesulfonate), etc., is used. The reaction solvent is not limited so long as it does not interfere with a reaction, and example of such solvent include halogenated solvents such as dichloromethane and chloroform, pentane, TFA, sulfolane, acetonitrile, etc.

The reaction is carried out under neutral or acidic condition.

When the reaction is carried out under acidic condition, examples of the acid to be used include sulfuric acid, nitric acid, acetic acid, and acetic anhydride. Also, only such acid may be used as a reaction solvent without using of the reaction solvent as mentioned above. The reaction temperature is generally within the range from -20°C to room temperature although it should vary depending on the compound and reagent to be used. Preferred reaction time is generally within the range from 30 minutes to 24 hours although it should vary depending on the starting material and the reaction temperature.

Step 4 This reaction is a reduction reaction of Compound [16] to an aromatic amine and can be carried out to prepare Compound [8A'] according to the similar process of the preparation of Compound [8A].

Compound [8B] can be prepared according to the method described in literature (e.g., J. Med. Chem., 1999, 42, 5020, WO2008/65508). When the ring A of Compound [8B] is a group represented by the general formula [4], the compound also can be prepared by the following process.

[Formula 8] 2 1 2 5 wherein A , X, X , X and R are as defined above.

Step 1 This reaction is a condensation reaction of Compound [17] with Compound [13] or its reactive derivative and can be carried out to prepare Compound [18] according to the similar procedure of Step 1 in the process for Compound [8A'].

Step 2 This reaction is an intramolecular cyclization reaction of acyl group and amino group using an acid catalyst and can be carried out to prepare Compound [8B’] according to the procedure of Step 2 in the above-mentioned process of the preparation of Compound [8A'].

For example, Compound [17] can be prepared according to the following process.

[Formula 9] wherein X and R are as defined above.

Step 1-1 This reaction is a halogenation reaction of Compound [19] and can be carried out according to a method known per se as halogenation reaction. Examples of halogenating agent which can be used include N-bromosuccinimide, N-iodosuccinimide, bromine, iodine, etc., and generally, the reaction can be carried out at a temperature within the range from 0°C to 200°C.

The solvent which can be used is not limited so long as it does not interfere with a reaction, and examples of such solvent include hydrocarbons, such as toluene and xylene, ethers such as 1,4-dioxane and THF, amides such as DMF and DMA, halogenated hydrocarbons such as chloroform and dichloromethane, acetonitrile, and a mixed solvent thereof. Also a suitable base may be added if necessary, and examples of such base which can be used include pyridine, N,N-diisopropylethylamine, etc. The amount of the base to be used, for example, is within the range from 1 Eq to 10 Eq, preferably within the range from 1 Eq - 4 Eq, to Compound [19]. Preferred reaction time is generally within the range from 30 minutes to 24 hours although it should vary depending on the starting material and the reaction temperature.

Step 1-2 This reaction is a reduction reaction of Compound [20] to an aromatic amine, and can be performed to prepare Compound [17A] according to the similar process of the above-mentioned Compound [8A].

Step 2-1 This reaction is a halogenation reaction of Compound [21] and can be performed to prepare Compound [17B] according to the similar procedure of Step 1-1 in the process of the preparation of Compound [17].

Process 2 [Formula 10] wherein ring A, R and R are as defined above.

This reaction is a condensation reaction of Compound [22A] with Compound [9A] and can be performed according to Process 1 to prepare a compound of the invention.

Also, a compound of the invention may be prepared by the following procedures.

[Formula 11] wherein ring A, R , R and X are as defined above.

This reaction is a coupling reaction of Compound [22B] with Compound [9B], and can be performed to prepare a compound of the invention according to the similar procedure of Step 1-B in the process of Compound [6].

Compound [22A] can be prepared according to the following process, for example.

[Formula 12] wherein ring A and R are as defined above.

Step 1 This reaction is a hydrolysis reaction of Compound [11] as starting material and can be performed to prepare Compound according to the similar procedure of Step 2 in the process of the preparation of Compound [6].

Step 2 This reaction is a condensation reaction of Compound [23] with Compound [7] and can be performed to prepare Compound [24] according to Process 1.

Step 3 This reaction is a reduction reaction of Compound [24] to an aromatic amine and can be performed to prepare Compound [22A] according to the process of the preparation of Compound [8A].

For example, Compound [22B] can also be prepared by the following process.

[Formula 13] wherein ring A, R and X are as defined above.

This reaction is a condensation reaction of Compound [25] with Compound [7], and can be performed to prepare Compound [22B] according to Process 1. Compound [25] can be prepared according to a method described in literature (e.g., EP234872B1; US6387938B1; Bioorg. Med. Chem., 1999, 7, 2271; J.

Med. Chem., 1999, 42, 5020), and can also be prepared by hydrolyzing Compound [8B] according to the similar procedure of Step 2 in the process of the preparation of Compound [6].

Process 3 When the ring A is a group represented by the general formula [4] and A is alkylthio, alkoxy or a group represented by the general formula [5], the compound can be prepared according to the following process.

[Formula 14] 1 2 1 0 wherein R , R and X are as defined above, and A represents halogen, mesylate, tosylate, etc., and A represents alkylthio, alkoxy or a group represented by the general formula [5].

This reaction is a nucleophilic substitution reaction of Compound [26] by amines, metal alkoxy or substituted thiol and can be carried out according to known method. The reaction is carried out in a suitable solvent or in the absence of a solvent, using an excessive amount of reagents, or in the presence of a base. Examples of suitable base to be used include pyridine, triethylamine, N,N-diisopropylethylamine, potassium carbonate, sodium hydrogencarbonate, etc. The solvent to be used is not limited so long as it does not interfere with a reaction, and examples of such solvent include ethers such as THF and diethyl ether, amides such as DMF and DMA, nitriles such as acetonitrile and propionitrile, hydrocarbons such as benzene and toluene, alcohols such as MeOH and EtOH, water, or a mixed solvent thereof. Also, an excessive amount of the amine may be used in the reaction instead of the solvent. The reaction is generally carried out at a temperature within the range from 0°C to 200°C although it should depend on the compound and reagents to be used. The amount of the base is, for example, within the range from 1 Eq to 10 Eq, preferably within the range from 1 Eq to 4 Eq, to Compound [26]. Preferred reaction time is generally within the range from 30 minutes to 24 hours although it should vary depending on the starting material and the reaction temperature.

Compound [26] can be prepared, for example, according to the following process.

[Formula 15] 1 1 2 5 0 wherein X , R , R , R and A are as defined above.

Step 1 This reaction is a nitration reaction of Compound [27] as a starting material and can be performed according to the similar procedure of Step 3 in the process for the preparation of Compound [8A']. Compound [27] can be prepared according to a method described in literature (e.g., WO2006/116412; J. Med.

Chem., 1993, 36, 2182).

Step 2 This reaction is a reduction reaction of Compound [28] to an aromatic amine and can be performed to prepare Compound according to the similar procedure of the process for the preparation of Compound [8A].

Step 3 This reaction is a condensation reaction of Compound [29] with Compound [9A] and can be performed to prepare Compound [30] according to the similar procedure in Process 1.

Step 4 This reaction is a hydrolysis reaction of Compound [30] and can be performed to prepare Compound [31] according to similar procedure in Step 2 in the preparation of Compound [6].

Step 5 This reaction is a condensation reaction of Compound [31] with Compound [7] and can be performed to prepare Compound [26] according to similar procedure in Process 1.

Process 4 The compound also can be prepared by the following process in case where the ring A is a group represented by the general formula [4] and A is alkylsulfinyl, alkylsulfonyl.

[Formula 16] 1 2 1 4 wherein R , R , and X are as defined above, A represents alkylthio and A represents alkylsulfinyl, alkylsulfonyl.

This reaction is an oxidation reaction of Compound [32] as a starting material and can be carried out according to a conventional method. For example, the reaction is achieved in a suitable solvent using a peroxide such as potassium permanganate, metachloro perbenzoic acid and oxone permonosulfate. The solvent should be selected according to the kind of starting material and not limited so long as it does not interfere with a reaction, and examples of such solvent include dichloromethane, chloroform, dichloroethane, THF, 1,4-dioxane, DME, toluene, MeOH, etc., and such solvent may be used alone or as a mixed solvent. The amount of the oxidizing agent is within the range from 0.5 Eq to 10 Eq, preferably within the range from 0.9 Eq to 3 Eq, to the starting material. The reaction temperature is usually within the range from -20°C to 80°C, preferably within the range from 0°C to 50°C although it should depend on the kinds of the compound and reagent to be used. Preferred reaction temperature is usually within the range from 30 minutes to 24 hours although it depends on the kind of starting material to be used and the reaction temperature.

The compound of the invention may be used as a pharmaceutical as it is, and also a pharmaceutically acceptable salt thereof formed according to known method may be used.

Examples of such salt include inorganic salt of acids such as hydrochloric acid, hydrobromic acid, sulfuric acid and phosphoric acid, and organic salt of acids such as acetic acid, citric acid, tartaric acid, maleic acid, succinic acid, fumaric acid, p-toluenesulfonic acid, benzenesulfonic acid, and methanesulfonic acid.

For example, a hydrochloride of a compound of the invention can be formed by dissolving the compound of the invention in a solution of hydrogen chloride in alcohol, ethyl acetate or diethyl ether.

The compound of the invention may have an asymmetrical carbon, and each of such optical isomers and a mixture thereof are within the scope of the present invention. Such optical isomer can be prepared by optical resolution from a racemic mixture as obtained in the following working examples, according to known method using an optically active acid such as tartaric acid, dibenzoyltartaric acid, mandelic acid, -camphor sulfonic acid, etc., or by the use of an optically active compound previously prepared as a starting material.

Alternatively, such compound may be prepared by optical resolution using a chiral column or asymmetric synthesis.

Some of the compounds of the invention may exist as tautomers, and each of such tautomers and a mixture thereof are within the scope of the invention.

For example, the heterocycle derivative represented by the general formula [1] (i.e., heterocycle derivative represented by the following genera formula [1X]), wherein the ring A is a group represented by the general formula [4] and X is NH, may form a heterocycle derivative represented by the following general formula [1XA].

[Formula 17] 1 2 2 wherein R , R , and A are as defined above.

As shown in the test examples as described below, the compound of the invention or a pharmaceutically acceptable salt thereof has mPGES-1 inhibiting activity. Also, since the compound of the invention or a pharmaceutically acceptable salt thereof has mPGES-1 inhibiting activity, it has PGE2 inhibitory effect, analgesic action and anti-inflammatory effect.

Therefore, the compound of the invention or a pharmaceutically acceptable salt thereof can be used as a preventing or treating agent for diseases that involve mPGES-1, diseases associated with PGE2, and diseases on which effectiveness is expected based on analgesic or anti-inflammatory action.

Examples of disease which can apply a compound of the invention or a pharmaceutically acceptable salt thereof include inflammatory bowel disease (e.g., see Non-Patent Document 11), irritable bowel syndrome, migraine, headache, low back pain, spinal stenosis, herniated disk, temporomandibular joint disorders, cervical syndrome, cervical spondylosis, endometriosis (e.g., see Non-Patent Document 12), adenomyosis, preterm labour and delivery, threatened premature delivery, dysmenorrhea, overactive bladder, nocturia (e.g., see Non-Patent Document 13), interstitial cystitis, neurodegenerative disease such as Alzheimer's disease, multiple sclerosis (e.g., see Non-Patent Document 14), psoriasis, rheumatoid arthritis (e.g., see Non-Patent Document and Non-Patent Document 16), rheumatic fever, fibromyalgia, neuralgia (e.g., see Non-Patent Document 17), complex regional pain syndrome, fascial dysfunction, viral infections such as influenza, common cold, zoster and AIDS, bacterial infection, mycosis, burn (e.g., see Non-Patent Document 18), inflammation and pain after operation, injury and dental extraction, malignant tumors such as colon cancer, breast cancer, lung cancer, prostatic cancer, etc. (e.g., see Non-Patent Document 19, Non-Patent Document 20, and Non-Patent Document 21), atherosclerosis (e.g., see Non-Patent Document 22), stroke (e.g., see Non-Patent Document 23), gout, arthritis, osteoarthritis (e.g., see Non-Patent Document 24 and Non-Patent Document 25), juvenile arthritis, ankylosing spondylitis, tenosynovitis, ligament ossification, systemic lupus erythematosus, vasculitis, pancreatitis, nephritis (e.g., see Non-Patent Document 26), conjunctivitis, iritis, scleritis, uveitis, wound therapy, dermatitis, eczema, osteoporosis, asthma (e.g., see Non-Patent Document 27), chronic obstructive pulmonary disease (e.g., see Non-Patent Document 28), pulmonary fibrosis (e.g., see Non-Patent Document 29), allergic disease (e.g., see Non-Patent Document 30), familial adenomatous polyposis (e.g., see Non-Patent Document 31), scleroderma (e.g., see Non-Patent Document 32), bursitis, leiomyoma of uterus, prostatitis, and a pain from cancer.

When administered as a pharmaceutical, a compound of the invention or a pharmaceutically acceptable salt thereof is administered as it is or as a pharmaceutical composition containing, for example, 0.001% to 99.5%, preferably 0.1% to 90%, in a pharmaceutically acceptable non-toxic and inactive carrier to a mammal including human.

In the pharmaceutical composition, a diluent in the form of a solid, a semi-solid or a liquid, a bulking agent, and one or more of other formulation additives can be used as a carrier.

Preferably, the pharmaceutical composition of the invention is administered in a unit dosage from. The pharmaceutical composition may be administered by intra-tissue administration, oral administration, intravenous administration, local administration such as dermal administration, ocular instillation, intraperitoneal administration, intrathoracic administration, etc., or transrectal administration. Of course, the composition should be administered in a dosage form suitable for these administration routes.

The dosage as a medicament should be adjusted preferably in consideration of conditions of the patient such as age, body weight, nature and severity of the disease, route of administration, the compound of the invention to be administered, whether such compound is a salt or not, and the kind of such salt. For oral administration, a daily dosage of the compound of the invention or a pharmaceutically acceptable salt thereof as an active ingredient for adult is generally within the range from 0.01 mg to 5 g, preferably 1 mg to 500 mg for adult human. However, a lower dosage under said range may be sufficient in some cases, or a higher dosage over the said range may be needed in other cases. Generally, a daily dosage is administered once in a day or may be administered in several divisions in a day. Alternatively, a daily dosage can be administered intravenously by prompt administration or continuous infusion over 24 hours.

[Example] Although the present invention is further described in detail in the following Reference Examples, Examples, Test Examples and Formulation Examples, present invention is not limited thereto.

The measurement conditions for high-performance liquid chromatography mass spectrometer; LCMS are as follows.

Analytical instrument: ACUITY UPLC MS/PDA System (Waters) Mass spectrometer: Waters 3100 MS detector Photodiode array detector: ACUITY PDA detector (210-400 nm) Column: Acuity BEH C , 1.7 μm, 2.1x50mm Flow rate: 0.5 mL/min Column temperature:40°C Solvent: A liquid: 0.1% formic acid/H O (v/v) B liquid: 0.1% formic acid / acetonitrile (v/v) Gradient condition: Method A: 0.0-2.5min; %A liquid / %B liquid = 90/10 → 10/90 2.5-3.0min; %A liquid / %B liquid = 10/90 3.0-3.5min; %A liquid / %B liquid = 0/100 Method B: 0.0-2.5min; %A liquid / %B liquid = 50/50 → 10/90 2.5-3.0min; %A liquid / %B liquid = 10/90 3.0-3.5min; %A liquid / %B liquid = 0/100 The values [MS(m/z)] (MS: mass spectrometry) observed in the mass spectrometry are expressed in m/z, and the retention times are expressed in Rt (minute).

Reference Example 1 2-Chloro(ethoxymethyl)benzoic acid The mixture of methyl 5-(bromomethyl)chlorobenzoate (prepared as described in WO2010/132999) (0.2g), potassium carbonate (0.21g), EtOH (3 mL) and THF (3 mL) was stirred at 80°C for 4 hours. The reaction mixture was cooled to room temperature, water was then added, and the mixture was extracted with ethyl acetate. The organic layer was separated and washed with brine, and dried over magnesium sulfate and concentrated in vacuo. The residue was purified on column chromatography to obatin ethyl 2-chloro(ethoxymethyl)benzoate (0.15g).

This was dissolved in THF-MeOH-H O (3:3:2, 8 mL), and lithium hydroxide hydrate (0.15g) was added, and the mixture was stirred at room temperature for 14 hours. The reaction mixture was acidified with 1N hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, and concentrated in vacuo to obtain the titled compound (0.12g) as pale yellow oil.

Reference Example 2 2-Chloro[(2-ethoxyethoxy)methyl]benzoic acid The titled compound was obtained according to the procedure as described in Reference Example 1, using 2-ethoxyethanol instead of EtOH.

Reference Example 3 2-Chloro(cyclopropylethynyl)benzoic acid To a solution of ethyl 5-bromochlorobenzoate(1.9g) in DMF (12 mL), toluene (0.3 mL), cyclopropylacetylene (714 mg), copper iodide (275 mg), dichloro bis(triphenylphosphine)palladium (1.01g) and triethylamine (20.1 mL) were added, and the mixture was degassed, stirred at 100°C under argon atmosphere for 8 hours later, and then the reaction mixture was cooled to room temperature and diluted with ethyl acetate. The insoluble material was filtered off on celite. The mother liquor was washed with brine, dried over magnesium sulfate and concentrated. By purification on column chromatography, ethyl 2-chloro(cyclopropylethynyl)benzoate (1.86g) was obtained as brown oil.

This was dissolved in MeOH-THF (1:1, 60 mL), 10% aqueous sodium hydroxide solution (20 mL) was added, and the solution was stirred at room temperature for 2 hours. The solvent was removed under reduced pressure, water was added to the residue, and the mixture was separated with diethyl ether.

The aqueous layer was separated, acidified with 1N hydrochloric acid and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and concentrated in vacuo. The residual solid was washed with n-hexane, and the titled compound (1.02g) was obtained as beige powder.

Reference Example 4 2-Chloro(2-cyclopropylethyl)benzoic acid To a solution of 2-chloro(cyclopropylethynyl)benzoic acid (200 mg) in ethyl acetate (20 mL) was added 10% palladium on carbon (40 mg), and the mixture was stirred under hydrogen atmosphere (0.2MPa)), for 14 hours later, then was filtered off on celite, and the mother liquor was concentrated in vacuo.

The residue was purified on silica gel column chromatography to obtain the titled compound (190 mg) as yellow oil.

Reference Example 5 2-Chloro(2-phenylethyl)benzoic acid [Step 1] 2-chloro(phenylethynyl)benzoic acid According to the procedure as described in Reference Example 3 using phenylacetylene instead of cyclopropylacetylene, 2-chloro(phenylethynyl)benzoic acid was obtained as yellow powder.

[Step 2] 2-Chloro(2-phenylethyl)benzoic acid The titled compound was obtained as pale yellow powder, according to the procedure as described in Reference Example 4, using 2-chloro(phenylethynyl)benzoic acid instead of 2-chloro(cyclopropylethynyl)benzoic acid.

Reference Example 6 -(3-tert-Butoxypropynyl)chlorobenzoic acid The titled compound was obtained as white powder according to the procedure as described in Reference Example 3, using tert-butylpropargyl ether was used instead of cyclopropylacetylene.

Reference Example 7 -(3-tert-Butoxypropyl)chlorobenzoic acid The titled compound was obtained as a pale yellow oil according to the procedure as described in Reference Example 4, using 5-(3-tert-butoxypropynyl)chlorobenzoic acid instead of 2-chloro(cyclopropylethynyl)benzoic acid.

Reference Example 8 2-Chloro(3-hydroxymethylbutyl)benzoic acid [Step 1] 2-Chloro(3-hydroxymethylbutynyl)benzoic acid The titled compound was obtained as white powder according to the procedure as described in Reference Example 3, using 2-methylbutynol instead of cyclopropylacetylene.

[Step 2] 2-Chloro(3-hydroxymethylbutyl)benzoic acid The titled compound was obtained as a pale yellow oil according to the procedure as described in Reference Example 4, using 2-chloro(3-hydroxymethylbutynyl)benzoic acid instead of 2-chloro(cyclopropylethynyl)benzoic acid.

Reference Example 9 3-Methoxy-N,2,2-trimethylpropanamine [Step 1] tert-Butyl (3-hydroxy-2,2-dimethylpropyl) carbamate A solution of 3-amino-2,2-dimethylpropanol (6.98g) and sodium carbonate (7.18g) in 1,4-dioxane-H O (1:1, 240 mL) was stirred under ice-cooling, and di-tert-butyl dicarbonate (14.77g) was added, and the mixture was stirred for 5 hours.

Ethyl acetate was added, and the organic layer was separated, washed sequentially with water and brine, dried over magnesium sulfate and concentrated in vacuo to obtain the titled compound (12.7g) as a colorless solid.

[Step 2] 3-Methoxy-N,2,2-trimethylpropanamine A solution of 60% sodium hydride (1.89g) in DMF (60 mL) was stirred under ice-cooling, a solution of tert-butyl (3-hydroxy-2,2-dimethylpropyl) carbamate (3.84g) in DMF (45 mL) was dropped slowly over 5 minutes. Methyl iodide (10.73g) was added and the mixture was stirred at room temperature for 3 hours. Diethyl ether was added to the reaction mixture. The organic layer was separated, washed sequentially with water and brine, dried over magnesium sulfate and concentrated in vacuo.

The residue was purified on column chromatography to obtain tert-butyl (3-methoxy-2,2-dimethylpropyl)methyl carbamate (3.1g) as a colorless oil. This was stirred under ice-cooling, TFA (8 mL) was added, and the mixture was stirred at room temperature for 1 hour later. The mixture was stirred under ice-cooling, and raised the pH to about pH 9 with 1N aqueous sodium hydroxide solution, and extracted with diethyl ether.

The diethyl ether layer was dried and concentrated in vacuo with magnesium sulfate to obtain the titled compound (2.6g) as pale yellow oil.

Reference Example 10 -Butoxychlorobenzoic acid To a solution of 2-chlorofluorobenzoic acid (50 mg) and 1-butanol (263 μL) in THF (0.5 mL) and DMF (3 mL) was added potassium t-butoxide (329 mg) and the solution was reacted at 120°C for 10 minutes in a microwave synthesizer (Biotage, Initiator). The reaction mixture was cooled and acidified by addition of water and 2M hydrochloric acid, extracted with diethyl ether, dried over anhydrous sodium sulfate. The solvent was removed in vacuo, and the residue was purified on column chromatography to obtain the titled compound (17 mg) as white powder.

Reference Example 11 2-Chloro(2,2-difluoroethoxy)benzoic acid [Step 1] Methyl 2-chloro(2,2-difluoroethoxy)benzoate To a suspension of methyl 2-chlorohydroxybenzoate (50 mg) and potassium carbonate (111 mg) in acetone (1 mL) was added 2-iodo-1,1-difluoroethane (35 μL), and the suspension was reacted at 120°C for 10 minutes in a microwave synthesizer (Biotage, Initiator). After reaction at 130°C for additional minutes, the reaction mixture was directly purified on silica gel column chromatography to obtain the titled compound (55 mg) as yellow oil.

[Step 2] 2-Chloro(2,2-difluoroethoxy)benzoic acid To a solution of methyl 2-chloro(2,2-difluoroethoxy)benzoate (55 mg) in MeOH (1 mL) was added 1M aqueous lithium hydroxide (0.88 mL), and the solution was stirred at room temperature for 12 hours. The reaction mixture was stirred under ice-cooling, 2M hydrochloric acid was added slowly to acidify to pH 2-3, and the precipitation solid was filtered. The solid was washed sequentially with a small amount of water and diethyl ether, dried under reduced pressure to obtain the titled compound (28 mg) as white powder.

Reference Example 12 2-Chloro(4,4,4-trifluorobutoxy)benzoic acid [Step 1] Methyl 2-chloro(4,4,4-trifluorobutoxy)benzoate To a suspension of methyl 2-chlorohydroxy benzoate (50 mg) and potassium carbonate (111 mg) in acetone (1 mL) was added 1-bromo-4,4,4-trifluorobutane (50 μL) and the suspension was reacted at 120°C for 10 minutes in a microwave synthesizer (Biotage, Initiator). The reaction mixture was directly purified on silica gel column chromatography to obtain the titled compound (74 mg) as colorless oil.

[Step 2] 2-Chloro(4,4,4-trifluorobutoxy)benzoic acid To a solution of methyl 2-chloro(4,4,4-trifluorobutoxy)benzoate (74 mg) in MeOH (1 mL) was added 1M aqueous lithium hydroxide solution (0.99 mL) and the reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was stirred under ice-cooling, and 2M hydrochloric acid was added slowly to acidify to pH 2-3.

The precipitated solid was filtered, washed with water, and dried under reduced pressure to obtain the titled compound (49 mg) as a colorless powder.

Example 1 N-[2-(Trifluoromethyl)benzyl]({[2-(trifluoromethyl)pheny l]carbonyl}amino)-1H-benzimidazolcarboxamide [Step 1] Methyl 1H-benzimidazolecarboxylate To a suspension of methyl 2-aminonitrobenzoate (1.0 g) in formic acid (> 87%) was added 5% palladium on carbon (100 mg) and the suspension was heated with stirring at 100°C for 23 hours. After the reaction mixture was cooled to room temperature, the catalyst was filtered off on celite, and the mother liquor was concentrated in vacuo. The residual solid was washed with diethyl ether under stirring, the solid was collected by filtration to obtain the titled compound (872 mg) as a colorless powder.

[Step 2] Methyl 6-nitro-1H-benzimidazolecarboxylate Methyl 1H-benzimidazolecarboxylate (315 mg) was dissolved in conc. sulfuric acid (3 mL), and the solution was stirred on ice bath. A small amount of potassium nitrate (199 mg) was added portion-wise, the solution was stirred at room temperature for 4 hours. The reaction mixture was poured into ice, alkalified with 3N aqueous sodium hydroxide solution under stirring on ice bath, and extracted with ethyl acetate. The ethyl acetate layer was washed sequentially with water and brine, dried over anhydrous magnesium sulfate. The titled compound (334 mg) was obtained as colorless powder after distilling off a solvent under reduced pressure.

[Step 3] Methyl 6-amino-1H-benzimidazolecarboxylate Methyl 6-nitro-1H-benzimidazolecarboxylate (304 mg) was suspended in MeOH (10 mL), the suspension was added with % palladium on carbon (30 mg), and stirred under hydrogen (1 atm) atmosphere. The catalyst was filtered off on celite and washed with MeOH, and the mother liquor was concentrated in vacuo to obtain the titled compound (269 mg) as pale yellow powder.

MS(ESI+) m/z 192(M+H) [Step 4] methyl 6-({[2-(Trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimida zolecarboxylate To a solution of methyl 6-amino-1H-benzimidazolecarboxylate (266 mg) in dehydrated THF (12 mL), N,N-diisopropylethylamine (284 μL) was added, and the solution was stirred under ice-cooling. To this solution, 2-(trifluoromethyl)benzoyl chloride (284 μL) in dehydrated THF (5 mL) was added slowly dropwise, and stirred at the same temperature for 3 hours. After ice water was added, THF was removed under reduced pressure, and aqueous saturated sodium bicarbonate was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The residue was purified on NH silica gel column chromatography (ethyl acetate -> ethyl acetate/MeOH) to obtain the titled compound (309 mg) as pale yellow powder.

[Step 5] 6-({[2-(Trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimida zolecarboxylic acid Methyl 6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimida zolecarboxylate (356 mg) was dissolved in MeOH (10 mL), and 1N aqueous sodium hydroxide solution (2 mL) was added, and the reaction mixture was stirred at room temperature overnight.

After MeOH was removed under reduced pressure, water was added to the residue, and the solution was acidified with 1N hydrochloric acid to pH 5 under ice-cooling. The precipitate was collected by filtration to obtain the titled compound (276 mg) as slightly brown powder.

[Step 6] N-[2-(Trifluoromethyl)benzyl]({[2-(trifluoromethyl)pheny l]carbonyl}amino)-1H-benzimidazolecarboxamide To a solution of 6-({[2-(Trifluoromethyl)phenyl]carbonyl}amino-1H-benzimidaz olecarboxylic acid (50 mg) in DMF (2 mL) were added N'-(ethylcarbonimidoyl)-N,N-dimethyl-1,3-propanediamine hydrochloride (33 mg), 1-hydroxybenzotriazol (23 mg) and triethylamine (24 μL), and 2-(trifluoromethyl)benzylamine (24 μL) was added under ice-cooling, and the solution was stirred at room temperature overnight. The mixture was poured into ice water and extracted with ethyl acetate. The ethyl acetate layer was washed sequentially with water and brine, dried over anhydrous magnesium sulfate, and removed the solvent under reduced pressure. The residue was washed with n-hexane/ethyl acetate (1:1), and collected by filtration to obtain the titled compound (61 mg) as colorless powder. MS(ESI+)m/z 507(M+H) Example 2 N-Cyclohexyl({[2-(trifluoromethyl)phenyl]carbonyl}amino) -1H-benzimidazolecarboxamide The titled compound was obtained as colorless powder according to the procedure as described in Step 6 of Example 1 using cyclohexylamine instead of 2-(trifluoromethyl)benzylamine. MS(ESI+)m/z 431(M+H) Example 3 N-(3-Chloromethylphenyl)({[2-(trifluoromethyl)phenyl] carbonyl}amino)-1H-benzimidazolecarboxamide To a solution of 6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimida zolecarboxylic acid (example 1, Step 5) (40 mg) in DMF (2 mL), HBTU (53 mg), triethylamine (20 μL) were added. Under ice-cooling, 3-chloromethylaniline (17 μL) was added and the solution was stirred at room temperature for 24 hours.

The reaction mixture was poured into ice water, extracted with ethyl acetate. The ethyl acetate layer was washed sequentially with water and brine, dried over anhydrous magnesium sulfate and removed the solvent under reduced pressure.

The residue was washed with n-hexane/ethyl acetate (1:1) and collected by filtration to obtain the titled compound (33 mg) as colorless powder. MS(ESI+)m/z 473(M+H) Example 5 N-[(1-Hydroxycyclohexyl)methyl]({[2-(trifluoromethyl)phe nyl]carbonyl}amino)-1H-benzimidazolecarboxamide The titled compound was obtained as colorless powder according to the procedure as described in Step 6 of Example 1, using 1-aminomethylcyclohexanol instead of 2-(trifluoromethyl)benzylamine. MS(ESI+)m/z 461(M+H) Example 6 N-[2-(Trifluoromethyl)benzyl]({[2-(trifluoromethyl)pheny l]carbonyl}amino)-2,3-dihydrobenzofurancarboxamide) [Step 1] Ethyl 5-bromo-2,3-dihydrobenzofurancarboxylate To a solution of -bromo-2,3-dihydrobenzofurancarboxylic acid (1.0g) in EtOH (15 mL), sulfuric acid (0.5 mL) was added, and the solution was heated at reflux for 30 hours. The reaction mixture was cooled to room temperature, and EtOH was removed. The residue was added with water, and the solution was extracted with ethyl acetate. The ethyl acetate layer was washed sequentially with saturated aqueous sodium bicarbonate and brine, dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure to obtain the titled compound (1.07g) as pale yellow powder.

[Step 2] Ethyl -({[2-(Trifluoromethyl)phenyl]carbonyl}amino)-2,3-dihydro- 1-benzofurancarboxylate 1,4-dioxane (20 ml) was added to ethyl -bromo-2,3-dihydrobenzofurancarboxylate (600 mg), 2-(trifluoromethyl)benzamide (501 mg), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos) (96 mg), cesium carbonate (1.01g) and tris(dibenzylideneacetone)dipalladium (114 mg). After degassing, the mixture was stirred at 100°C under argon atmosphere for 24 hours. The reaction mixture was filtered off on celite, the solvent was removed under reduced pressure. The resultant residue was purified on silica gel column chromatography to obtain the titled compound (220 mg) as slightly yellow powder.

[Step 3] -({[2-(Trifluoromethyl)phenyl]carbonyl}amino)-2,3-dihydro- 1-benzofurancarboxylic acid To a suspension of ethyl -({[2-(trifluoromethyl)phenyl]carbonyl}amino)-2,3-dihydro- 1-benzofurancarboxylate (220 mg) obtained in Step 2 in EtOH (5 mL), 1N aqueous sodium hydroxide solution (1 mL) was added and the mixture was stirred at 80°C for 4 hours. The reaction mixture was cooled to room temperature, and EtOH was removed under reduced pressure. The residue was added with water, and acidified to pH 3 with 1N hydrochloric acid under ice-cooling and extracted with ethyl acetate. The organic layer was washed sequentially with water and brine, dried over anhydrous magnesium sulfate, and removed the solvent under reduced pressure to obtain the titled compound (195 mg) as slightly yellow powder.

[Step 4] N-[2-(Trifluoromethyl)benzyl]({[2-(trifluoromethyl)pheny l]carbonyl}amino)-2,3-dihydrobenzofurancarboxamide To a solution of -({[2-(trifluoromethyl)phenyl]carbonyl}amino)-2,3-dihydro- 1-benzofurancarboxylic acid (35 mg) in DMF (2 mL), N'-(ethylcarbonimidoyl)-N,N-dimethyl-1,3-propanediamine hydrochloride (23 mg), 1-hydroxybenzotriazol (23 mg) and triethylamine (17 μL) were added. Under ice-cooling, The mixture was added 2-(trifluoromethyl)benzylamine (15 μL), and stirred at room temperature overnight. The reaction mixture was poured into ice water, and extracted with ethyl acetate.

The ethyl acetate layer was washed sequentially with water and brine, dried over anhydrous magnesium sulfate and removed the solvent under reduced pressure. The residue was washed with n-hexane/ethyl acetate (1:1) and collected by filtration to obtain the titled compound (43 mg) as colorless powder.

MS(ESI+) m/z 509 (M+H) , Rt = 2.31 minutes (method A) Example 7 N-Cyclohexyl({[2-(trifluoromethyl)phenyl]carbonyl}amino) -2,3-dihydrobenzofurancarboxamide The titled compound was obtained as colorless powder according to the procedure as described in Step 4 of Example 6 using cyclohexylamine instead of 2-(trifluoromethyl)benzylamine.

MS(ESI+) m/z 433 (M+H) , Rt= 2.25 minutes (method A) Example 8 N-(3-Chloromethylphenyl)({[2-(trifluoromethyl)phenyl] carbonyl}amino)-2,3-dihydrobenzofurancarboxamide The titled compound was obtained as colorless powder according to the procedure as described in Example 3, using -({[2-(trifluoromethyl)phenyl]carbonyl}amino)-2,3-dihydro- 1-benzofurancarboxylic acid instead of 6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimida zolecarboxylic acid. MS(ESI+) m/z 475 (M+H) , Rt= 2.47 minutes (method A) Example 9 N-Cyclohexyl({[2-(trifluoromethyl)phenyl]carbonyl}amino) -1H-indazolecarboxamide [Step 1] Methyl -bromo{[2-(trimethylsilyl)ethoxy]methyl}-1H-indazole carboxylate Under argon atmosphere, a solution of methyl -bromo-1H-indazolecarboxylate (as prepared according to WO2008/65508) (658 mg) in DMF (20 mL) was stirred under ice-cooling. 60% Sodium hydride (124 mg) was added slowly, and the mixture was stirred for 30 minutes at same temperature. 2-(Trimethylsilyl)ethoxymethyl chloride (544 μL) was added dropwise slowly using a syringe, and the mixture was stirred at room temperature for 4 hours. The mixture was poured into ice water and extracted with ethyl acetate. The ethyl acetate layer was washed sequentially with water and brine, dried over anhydrous magnesium sulfate, and removed the solvent under reduced pressure. The residue was purified on silica gel column chromatography to obtain the titled compound (696 mg) as slightly yellow oil.

[Step 2] Methyl -{[(benzyloxy)carbonyl]amino}{[2-(trimethylsilyl)ethoxy ]methyl}-1H-indazolecarboxylate The titled compound was obtained as slightly yellow oil from methyl -bromo{[2-(trimethylsilyl)ethoxy]methyl}-1H-indazole carboxylate prepared in Step 1, according to the procedure as described in Step 2 of Example 6, using benzyl carbamate instead of 2-(trifluoromethyl)benzamide.

[Step 3] Methyl -amino{[2-(trimethylsilyl)ethoxy]methyl}-1H-indazole carboxylate To a solution of methyl -{[(benzyloxy)carbonyl]amino}{[2-(trimethylsilyl)ethoxy ]methyl}-1H-indazolecarboxylate (364 mg) in MeOH (10 mL) was added 5% palladium on carbon (55 mg), and the reaction mixture was stirred overnight under hydrogen atmosphere at an ordinary pressure. The reaction mixture was filtered off on celite and washed with MeOH. The mother liquor was concentrated under reduced pressure to obtain the titled compound (234 mg) as green powder.

[Step 4] Methyl -({[2-(trifluoromethyl)phenyl]carbonyl}amino){[2-(trime thylsilyl)ethoxy]methyl}-1H-indazolecarboxylate The titled compound (323 mg) was obtained as colorless powder according to the procedure as described in Step 4 of Example 1, using methyl -amino{[2-(trimethylsilyl)ethoxy]methyl}-1H-indazole carboxylate (231 mg).

[Step 5] -({[2-(Trifluoromethyl)phenyl]carbonyl}amino){[2-(trime thylsilyl)ethoxy]methyl}-1H-indazolecarboxylic acid The titled compound (291 mg) was obtained as colorless powder according to the procedure as described in Step 5 of Example 1, using methyl -({[2-(trifluoromethyl)phenyl]carbonyl}amino){[2-(trime thylsilyl)ethoxy]methyl}-1H-indazolecarboxylate (321 mg).

[Step 6] N-Cyclohexyl({[2-(trifluoromethyl)phenyl]carbonyl}amino) -1H-indazolecarboxamide To a solution of -({[2-(trifluoromethyl)phenyl]carbonyl}amino){[2-(trime thylsilyl)ethoxy]methyl}-1H-indazolecarboxylic acid (obtained in Step 5) (48 mg) in DMF (2 mL) were added HBTU (46 mg) and triethylamine (17 μL), and the mixture was stirred at room temperature, and added with cyclohexylamine (12.5 μL) and stirred at same temperature overnight. The reaction mixture was poured into ice water, extracted with ethyl acetate. The ethyl acetate layer was washed sequentially with saturated aqueous sodium bicarbonate and brine, dried over anhydrous magnesium sulfate, and removed the solvent under reduced pressure. The residue is triturated in n-hexane/ethyl acetate (10:1), and collected by filtration to obtain 59 mg of N-cyclohexyl({[2-(trifluoromethyl)phenyl]carbonyl}amino) [2-(trimethylsilyl)ethoxymethyl]-indazolecarboxamide as colorless powder. This was dissolved in MeOH (2 mL), 6N hydrochloric acid (2 mL) was added, and the solution was stirred on oil bath at 60-80°C for 10 hours. The solvent was removed, and ice water was added to the residue. The precipitate was collected by filtration and dried to obtain the titled compound (33 mg) as colorless powder.

MS(ESI+) m/z 431 (M+H) , Rt= 1.91 minutes (method A) Elemental Analysis for C H F N O +0.1H O 22 21 3 4 2 2 Calcd.(%) C:61.13 H:4.94 N:12.96 Found.(%) C:60.93 H:4.91 N:12.71 Example 10 N-[2-(Trifluoromethyl)benzyl]({[2-(trifluoromethyl)pheny l]carbonyl}amino)-1H-indazolecarboxamide The titled compound was obtained as colorless powder according to the procedure as described in Step 6 of Example 9, using 2-(trifluoromethyl)benzylamine instead of cyclohexylamine.

MS(ESI+) m/z 507 (M+H) , Rt= 2.05 minutes (method A) Example 11 N-(3-Chloromethylphenyl)(methoxymethyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide hydrochloride [Step 1] Methyl 2-amino[(methoxyacetyl)amino]benzoate To a solution of methyl 2,3-diaminobenzoate (3.0g) in THF (50 mL) was added N,N-diisopropylethylamine (4.0 mL). The solution was stirred under ice-cooling, and added with methoxyacetyl chloride (1.81 mL) in THF (10 mL) dropwise slowly and stirred for 3 hours at same temperature. The reaction mixture was added with saturated aqueous sodium bicarbonate, and removed THF under reduced pressure. The residue was added with saturated aqueous sodium bicarbonate, and extracted with ethyl acetate, dried over anhydrous magnesium sulfate, and removed the solvent under reduced pressure. The residue was purified on silica gel column chromatography to obtain the titled compound (3.60g) as pale yellow powder.

[Step 2] Methyl 2-(methoxymethyl)-1H-benzimidazolecarboxylate Methyl 2-amino[(methoxyacetyl)amino]benzoate (280 mg) was dissolved in acetic acid (6 mL), and the solution was heated at 100°C for 0.5 hour with stirring. After cooling the reaction mixture to room temperature, acetic acid was removed.

The residue was added with saturated aqueous sodium bicarbonate under ice-cooling, and extracted with ethyl acetate. The organic layer was washed sequentially with water and brine, dried over anhydrous magnesium sulfate and removed the solvent under reduced pressure to obtain the titled compound (241 mg) as pale yellow powder.

[Step 3] Methyl 2-(methoxymethyl)nitro-1H-benzimidazolecarboxylate The titled compound (274 mg) was obtained as colorless powder according to the procedure as described in Step 2 of Example 1, using methyl 2-(methoxymethyl)-1H-benzimidazolecarboxylate (240 mg) instead of methyl 1H-benzimidazolecarboxylate.

[Step 4] Methyl 6-amino(methoxymethyl)-1H-benzimidazolecarboxylate The titled compound (202 mg) was obtained as yellow powder according to the procedure as described in Step 3 of Example 1, using methyl 2-(methoxymethyl)nitro-1H-benzimidazolecarboxylate (271 mg) instead of methyl 6-nitro-1H-benzimidazolecarboxylate.

[Step 5] Methyl 2-(methoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxylate The titled compound (281 mg) was obtained as colorless powder according to the procedure as described in Step 4 of Example 1, using methyl 6-amino(methoxymethyl)-1H-benzimidazolecarboxylate (200 mg) instead of methyl 6-amino-1H-benzimidazolecarboxylate.

[Step 6] 2-(Methoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxylic acid The titled compound (263 mg) was obtained as colorless powder according to the procedure as described in Step 5 of Example 1, using methyl 2-(methoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxylate (278 mg) instead of methyl 6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimida zolecarboxylate.

[Step 7] N-(3-Chloromethylphenyl)(methoxymethyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide To a solution of 2-(methoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxylic acid (153 mg) in DMF (5 mL), were added HBTU (178 mg) and triethylamine (65 μL). The mixture was added with 3-chloromethylaniline (56 μL) under stirring at room temperature, and the mixture was stirred overnight. The reaction mixture was poured into saturated aqueous sodium bicarbonate, extracted with ethyl acetate. The ethyl acetate layer was washed sequentially with water and brine, dried over anhydrous magnesium sulfate, and removed the solvent under reduced pressure. The residue was purified on silica gel column chromatography to obtain N-(3-chloromethylphenyl)(methoxymethyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide (165 mg) as colorless powder.

[Step 8] N-(3-Chloromethylphenyl)(methoxymethyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide hydrochloride N-(3-chloromethylphenyl)(methoxymethyl)({[2- (trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide (165 mg) obtained in Step 7 was suspended in EtOH (3 mL). The suspension was added with 1M hydrochloric acid (0.32 mL) and stirred to obtain a homogeneous solution, and removed the solvent under reduced pressure. The residue was triturated in ethyl acetate, collected by filtration, and dried to obtain the titled compound (167 mg) as colorless powder.

MS(ESI+) m/z 517 (M+H) , Rt= 2.41 minutes (method A) Elemental Analysis for C H ClF N O •HCl+1.0H O 20 3 4 3 2 Calcd. (%) C:52.55 H:4.06 N:9.81 Found. (%) C:52.35 H:3.96 N:9.89 Example 12 2-Methyl-N-[2-(trifluoromethyl)benzyl]({[2-(trifluoromet hyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 11, using acetyl chloride instead of methoxyacetyl chloride, and 2-(trifluoromethyl)benzylamine instead of 3-chloromethyl-aniline.

MS(ESI+) m/z 521 (M+H) , Rt= 1.74 minutes (method A) Elemental Analysis for C H F N O •HCl+1.5H O 18 6 4 2 2 Calcd.(%) C:51.42 H:3.80 N:9.60 Found.(%) C:51.68 H:3.81 N:9.45 Example 13 N-Cyclohexylmethyl({[2-(trifluoromethyl)phenyl]carbon yl}amino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 11, using acetyl chloride instead of methoxyacetyl chloride, cyclohexylamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 445 (M+H) , Rt= 1.52 minutes (method A) Example 14 N-(3-Chloromethylphenyl)methyl({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 11, using acetyl chloride instead of methoxyacetyl chloride.

MS(ESI+) m/z 487 (M+H) , Rt= 2.10 minutes (method A) Example 15 N-Cyclopentylmethyl({[2-(trifluoromethyl)phenyl]carbo nyl}amino)-1H-benzimidazolecarboxamide The titled compound was obtained as colorless powder according to the procedure as described in Step 1 to Step 7 of Example 11, using acetyl chloride instead of methoxyacetyl chloride, and cyclopentylamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 431 (M+H) , Rt= 1.39 minutes (method A) Example 16 N-Cyclobutylmethyl({[2-(trifluoromethyl)phenyl]carbon yl}amino)-1H-benzimidazolecarboxamide The titled compound was obtained as colorless powder according to the procedure as described in Step 1 to Step 7 of Example 11, using acetyl chloride instead of methoxyacetyl chloride, and cyclobutylamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 417 (M+H) , Rt= 1.29 minutes (method A) Example 17 N-(3-Chloromethylphenyl)ethyl({[2-(trifluoromethyl )phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide The titled compound was obtained as white powder according to the procedure as described in Step 1 to Step 7 of Example 11, using propionyl chloride instead of methoxyacetyl chloride.

MS(ESI+) m/z 501 (M+H) , Rt= 2.39 minutes (method A) Example 18 N-Cyclohexylethyl({[2-(trifluoromethyl)phenyl]carbony l}amino)-1H-benzimidazolecarboxamide The titled compound was obtained as colorless powder according to the procedure as described in Step 1 to Step 7 of Example 11, using propionyl chloride instead of methoxyacetyl chloride, and cyclohexylamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 459 (M+H) , Rt= 1.75 minutes (method A) Example 19 2-Ethyl-N-[2-(trifluoromethyl)benzyl]({[2-(trifluorometh yl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide The titled compound was obtained as colorless powder according to the procedure as described in Step 1 to Step 7 of Example 11, using propionyl chloride instead of methoxyacetyl chloride, and 2-(trifluoromethyl)benzylamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 535 (M+H) , Rt= 1.96 minutes (method A) Example 20 N-Cyclohexyl(methoxymethyl)({[2-(trifluoromethyl)phen yl]carbonyl}amino)-1H-benzimidazolecarboxamide The titled compound was obtained as colorless powder according to the procedure as described in Step 1 to Step 7 of Example 11, using cyclohexylamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 475 (M+H) , Rt= 1.97 minutes (method A) Example 21 2-(Methoxymethyl)-N-[2-(trifluoromethyl)benzyl]({[2-(tri fluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarb oxamide The titled compound was obtained as colorless powder according to the procedure as described in Step 1 to Step 7 of Example 11, using 2-(trifluoromethyl)benzylamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 551 (M+H) , Rt= 2.12 minutes (method A) Example 22 2-(Methoxymethyl)-N-(2-methylphenyl)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using ortho-toluidine instead of 3-chloromethylaniline.

MS(ESI+) m/z 483 (M+H) , Rt= 1.06 minutes (method B) Example 23 2-(Methoxymethyl)-N-(4-methylphenyl)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using para-toluidine instead of 3-chloromethylaniline.

MS(ESI+) m/z 483 (M+H) , Rt= 1.06 minutes (method B) Example 24 N-(2-Chlorobenzyl)(methoxymethyl)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 11, using 2-chlorobenzylamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 517 (M+H) , Rt= 2.04 minutes (method A) Example 25 2-(Methoxymethyl)-N-(4-methylbenzyl)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using 4-methylbenzylamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 497 (M+H) , Rt= 1.99 minutes (method A) Example 26 N-(4,4-Difluorocyclohexyl)(methoxymethyl)({[2-(triflu oromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxa mide hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using 4,4-difluorocyclohexylamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 511 (M+H) , Rt= 1.88 minutes (method A) Example 27 N-(4-tert-Buthylphenyl)(methoxymethyl)({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamid e hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using 4-tert-butylaniline instead of 3-chloromethylaniline.

MS(ESI+) m/z 525 (M+H) , Rt= 1.63 minutes (method B) Example 28 2-(Methoxymethyl)-N-[4-(trifluoromethyl)phenyl]({[2-(tri fluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarb oxamide hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using 1-amino(trifluoromethyl)benzene instead of 3-chloromethylaniline.

MS(ESI+) m/z 537 (M+H) , Rt= 1.39 minutes (method B) Example 29 N-(2,4-Dimethylphenyl)(methoxymethyl)({[2-(trifluorom ethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using 2,4-dimethylaniline instead of 3-chloromethylaniline.

MS(ESI+) m/z497 (M+H) , Rt= 1.24 minutes (method B) Example 30 N-(2-Chloromethylphenyl)(methoxymethyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using 2-chloromethylaniline instead of 3-chloromethylaniline.

MS(ESI+) m/z 517 (M+H) , Rt= 1.42 minutes (method B) Example 31 N-(3,4-Dimethylphenyl)(methoxymethyl)({[2-(trifluorom ethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using 3,4-dimethylaniline instead of 3-chloromethylaniline.

MS(ESI+) m/z 497 (M+H) , Rt= 1.22 minutes (method B) Example 32 N-(3-Chloromethylphenyl)(methoxymethyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using 3-chloromethylaniline instead of 3-chloromethylaniline.

MS(ESI+) m/z 517 (M+H) , Rt= 1.46 minutes (method B) Example 33 N-(2,3-Dihydro-1H-indenyl)(methoxymethyl)({[2-(tri fluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarb oxamide hydrochloride The titled compound was obtained as gray powder according to the procedure as described in Example 11, using 5-aminoindan instead of 3-chloromethylaniline.

MS(ESI+) m/z 509 (M+H) , Rt= 2.36 minutes (method A) Example 34 2-(Methoxymethyl)-N-(5,6,7,8-tetrahydronaphthalenyl)( {[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazol ecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 11, using ,6,7,8-tetrahydronaphthylamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 523 (M+H) , Rt= 2.44 minutes (method A) Example 35 N-(2-Fluorophenyl)(methoxymethyl)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide A stirring solution of 2-(methoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxylic acid in THF (2 mL) was stirred under ice-cooling, addedwith catalytic amount of DMF, and then oxalyl chloride (7.7 μL) was added. One hour later, the reaction mixture was added with additional oxalyl chloride (7.7 μL) and stirred for additional one hour, and removed volatile elements under reduced pressure. The residue was dissolved in THF (2 mL), and 2-fluoroaniline (8.8 μL) and triethylamine (11 μL) were added sequentially, and the mixture was stirred at room temperature for 1 hour and added with saturated aqueous sodium bicarbonate, and extracted with ethyl acetate.

The ethyl acetate layer was washed with brine, dried over anhydrous magnesium sulfate, and concentrated. The residue was triturated in n-hexane/diethyl ether to obtain the titled compound (21 mg) as colorless powder.

MS(ESI+) m/z 487 (M+H) , Rt= 2.14 minutes (method A) Example 36 2-(Methoxymethyl)-N-(2-methoxypheny)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide The titled compound was obtained as colorless powder according to the procedure as described in Step 1 to Step 7 of Example 11, using ortho-anisidine instead of 3-chloromethylaniline.

MS(ESI+) m/z 499 (M+H) , Rt= 2.07 minutes (method A) Example 37 2-(Methoxymethyl)-N-(4-methoxypheny)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide The titled compound was obtained as colorless powder according to the procedure as described in Step 1 to Step 7 of Example 11, using para-anisidine instead of 3-chloromethylaniline.

MS(ESI+) m/z 499 (M+H) , Rt= 1.96 minutes (method A) Example 38 N-(3-Bromomethylphenyl)(methoxymethyl)({[2-(triflu oromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxa mide The titled compound was obtained as colorless powder according to the procedure as described in Step 1 to Step 7 of Example 11, using 3-bromomethylaniline instead of 3-chloromethylaniline.

MS(ESI+) m/z 563 (M+H) , Rt= 2.45 minutes (method A) Example 39 N-(3-Chloromethylbenzyl)(methoxymethyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Step 1 to Step 7 of Example 11, using 3-chloromethylbenzylamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 531 (M+H) , Rt= 2.19 minutes (method A) Example 40 N-(2,6-Difluorophenyl)(methoxymethyl)({[2-(trifluorom ethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide The titled compound was obtained as colorless powder according to the procedure as described in Example 35, using 2,6-difluoroaniline instead of 2-fluoroaniline.

MS(ESI+) m/z 505 (M+H) , Rt= 1.94 minutes (method A) Example 41 N-(3-Cyanomethylphenyl)(methoxymethyl)({[2-(triflu oromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxa mide To a solution of N-(3-bromomethylphenyl)(methoxymethyl)({[2-(triflu oromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxa mide (Example 38) (85 mg) in DMF (0.5 mL), was added zinc cyanide (60% content, 60 mg). After degassing, the mixture was added with tetrakis(triphenylphosphine)palladium (88 mg), and stirred at 100°C for 24 hours. The reaction mixture was added with ice water, and extracted with ethyl acetate. The ethyl acetate layer was washed sequentially with water and brine, dried over anhydrous magnesium sulfate, and removed the solvent under reduced pressure. The residue was purified on preparative thin-layer chromatography to obtain the titled compound (14 mg) as colorless powder.

MS(ESI+) m/z 508 (M+H) , Rt= 1.02 minutes (method B) Example 42 2-(Methoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-N-{[3-(trifluoromethyl)pyridinyl]methyl}-1H-benzim idazolecarboxamide dihydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using 2-(aminomethyl)(trifluoromethyl)pyridine instead of 3-chloromethylaniline.

MS(ESI+) m/z 552 (M+H) , Rt= 1.86 minutes (method A) Example 43 N-(2-Chloromethylphenyl)(methoxymethyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using 2-chloromethylaniline instead of 3-chloromethylaniline.

MS(ESI+) m/z 517 (M+H) , Rt= 2.35 minutes (method A) Example 44 2-(2-Aminooxoethyl)-N-(3-chloromethylphenyl)({[2-( trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolec arboxamide hydrochloride [Step 1] Methyl 2-(2-aminooxoethyl)nitro-1H-benzimidazolecarboxyla Under ice-cooling, potassium nitrate (117 mg) was added slowly portion wise to a stirring solution of methyl 2-(cyanomethyl)-1H-benzimidazolecarboxylate (prepared as described in EP1479681) (226 mg) in conc. sulfuric acid (5 mL), and the mixture was stirred at room temperature for 5 hours.

The reaction mixturewas poured into ice, and alkalified with 3N aqueous sodium hydroxide solution, and extracted with ethyl acetate. The ethyl acetate layer was washed with sequentially with water and brine, dried over anhydrous magnesium sulfate and removed the solvent under reduced pressure. The residue was washed with MeOH, filtered and dried to obtain the titled compound (243 mg).

[Step 2] Methyl 6-amino(2-aminooxoethyl)-1H-benzimidazolecarboxyla The titled compound was obtained as yellow powder according to the procedure as described in Step 4 of Example 11, using methyl 2-(2-aminooxoethyl)nitro-1H-benzimidazolecarboxyla te instead of methyl 2-(methoxymethyl)nitro-1H-benzimidazolecarboxylate.

[Step 3] Methyl 2-(2-aminooxoethyl)({[2-(trifluoromethyl)phenyl]carbo nyl}amino)-1H-benzimidazolecarboxylate The titled compound was obtained as orange powder according to the procedure as described in Step 4 of Example 1, using methyl 6-amino(2-aminooxoethyl)-1H-benzimidazolecarboxyla te instead of methyl 6-amino-1H-benzimidazolecarboxylate.

[Step 4] 2-(2-Aminooxoethyl)({[2-(trifluoromethyl)phenyl]carbo nyl}amino)-1H-benzimidazolecarboxylic acid The titled compound was obtained as brown powder according to the procedure as described in Step 5 of Example 1, using methyl 2-(2-aminooxoethyl)({[2-(trifluoromethyl)phenyl]carbo nyl}amino)-1H-benzimidazolecarboxylate instead of methyl 6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimida zolecarboxylate.

[Step 5] 2-(2-Aminooxoethyl)-N-(3-chloromethylphenyl)({[2-( trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolec arboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Step 7 of Example 11, using 2-(2-aminooxoethyl)({[2-(trifluoromethyl)phenyl]carbo nyl}amino)-1H-benzimidazolecarboxylic acid instead of 2-(methoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxylic acid.

MS(ESI+) m/z 530 (M+H) , Rt= 1.86 minutes (method A) Example 45 2-(2-Aminooxoethyl)-N-[2-(trifluoromethyl)benzyl]({[2 -(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4 -carboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Step 7 of Example 11, using 2-(2-aminooxoethyl)({[2-(trifluoromethyl)phenyl]carbo nyl}amino)-1H-benzimidazolecarboxylic acid instead of 2-(methoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxylic acid, and 2-(trifluoromethyl)benzylamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 564 (M+H) , Rt= 1.72 minutes (method A) Example 46 N-(3-Chloromethylphenyl)methyl({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide [Step 1] Methyl 1-methyl({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H- benzimidazolecarboxylate To a solution of methyl 6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimida zolecarboxylate (Example 1, Step 4) (189 mg) in THF (5 mL), NaH (60%, 25 mg) was added slowly under ice-cooling, and the mixture was stirred at same temperature for 30 minutes and additionally at room temperature for 1 hour. The reaction mixture was further stirred under ice-cooling, and was added with methyl iodide (81 μL) slowly, and stirred at room temperature overnight. The reaction mixture was added with saturated aqueous ammonium chloride, and extracted with ethyl acetate. The organic layer was washed sequentially with water and brine, dried over anhydrous magnesium sulfate, and removed the solvent under reduced pressure. The residue was purified on column chromatography to obtain the titled compound (78 mg) as colorless powder.

[Step 2] 1-Methyl({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H- benzimidazolecarboxylic acid The titled compound was obtained as colorless powder according to the procedure as described in Step 5 of Example 1, using methyl 1-methyl({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H- benzimidazolecarboxylate instead of methyl 6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimida zolecarboxylate.

[Step 3] N-(3-Chloromethylphenyl)methyl({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide The titled compound was obtained as colorless powder according to the procedure as described in Step 7 of Example 11, using 1-methyl({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H- benzimidazolecarboxylic acid instead of 2-(methoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxylic acid.

MS(ESI+) m/z 487 (M+H) , Rt= 1.44 minutes (method B) Example 47 N-Cyclohexylmethyl({[2-(trifluoromethyl)phenyl]carbon yl}amino)-1H-benzimidazolecarboxamide The titled compound was obtained as colorless powder according to the procedure as described in Example 46, using cyclohexylamine instead of 3-chloromethylaniline.

MS(ESI+)m/z 445(M+H) Example 48 1-Methyl-N-[2-(trifluoromethyl)benzyl]({[2-(trifluoromet hyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide The titled compound was obtained as colorless powder according to the procedure as described in Example 46, using 2-(trifluoromethyl)benzylamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 521 (M+H) , Rt= 1.06 minutes (method B) Example 49 N-(3-Chloromethylphenyl)ethyl({[2-(trifluoromethyl )phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide The titled compound was obtained as white powder according to the procedure as described in Example 46, using ethyl iodide instead of methyl iodide.

MS(ESI+) m/z 501 (M+H) , Rt= 2.53 minutes (method A) Example 50 N-Cyclohexylethyl({[2-(trifluoromethyl)phenyl]carbony l}amino)-1H-benzimidazolecarboxamide The titled compound was obtained as colorless powder according to the procedure as described in Example 46, using ethyl iodide instead of methyl iodide, and cyclohexylamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 459 (M+H) , Rt= 2.14 minutes (method A) Example 51 1-Ethyl-N-[2-(trifluoromethyl)benzyl]({[2-(trifluorometh yl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide The titled compound was obtained as colorless powder according to the procedure as described in Example 46, using ethyl iodide instead of methyl iodide, and 2-(trifluoromethyl)benzylamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 535 (M+H) , Rt= 2.28 minutes (method A) Example 52 N-(3-Chloromethylphenyl)methyl({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1,3-benzoxazolecarboxamide [Step 1] 6-Bromomethyl-1,3-benzoxazolecarboxylic acid To a solution of 5-bromohydroxyanthranilic acid (prepared as described in Eur. J. Med. Chem., 1999, 34,729) (400 mg) in xylene (30 mL), were added acetyl chloride (135 μL), triethylamine (265 μL) and pyridinium p-toluenesulfonate (130 mg), and the mixture was heated at reflux for 8 hours. The reaction mixture was cooled to room temperature, diluted with ethyl acetate, washed sequentially with water and brine, and dried over anhydrous magnesium sulfate, and removed the solvent under reduced pressure. The residue was purified on silica gel column chromatography to obtain the titled compound (471 mg).

[Step 2] 6-Bromo-N-(3-chloromethylphenyl)methyl-1,3-benzoxazol ecarboxamide To a solution of 6-bromomethyl-1,3-benzoxazolecarboxylic acid (136 mg) in DMF (2 mL), were added HBTU (242 mg) and triethylamine (110 μL). The mixture was added with 3-chloromethylaniline (76 μL)and stirred at room temperature over night. The reaction mixture was poured into ice water and extracted with ethyl acetate. The ethyl acetate layer was washed sequentially with water and brine, dried over anhydrous magnesium sulfate, and removed the solvent under reduced pressure. The residue was purified on silica gel column chromatography to obtain the titled compound (53 mg) as white powder.

[Step 3] N-(3-Chloromethylphenyl)methyl({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1,3-benzoxazolecarboxamide The titled compound was obtained as white powder according to the procedure as described in Step 2 of Example 6, using 6-bromo-N-(3-chloromethylphenyl)methyl-1,3-benzoxazol ecarboxamide instead of ethyl -bromo-2,3-dihydrobenzofurancarboxylate.

MS(ESI) m/z 488 (M+H) , Rt= 1.96 minutes (method B) Example 53 2-Methyl-N-[2-(trifluoromethyl)benzyl]({[2-(trifluoromet hyl)phenyl]carbonyl}amino)-1,3-benzoxazolecarboxamide [Step 1] 6-Bromomethyl-N-[2-(trifluoromethyl)benzyl]-1,3-benzoxaz olecarboxamide The titled compound was obtained as white powder according to the procedure as described in Step 2 of Example 52, using 2-(trifluoromethyl)benzylamine instead of 3-chloromethylaniline.

[Step 2] 2-Methyl-N-[2-(trifluoromethyl)benzyl]({[2-(trifluoromet hyl)phenyl]carbonyl}amino)-1,3-benzoxazolecarboxamide The titled compound was obtained as white powder according to the procedure as described in Step 2 of Example 6, using 6-bromomethyl-N-[2-(trifluoromethyl)benzyl]-1,3-benzoxaz olecarboxamide instead of ethyl -bromo-2,3-dihydrobenzofurancarboxylate.

MS(ESI) m/z 522 (M+H) , Rt= 2.49 minutes (method A) Example 54 N-(3-Chloromethylphenyl)ethyl({[2-(trifluoromethyl )phenyl]carbonyl}amino)-1,3-benzoxazolecarboxamide [Step 1] 6-Bromoethyl-1,3-benzoxazolecarboxylic acid The titled compound was obtained according to the procedure as described in Step 1 of Example 52, using propionyl chloride instead of acetyl chloride.

[Step 2] 6-Bromo-N-(3-chloromethylphenyl)ethyl-1,3-benzoxazole carboxamide The titled compound was obtained according to the procedure as described in Step 2 of Example 52, using 6-bromoethyl-1,3-benzoxazolecarboxylic acid instead of 6-bromomethyl-1,3-benzoxazolecarboxylic acid.

[Step 3] N-(3-Chloromethylphenyl)ethyl({[2-(trifluoromethyl )phenyl]carbonyl}amino)-1,3-benzoxazolecarboxamide The titled compound was obtained as powder according to the procedure as described in Step 2 of Example 6, using 6-bromo-N-(3-chloromethylphenyl)ethyl-1,3-benzoxazole carboxamide instead of ethyl -bromo-2,3-dihydrobenzofurancarboxylate.

MS(ESI) m/z 502 (M+H) , Rt= 2.29 minutes (method B) Example 55 N-(3-Chloromethylphenyl)ethoxy({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide [Step 1] Methyl 2-ethoxynitro-1H-benzimidazolecarboxylate To a stirring solution of methyl 2-ethoxy-1H-benzimidazolecarboxylate (prepared as described in J. Med. Chem., 1993, 36, 2182) (500 mg) in conc. sulfuric acid (5 mL), potassium nitrate (275 mg) was added portion-wise under ice-cooling, and the mixture was stirred at room temperature for 2.5 hours. The reaction mixture was poured into ice, alkalified with aqueous sodium hydroxide solution, and extracted with ethyl acetate. The ethyl acetate layer was washed sequentially with water and brine, dried over anhydrous magnesium sulfate, and removed the solvent under reduced pressure to obtain the titled compound (595 mg) as white powder.

[Step 2] Methyl 6-aminoethoxy-1H-benzimidazolecarboxylate The titled compound was obtained as pale yellow powder according to the procedure as described in Step 3 of Example 1, using methyl 2-ethoxynitro-1H-benzimidazolecarboxylate instead of methyl 6-nitro-1H-benzimidazolecarboxylate.

[Step 3] Methyl 2-ethoxy({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H- benzimidazolecarboxylate The titled compound was obtained as colorless powder according to the procedure as described in Step 4 of Example 1, using methyl 6-aminoethoxy-1H-benzimidazolecarboxylate instead of methyl 6-amino-1H-benzimidazolecarboxylate.

[Step 4] 2-Ethoxy({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H- benzimidazolecarboxylic acid The titled compound was obtained as colorless powder according to the procedure as described in Step 5 of Example 1, using methyl 2-ethoxy({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H- benzimidazolecarboxylate instead of methyl 6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimida zolecarboxylate.

[Step 5] N-(3-Chloromethylphenyl)ethoxy({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide The titled compound was obtained as white powder according to the procedure as described in Step 7 of Example 11, using 2-ethoxy({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H- benzimidazolecarboxylic acid instead of 2-(methoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxylic acid.

MS(ESI+) m/z 517 (M+H) , Rt= 1.72 minutes (method B) Example 56 2-Ethoxy-N-[2-(trifluoromethyl)benzyl]({[2-(trifluoromet hyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide The titled compound was obtained as white powder according to the procedure as described in Example 55, using 2-(trifluoromethyl)benzylamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 551 (M+H) , Rt= 1.32 minutes (method B) Example 57 N-(3-Chloromethylphenyl)(1-chloromethylpropanyl )({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimi dazolecarboxamide The titled compound was obtained as white powder according to the procedure as described in Example 11, using 3-chloro-2,2-dimethylpropionyl chloride instead of methoxyacetyl chloride.

MS(ESI+) m/z 563 (M+H) , Rt= 2.75 minutes (method A) Example 58 N-(3-Chloromethylphenyl)[(dimethylamino)methyl]({[ 2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole- 4-carboxamide hydrochloride [Step 1] Methyl 2-(chloromethyl)nitro-1H-benzimidazolecarboxylate The titled compound was obtained as slightly yellow powder according to the procedure as described in Step 2 of Example 1, using methyl 2-(chloromethyl)-1H-benzimidazolecarboxylate (prepared as described in WO2003/106430) instead of methyl 1H-benzimidazolecarboxylate.

[Step 2] Methyl 2-[(dimethylamino)methyl]nitro-1H-benzimidazolecarbox ylate To a solution of methyl 2-(chloromethyl)nitro-1H-benzimidazolecarboxylate (72 mg) in acetonitrile (3 mL), was added 2M dimethylamine/MeOH solution (1.3 mL), and the mixture was stirred at 80°C overnight.

The solvent was removed under reduced pressure, and the residue was purified on silica gel chromatography to obtain the titled compound (68 mg) as slightly yellow solid.

[Step 3] Methyl 6-amino[(dimethylamino)methyl]-1H-benzimidazolecarbox ylate The titled compound was obtained as yellow amorphous according to the procedure as described in Step 3 of Example 1, using methyl 2-[(dimethylamino)methyl]nitro-1H-benzimidazolecarbox ylate instead of methyl 6-nitro-1H-benzimidazolecarboxylate.

[Step 4] Methyl 2-[(dimethylamino)methyl]({[2-(trifluoromethyl)phenyl]ca rbonyl}amino)-1H-benzimidazolecarboxylate The titled compound was obtained as colorless powder according to the procedure as described in Step 4 of Example 1, using methyl 6-amino[(dimethylamino)methyl]-1H-benzimidazolecarbox ylate instead of methyl 6-amino-1H-benzimidazolecarboxylate.

[Step 5] 2-[(Dimethylamino)methyl]({[2-(trifluoromethyl)phenyl]ca rbonyl}amino)-1H-benzimidazolecarboxylic acid The titled compound was obtained as yellow amorphous according to the procedure as described in Step 5 of Example 1, using methyl 2-[(dimethylamino)methyl]({[2-(trifluoromethyl)phenyl]ca rbonyl}amino)-1H-benzimidazolecarboxylate instead of methyl 6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimida zolecarboxylate.

[Step 6] N-(3-Chloromethylphenyl)[(dimethylamino)methyl]({[ 2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole- 4-carboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Step 7 of Example 11, using 2-[(dimethylamino)methyl]({[2-(trifluoromethyl)phenyl]ca rbonyl}amino)-1H-benzimidazolecarboxylic acid instead of 2-(methoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxylic acid.

MS(ESI+) m/z 530 (M+H) , Rt= 1.54 minutes (method A) Example 59 N-(3-Chloromethylphenyl)(2-methylpropyl)({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 11, using isovaleryl chloride instead of methoxyacetyl chloride.

MS(ESI+) m/z 529 (M+H) , Rt= 1.95 minutes (method B) Example 60 2-(2-Methylpropyl)-N-[2-(trifluoromethyl)benzyl]({[2-(tr ifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecar boxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 11, using isovaleryl chloride instead of methoxyacetyl chloride, and 2-(trifluoromethyl)benzylamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 563 (M+H) , Rt= 1.20 minutes (method B) Example 61 tert-Butyl 3-{4-[(3-chloromethylphenyl)carbamoyl]({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolyl}azetidin ecarboxylate The titled compound was obtained as pale yellow powder according to the procedures as described in Steps 1 to 7 of Example 11, using 1-(tert-butoxycarbonyl)azetidinecarbonyl chloride (prepared as described in US6020368) instead of methoxyacetyl chloride.

MS(ESI+) m/z 628 (M+H) , Rt= 1.87 minutes (method B) Example 62 N-(3-Chloromethylphenyl)[(methylamino)methyl]({[2- (trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide dihydrochloride [Step 1] Methyl 2-{[(tert-butoxycarbonyl)(methyl)amino]methyl}nitro-1H-b enzimidazolecarboxylate To a solution of methyl 2-(chloromethyl)nitro-1H-benzimidazolecarboxylate (Example 58, Step 1) (72 mg) in acetonitrile (2 mL), was added 40% methylamine/MeOH solution (0.27 mL), and the mixture was stirred at 80°C for 1 hour. The solvent was removed under reduced pressure. The residue was added with water, and extracted with ethyl acetate. The ethyl acetate layer was washed with brine, dried over anhydrous magnesium sulfate, and concentrated. The obtained residue (68 mg) was dissolved in anhydrous THF (2 mL), triethylamine (93 μL) was added to the solution. Di-tert-butyl dicaronate (141 μL) was added to the solution with stirring under ice-cooling for 3 hours. The reaction mixture was added with water , and extracted with ethyl acetate. The ethyl acetate layer was washed with brine, dried over anhydrous magnesium and concentrated under reduced pressure. The residue was purified on column chromatography to obtain the titled compound (54 mg) as slightly yellow amorphous.

[Step 2] Methyl 6-amino{[(tert-butoxycarbonyl)(methyl)amino]methyl}-1H-b enzimidazolecarboxylate The titled compound was obtained as yellow amorphous according to the procedure as described in Step 3 of Example 1, using methyl 2-{[(tert-butoxycarbonyl)(methyl)amino]methyl}nitro-1H-b enzimidazolecarboxylate instead of methyl 6-nitro-1H-benzimidazolecarboxylate.

[Step 3] Methyl 2-{[(tert-butoxycarbonyl)(methyl)amino]methyl}({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xylate The titled compound was obtained as slightly yellow amorphous according to the procedure as described in Step 4 of Example 1, using methyl 6-amino{[(tert-butoxycarbonyl)(methyl)amino]methyl}-1H-b enzimidazolecarboxylate instead of methyl 6-amino-1H-benzimidazolecarboxylate.

[Step 4] 2-{[(tert-Butoxycarbonyl)(methyl)amino]methyl}({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xylic acid The titled compound was obtained as yellow amorphous according to the procedure as described in Step 5 of Example 1, using methyl 2-{[(tert-butoxycarbonyl)(methyl)amino]methyl}({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xylate instead of methyl 6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimida zolecarboxylate.

[Step 5] N-(3-Chloromethylphenyl)[(methylamino)methyl]({[2- (trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide dihydrochloride 2-{[(tert-Butoxycarbonyl)(methyl)amino]methyl}-N-(3-c hloromethylphenyl)({[2-(trifluoromethyl)phenyl]carbon yl}amino)-1H-benzimidazolecarboxamide (9 mg) was obtained according to the procedure as described in Step 7 of Example 11, using 2-{[(tert-butoxycarbonyl)(methyl)amino]methyl}({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xylic acid instead of 2-(methoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxylic acid. This was dissolved in methylene chloride (1 mL). The residue was added with TFA (0.5 mL) under ice-cooling, and stirred for 0.5 hour. The reaction miature was added with ice and then saturated aqueous sodium bicarbonate, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.

The residue was purified on column chromatography to obtain N-(3-chloromethylphenyl)[(methylamino)methyl]({[2- (trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide (5 mg) as slightly yellow powder. This was dissolved in MeOH (0.5 mL), and treated with 1M hydrochloric acid (2 Eq), and concentrated to obtain the titled compound (5 mg) as slightly yellow powder.

MS(ESI+) m/z 516 (M+H) , Rt= 1.55 minutes (method A) Example 63 {4-[(3-Chloromethylphenyl)carbamoyl]({[2-(trifluorome thyl)phenyl]carbonyl}amino)-1H-benzimidazolyl}methyl acetate [Step 1] Methyl 2-[(acetyloxy)methyl]nitro-1H-benzimidazolecarboxylat To a solution of methyl 2-(chloromethyl)nitro-1H-benzimidazolecarboxylate (Example 58, Step 1) (99 mg) in DMF (1 mL), was added sodium acetate (17 mg), and the mixture was stirred at 50°C for 6 hours.

The reaction mixture was added with ice water, and extracted with ethyl acetate. The ethyl acetate layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated.

The residue was purified on column chromatography to obtain the titled compound (65 mg) as colorless powder.

[Step 2] Methyl 2-[(acetyloxy)methyl]amino-1H-benzimidazolecarboxylat The titled compound was obtained as pale yellow powder according to the procedure as described in Step 3 of Example 1, using methyl 2-[(acetyloxy)methyl]nitro-1H-benzimidazolecarboxylat e instead of methyl 6-nitro-1H-benzimidazolecarboxylate.

[Step 3] Methyl 2-[(acetyloxy)methyl]({[2-(trifluoromethyl)phenyl]carbon yl}amino)-1H-benzimidazolecarboxylate The titled compound was obtained as pale yellow amorphous according to the procedure as described in Step 4 of Example 1, using methyl 2-[(acetyloxy)methyl]amino-1H-benzimidazolecarboxylat e instead of methyl 6-amino-1H-benzimidazolecarboxylate.

[Step 4] 2-(Hydroxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxylic acid The titled compound was obtained as colorless powder according to the procedure as described in Step 5 of Example 1, using methyl 2-[(acetyloxy)methyl]({[2-(trifluoromethyl)phenyl]carbon yl}amino)-1H-benzimidazolecarboxylate instead of methyl 6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimida zolecarboxylate.

[Step 5] {4-[(3-Chloromethylphenyl)carbamoyl]({[2-(trifluorome thyl)phenyl]carbonyl}amino)-1H-benzimidazolyl}methyl acetate A mixture of 2-(hydroxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxylic acid (50 mg) and N,N-diisopropylethylamine (49 μL) in methylene chloride-THF (1:1)(2 mL) was stirred under ice-cooling, added with acetyl chloride (19 μL), and stirred at room temperature overnight.

The reaction mixture was poured into a cold 10% aqueous citric acid solution, and extracted with ethyl acetate. The organic layer was separated, and washed with brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.

The residue was dissolved in DMF (3 mL), and added with HBTU (65 mg) and triethylamine (24 μL), and stirred at room temperature. The mixture was added with 3-chloromethylaniline (16 μL) and stirred overnight. The reaction mixture was poured into ice water, and extracted with ethyl acetate. The organic layer was washed sequentially with water and brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.

The obtained residue was purified on column chromatography to obtain the titled compound (6 mg) as colorless powder.

MS(ESI+) m/z 545 (M+H) , Rt= 2.41 minutes (method A) Example 64 N-(3-Chloromethylphenyl)[(2R)-tetrahydrofuranyl]-6 -({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidaz olecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 11, using (2R)-tetrahydrofurancarbonyl chloride (prepared as described in WO2006/79642) instead of methoxyacetyl chloride.

MS(ESI+) m/z 543 (M+H) , Rt= 2.56 minutes (method A) Elemental Analysis for C H ClF N O •HCl+1.5H O 27 22 3 4 3 2 Calcd.(%) C:53.48 H:4.32 N:9.24 Found.(%) C:53.26 H:4.17 N:9.19 Example 65 2-[(2R)-Tetrahydrofuranyl]-N-[2-(trifluoromethyl)benzyl] ({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimid azolecarboxamide The titled compound was obtained as white powder according to the procedure as described in Example 11, using (2R)-tetrahydrofurancarbonyl chloride (prepared as described in WO2006/79642) instead of methoxyacetyl chloride, and 2-(trifluoromethyl)benzylamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 577 (M+H) , Rt= 2.25 minutes (method A) Example 66 N-(3-Chloromethylphenyl)[(2S)-tetrahydrofuranyl]-6 -({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidaz olecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 11, using (2S)-tetrahydrofurancarbonyl chloride (prepared as described in WO2006/79642) instead of methoxyacetyl chloride.

MS(ESI+) m/z 543 (M+H) , Rt= 2.56 minutes (method A) Example 67 2-[(2S)-Tetrahydrofuranyl]-N-[2-(trifluoromethyl)benzyl] ({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimid azolecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 11, using (2S)-tetrahydrofurancarbonyl chloride (prepared as described in WO2006/79642) instead of methoxyacetyl chloride, and 2-(trifluoromethyl)benzylamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 577 (M+H) , Rt= 2.25 minutes (method A) Example 68 2-(1-Acetylazetidinyl)-N-(3-chloromethylphenyl)({[ 2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole- 4-carboxamide hydrochloride To a solution of tert-butyl 3-{4-[(3-chloromethylphenyl)carbamoyl]({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazoleanyl}azeti dinecarboxylate (Example 61) (50 mg) in methylene chloride (2 mL), was added thioanisole (50 μL). The mixture was added with TFA (1 mL) under ice-cooling, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate, and removed the solvent under reduced pressure. The residue was triturated in n-hexane/ethyl acetate, and the precipitate was collected by filtration and dried to obtain 2-(azetidinyl)-N-(3-chloromethylphenyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide (38 mg). This was dissolved in THF (1 mL), and added with pyridine (23 μL), and the mixture was stirred under ice-cooling.

The mixture was added dropwise with acetyl chloride (7.7 μL), and stirred at room temperature for 2 hours. The reaction mixture was poured into ice water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate, and removed the solvent under reduced pressure. The residue was purified on column chromatography to obtain 2-(1-acetylazetidinyl)-N-(3-chloromethylphenyl)({[ 2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole- 4-carboxamide (7.5 mg). This was dissolved in MeOH (0.5 mL), treated with 1M hydrogen chloride/MeOH, and concentrated to obtain the titled compound (5.5 mg) as slightly gray powder.

MS(ESI+) m/z 570 (M+H) , Rt= 1.98 minutes (method A) Example 69 tert-Butyl (2S){4-[(3-chloromethylphenyl)carbamoyl]({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolyl}pyr rolidine 1-carboxylate The titled compound was obtained as white powder according to the procedures as described in Steps 1 to 7 of Example 11, using tert-butyl (2S)(chlorocarbonyl)pyrrolidinecarboxylate (prepared as described in Tetrahedron Asymmetry, 2007, 18, 2011) instead of methoxyacetyl chloride.

MS(ESI+) m/z 642 (M+H) , Rt= 2.77 minutes (method A) Example 70 tert-Butyl (2R){4-[(3-chloromethylphenyl)carbamoyl]({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolyl}pyr rolidinecarboxylate The titled compound was obtained as white powder according to the procedures as described in Steps 1 to 7 of Example 11, using tert-butyl (2R)(chlorocarbonyl)pyrrolidinecarboxylate (prepared as described in Tetrahedron Asymmetry, 2007, 18, 2011) instead of methoxyacetyl chloride.

MS(ESI+) m/z 642 (M+H) , Rt= 2.77 minutes (method A) Example 71 N-(3-Chloromethylphenyl)[(2S)-pyrrolidinyl]({[2 -(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4 -carboxamide dihydrochloride To a solution of tert-butyl (2S){4-[(3-chloromethylphenyl)carbamoyl]({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazoleyl}py rrolidinecarboxylate (26 mg) (Example 69) in ethyl acetate (2 mL), was added 4N hydrogen chloride/ethyl acetate solution (2 mL), and the mixture was stirred at room temperature for 2 hours. N-hexane was added to the reaction mixture, the precipitates was collected, and dried to obtain the titled compound (20 mg) as pale yellow powder.

MS(ESI+) m/z 542 (M+H) , Rt= 1.65 minutes (method A) Example 72 N-(3-Chloromethylphenyl)[(2S)methylpyrrolidinyl ]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimi dazolecarboxamide To a solution of N-(3-chloromethylphenyl)[(2S)-pyrrolidinyl]({[2 -(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4 -carboxamide (Example 71) (25 mg) in MeOH (0.4 mL), was added 38% aqueous formaldehyde solution (7.2 μL), and the mixture was stirred at room temperature overnight. The mixture was added with 2-picoline borane (10 mg), and stirred for 3 hours, removed the solvent under reduced pressure. The residue was purified on column chromatography to obtain the titled compound (11 mg) as white powder.

MS(ESI+) m/z 556 (M+H) , Rt= 1.67 minutes (method A) Example 73 2-[(2S)Acetylpyrrolidinyl]-N-(3-chloromethylphenyl )({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimi dazolecarboxamide To a solution of N-(3-chloromethylphenyl)[(2S)-pyrrolidinyl]({[2 -(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4 -carboxamide (Example 71) (26 mg) in THF solution (0.5 mL), was added pyridine (12 μL), and the mixture was stirred under ice-cooling. The mixture was deed with acetyl chloride (5.1 μL), and stirred at room temperature for 1 hour. The reaction mixture was added with ice water, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate, and removed the solvent under reduced pressure. The residue was purified on column chromatography to obtain the titled compound (15 mg) as white powder.

MS(ESI+) m/z 584 (M+H) , Rt= 2.26 minutes (method A) Example 74 N-(3-Chloromethylphenyl)[(2-methoxyethoxy)methyl]( {[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazol ecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 11, using 2-(methoxyethoxy)acetyl chloride instead of methoxyacetyl chloride.

MS(ESI+) m/z 561 (M+H) , Rt= 2.43 minutes (method A) Example 75 N-(3-Chloromethylphenyl)(1-methoxymethylpropany l)({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzim idazolecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 11, using 3-methoxy-2,2-dimethylpropanoyl chloride (prepared as described in Bull. Chem. Soc. Jpn., 2001, 74, 1695) instead of methoxyacetyl chloride.

MS(ESI+) m/z 559 (M+H) , Rt= 2.82 minutes (method A) Example 76 2-tert-Butyl-N-(3-chloromethylphenyl)({[2-(trifluorom ethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 11, using pivaloyl chloride instead of methoxyacetyl chloride.

MS(ESI+) m/z 529 (M+H) , Rt= 3.03 minutes (method A) Example 77 2-tert-Butyl({[2-(trifluoromethyl)phenyl]carbonyl}amino) -N-{[3-(trifluoromethyl)pyridinyl]methyl}-1H-benzimidazo lecarboxamide dihydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 11, using pivaloyl chloride instead of methoxyacetyl chloride, and 2-(aminomethyl)(trifluoromethyl)pyridine instead of 3-chloromethylaniline.

MS(ESI+) m/z 564 (M+H) , Rt= 2.39 minutes (method A) Example 78 N-(3-Chloromethylphenyl)(2-ethoxyethyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 11, using 3-ethoxy-propionylchloride (prepared as described in EP1803350) instead of methoxyacetyl chloride.

MS(ESI+) m/z 545 (M+H) , Rt= 2.69 minutes (method A) Example 79 N-(3-Chloromethylphenyl)(ethoxymethyl)({[2-(triflu oromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxa mide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 11, using ethoxyacetyl chloride (prepared as described in US2004/39038) instead of methoxyacetyl chloride.

MS(ESI+) m/z 531 (M+H) , Rt= 2.77 minutes (method A) Example 80 2-(Ethoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}am ino)-N-{[3-(trifluoromethyl)pyridinyl]methyl}-1H-benzimi dazolecarboxamide dihydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 11, using ethoxyacetyl chloride (prepared as described in US2004/39038) instead of methoxyacetyl chloride, and 2-(aminomethyl)(trifluoromethyl)pyridine instead of 3-chloromethylaniline.

MS(ESI+) m/z 566 (M+H) , Rt= 2.18 minutes (method A) Example 81 N-(3-Chloromethylphenyl)(2-methoxyethyl)({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 11, using methoxypropionyl chloride instead of methoxyacetyl chloride.

MS(ESI+) m/z 531 (M+H) , Rt= 2.58 minutes (method A) Example 82 N-(3-Chloromethylphenyl)(2,2-dimethylpropyl)({[2-( trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolec arboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 11, using tert-butylacetyl chloride instead of methoxyacetyl chloride.

MS(ESI+) m/z 543 (M+H) , Rt= 3.25 minutes (method A) Example 83 N-(3-Chloromethylphenyl)cyclopropyl({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamid e hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 11, using cyclopropanecarbonyl chloride instead of methoxyacetyl chloride.

MS(ESI+) m/z 513 (M+H) , Rt= 2.91 minutes (method A) Example 84 N-(3-chloromethylphenyl)(2-methylpentanyl)({[2- (trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 11, using 2,2-dimethylpentanoyl chloride (prepared as described in J. Am.

Chem. Soc., 1974, 96, 1518) instead of methoxyacetyl chloride.

MS(ESI+) m/z 557 (M+H) , Rt= 3.16 minutes (method B) Example 85 N-(3-Chloromethylphenyl)(1-methylcyclopropyl)({[2- (trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 11, using 1-methyl-cyclopropanecarbonyl chloride (prepared as described in WO2009/68512) instead of methoxyacetyl chloride.

MS(ESI+) m/z 527 (M+H) , Rt= 3.16 minutes (method A) Elemental Analysis for C H ClF N O •HCl+1.0H O 27 22 3 4 2 2 Calcd.(%) C:55.78 H:4.33 N:9.64 Found.(%) C:55.48 H:3.94 N:9.63 Example 86 2-tert-Butyl-N-(3-chloromethylphenyl)({[2-(trifluorom ethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 11, using pivaloyl chloride instead of methoxyacetyl chloride, and 3-chloromethylaniline instead of 3-chloromethylaniline.

MS(ESI+) m/z 529 (M+H) , Rt= 2.83 minutes (method B) Example 87 2-tert-Butyl-N-(3-chloromethylphenyl){[(2,5-dichlorop henyl)carbonyl]amino}-1H-benzimidazolecarboxamide hydrochloride [Step 1] Methyl 6-aminotert-butyl-1H-benzimidazolecarboxylate The title compound was obtained as white powder according to the procedures as described in step 1 to step 4 of Example 11, using pivaloyl chloride instead of methoxyacetyl chloride in Step 1.

[Step 2] 2-tert-Butyl{[2,5-dichlorophenyl]carbonyl]amino}-1H-benz imidazolecarboxylic acid The title compound was obtained according to the procedures as described in step 4 and step 5 of Example 1, using methyl 6-aminotert-butyl-1H-benzimidazolecarboxylate instead of methyl 6-amino-1H-benzimidazolecarboxylate, and 2,5-dichlorobenzoyl chloride instead of 2-(trifluoromethyl)benzoyl chloride.

[Step 3] 2-tert-Butyl-N-(3-chloromethylphenyl){[(2,5-dichlorop henyl)carbonyl]amino}-1H-benzimidazolecarboxamide hydrochloride The title compound was obtained according to the procedures as described in step 7 and step 8 of Example 11, using 2-tert-Butyl{[2,5-dichlorophenyl]carbonyl]amino}-1H-benz imidazolecarboxylic acid instead of 2-(methoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxylic acid.

MS(ESI+) m/z 529 (M+H) , Rt= 2.97 minutes (method B) Example 88 2-tert-Butyl-N-(3-chloromethylphenyl){[(2,5-dichlorop henyl)carbonyl]amino}-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedures as described in step 7 and step 8 of Example 11, using 2-tert-Butyl{[2,5-dichlorophenyl]carbonyl]amino}-1H-benz imidazolecarboxylic acid instead of 2-(methoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxylic acid, and 3-chloromethylaniline instead of 3-chloromethylaniline.

MS(ESI+) m/z 529 (M+H) , Rt= 3.05 minutes (method B) Example 89 N-(3-Chloromethylphenyl)[1-(trifluoromethyl)cycloprop yl]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzi midazolecarboxamide The titled compound was obtained as white powder according to the procedures as described in Steps 1 to 7 of Example 11, using 1-(trifluoromethyl)cyclopropanecarbonyl chloride (prepared as described in WO2005/23773) instead of methoxyacetyl chloride.

MS(ESI+) m/z 581 (M+H) , Rt= 3.15 minutes (method A) Example 90 N-(3-Chloromethylphenyl)(methoxymethyl)methyl({ [2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide [Step 1] 2-(Methoxymethyl)methyl({[2-(trifluoromethyl)phenyl]c arbonyl}amino)-1H-benzimidazolecarboxylic acid The titled compound was obtained according to the procedure as described in Example 46, using methyl 2-(methoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxylate instead of methyl 6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimida zolecarboxylate.

[Step 2] N-(3-Chloromethylphenyl)(methoxymethyl)methyl({ [2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide The titled compound was obtained as colorless powder according to the procedure as described in Step 7 of Example 11, using 2-(methoxymethyl)methyl({[2-(trifluoromethyl)phenyl]c arbonyl}amino)-1H-benzimidazolecarboxylic acid instead of 2-(methoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxylic acid.

MS(ESI+) m/z 531 (M+H) , Rt= 2.58 minutes (method A) Example 91 N-(2-Chlorobenzyl)(methoxymethyl)methyl({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide The titled compound was obtained as colorless powder according to the procedure as described in Step 7 of Example 11, using 2-(methoxymethyl)methyl({[2-(trifluoromethyl)phenyl]c arbonyl}amino)-1H-benzimidazolecarboxylic acid instead of 2-(methoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxylic acid, and 2-chloro benzylamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 531 (M+H) , Rt= 2.25 minutes (method A) Example 92 6-{[(2-Chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)(methoxymethyl)-1H-benzimidazolecarboxam ide hydrochloride [Step 1] 6-Amino-N-(3-chloromethylphenyl)(methoxymethyl)-1H-be nzimidazolecarboxamide To a suspension of methyl 2-(methoxymethyl)nitro-1H-benzimidazolecarboxylate (Example 11, Step 3) (4.8g) in MeOH (120 mL), were added lithium hydroxide hydrate (4.56g) and water (54 mL). The mixture was stirred at room temperature for 16 hours. Under ice-cooling, 1N hydrochloric acid was added slowly to the reaction mixture to adjust the pH to about 2. The precipitate was collected by filtration and dried to obtain 2-(methoxymethyl)nitro-1H-benzimidazolecarboxylic acid (4.6g). To the solution of 2-(methoxymethyl)nitro-1H-benzimidazolecarboxylic acid (4.6g) in DMF (90 mL), HBTU (8.23g), triethylamine (2.19g) and 3-chloromethylaniline (3.07g) were added sequentially, and the solution was stirred for 18 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate and stirred for 1 hour. The precipitate was collected by filtration and washed sequentially with water and ethyl acetate to obtain N-(3-chloromethylphenyl)(methoxymethyl)nitro-1H-be nzimidazolecarboxamide (7.2g) as pale yellow powder. To the solution of N-(3-chloromethylphenyl)(methoxymethyl)nitro-1H-be nzimidazolecarboxamide (7.2g) in MeOH-THF (1:1, 120 mL), were added 1% platinum + 0.1% copper-activated carbon (Degussa type CF105 R/W) (1.4g). The mixture was stirred under hydrogen atmosphere (3 atm) for 4 hours. The catalyst was filtered off, and the mother liquid was concentrated. The residual solid was washed with ethyl acetate to obtain 6-amino-N-(3-chloromethylphenyl)(methoxymethyl)-1H-be nzimidazolecarboxamide (5.1g) as pale yellow powder.

[Step 2] 6-{[(2-Chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)(methoxymethyl)-1H-benzimidazolecarboxam ide hydrochloride To a solution of 6-amino-N-(3-chloromethylphenyl)(methoxymethyl)-1H-be nzimidazolecarboxamide (40 mg) in THF (1 mL), was added N,N-diisopropylethylamine (24 μL), and the mixture was stirred under ice-cooling. The mixture was added with 2-chlorofluorobenzoyl chloride (24 mg), and stirred for 3 hours. The reaction mixture was added with saturated aqueous sodium bicarbonate, and extracted with ethyl acetate. The ethyl acetate layer was washed with brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.

The residue was purified on column chromatography to obtain 6-{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)(methoxymethyl)-1H-benzimidazolecarboxam ide (50 mg). This was dissolved in ethyl acetate (2 mL), and treated with 4N hydrogen chloride/ethyl acetate (1.2 Eq). The precipitate was collected by filtration, and dried to obtain the titled compound (40 mg) as white powder.

MS(ESI+) m/z 501 (M+H) , Rt= 2.39 minutes (method A) Example 93 6-{[(2-Chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)methoxymethyl-1H-benzimidazolecarboxamid e hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Step 2 of Example 92, using 2-chlorofluorobenzoyl chloride instead of 2-chlorofluorobenzoyl chloride.

MS(ESI+) m/z 501 (M+H) , Rt= 2.40 minutes (method A) Example 94 6-{[(2-Chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)(methoxymethyl)-1H-benzimidazolecarboxam ide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Step 2 of Example 92, using 2-chlorofluorobenzoyl chloride instead of 2-chlorofluorobenzoyl chloride.

MS(ESI+) m/z 501 (M+H) , Rt= 2.41 minutes (method A) Example 95 N-(3-Chloromethylphenyl){[(2-chlorophenyl)carbonyl]am ino}(methoxymethyl)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Step 2 of Example 92, using 2-chlorobenzoyl chloride instead of 2-chlorofluorobenzoyl chloride.

MS(ESI+) m/z 483 (M+H) , Rt= 2.36 minutes (method A) Example 96 N-(3-Chloromethylphenyl){[(2-chloropyridinyl)carbo nyl]amino}(methoxymethyl)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Step 2 of Example 92, using 2-chloronicotinoyl chloride instead of 2-chlorofluorobenzoyl chloride.

MS(ESI+) m/z 484 (M+H) , Rt= 2.16 minutes (method A) Example 97 6-{[(2-Bromophenyl)carbonyl]amino}-N-(3-chloromethylphen yl)(methoxymethyl)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Step 2 of Example 92, using 2-bromobenzoyl chloride instead of 2-chlorofluorobenzoyl chloride.

MS(ESI+) m/z 527 (M+H) , Rt= 2.39 minutes (method A) Example 98 N-(3-Chloromethylphenyl){[(2,6-dichlorophenyl)carbony l]amino}(methoxymethyl)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Step 2 of Example 92, using 2,6-dichlorobenzoyl chloride instead of 2-chlorofluorobenzoyl chloride.

MS(ESI+) m/z 517 (M+H) , Rt= 2.46 minutes (method A) Example 99 N-(3-Chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}(methoxymethyl)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Step 2 of Example 92, using 2,5-dichlorobenzoyl chloride instead of 2-chlorofluorobenzoyl chloride.

MS(ESI+) m/z 517 (M+H) , Rt= 2.54 minutes (method A) Example 100 6-{[(2-Chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)(methoxymethyl)-1H-benzimidazolecarboxam ide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Step 2 of Example 92, using 2-chlorofluorobenzoyl chloride instead of 2-chlorofluorobenzoyl chloride.

MS(ESI+) m/z 501 (M+H) , Rt= 2.43 minutes (method A) Example 101 6-{[(2-Chloro-3,6-difluorophenyl)carbonyl]amino}-N-(3-chlor omethylphenyl)(methoxymethyl)-1H-benzimidazolecarb oxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Step 2 of Example 92, using 2-chloro-3,6-difluorobenzoyl chloride instead of 2-chlorofluorobenzoyl chloride.

MS(ESI+) m/z 519 (M+H) , Rt= 2.46 minutes (method A) Example 102 6-{[(2-Bromochlorophenyl)carbonyl]amino}-N-(3-chlorom ethylphenyl)(methoxymethyl)-1H-benzimidazolecarboxami de hydrochloride The titled compound was obtained as white powder according to the procedure as described in Step 2 of Example 92, using 2-chlorobromobenzoyl chloride (prepared as described in WO2008/124575) instead of 2-chlorofluorobenzoyl chloride.

MS(ESI+) m/z 561 (M+H) , Rt= 2.50 minutes (method A) Example 103 6-{[(2-Bromofluorophenyl)carbonyl]amino}-N-(3-chlorom ethylphenyl)(methoxymethyl)-1H-benzimidazolecarboxami de hydrochloride To a solution of 6-amino-N-(3-chloromethylphenyl)(methoxymethyl)-1H-be nzimidazolecarboxamide (50 mg) in DMF (1.5 mL), were added HBTU (66 mg), N,N-diisopropylethylamine (30 μL) and 2-bromofluorobenzoic acid (38 mg) in turn, and the mixture was stirred at room temperature for 24 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate, and extracted with ethyl acetate. The organic layer was separated, washed sequentially with water and brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified on column chromatography to obtain 6-{[(2-bromofluorophenyl)carbonyl]amino}-N-(3-chlorom ethylphenyl)(methoxymethyl)-1H-benzimidazolecarboxami de (46 mg). This was dissolved in ethyl acetate (2 mL), and treated with 4N hydrogen chloride/ethyl acetate (1.2 Eq). The precipitate was collected by filtration, and dried to obtain the titled compound (24 mg) as white powder.

MS(ESI+) m/z 545 (M+H) , Rt= 2.44 minutes (method A) Example 104 N-(3-Chloromethylphenyl){[(2-chloromethylphenyl)ca rbonyl]amino}(methoxymethyl)-1H-benzimidazolecarboxam ide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 103, using 2-chloromethylbenzoic acid instead of 2-bromofluorobenzoic acid.

MS(ESI+) m/z 497 (M+H) , Rt= 2.44 minutes (method A) Example 105 N-(3-Chloromethylphenyl){[(2-chloromethylphenyl)ca rbonyl]amino}(methoxymethyl)-1H-benzimidazolecarboxam ide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 103, using 2-chloromethylbenzoic acid instead of 2-bromofluorobenzoic acid.

MS(ESI+) m/z 497 (M+H) , Rt= 2.47 minutes (method A) Example 106 6-{[(5-Bromochlorophenyl)carbonyl]amino}-N-(3-chlorom ethylphenyl)(methoxymethyl)-1H-benzimidazolecarboxami de hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 103, using -bromochlorobenzoic acid instead of 2-bromofluorobenzoic acid.

MS(ESI+) m/z 561 (M+H) , Rt= 2.62 minutes (method A) Example 107 6-{[(2-Bromochlorophenyl)carbonyl]amino}-N-(3-chlorom ethylphenyl)(methoxymethyl)-1H-benzimidazolecarboxami de hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 103, using 2-bromochlorobenzoic acid instead of 2-bromofluorobenzoic acid.

MS(ESI+) m/z 561 (M+H) , Rt= 2.63 minutes (method A) Example 108 N-(3-Chloromethylphenyl){[(2-chloromethylphenyl)ca rbonyl]amino}(methoxymethyl)-1H-benzimidazolecarboxam ide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 103, using 2-chloromethylbenzoic acid instead of 2-bromofluorobenzoic acid.

MS(ESI+) m/z 497 (M+H) , Rt= 2.54 minutes (method A) Example 109 N-(3-Chloromethylphenyl)(methoxymethyl)({[5-methyl (trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 103, using -methyl(trifluoromethyl)benzoic acid instead of 2-bromofluorobenzoic acid.

MS(ESI+) m/z 531 (M+H) , Rt= 2.59 minutes (method A) Example 110 6-({[2,5-Bis(trifluoromethyl)phenyl]carbonyl}amino)-N-(3-ch loromethylphenyl)(methoxymethyl)-1H-benzimidazolec arboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 103, using 2,5-bis(trifluoromethyl)benzoic acid instead of 2-bromofluorobenzoic acid.

MS(ESI+) m/z 585 (M+H) , Rt= 2.76 minutes (method A) Example 111 6-({[2,4-Bis(trifluoromethyl)phenyl]carbonyl}amino)-N-(3-ch loromethylphenyl)(methoxymethyl)-1H-benzimidazolec arboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 103, using 2,4-bis(trifluoromethyl)benzoic acid instead of 2-bromofluorobenzoic acid.

MS(ESI+) m/z 585 (M+H) , Rt= 2.80 minutes (method A) Example 112 N-(3-Chloromethylphenyl)({[5-fluoro(trifluoromethy l)phenyl]carbonyl}amino)(methoxymethyl)-1H-benzimidazole carboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 103, using -fluoro(trifluoromethyl)benzoic acid instead of 2-bromofluorobenzoic acid.

MS(ESI+) m/z 535 (M+H) , Rt= 2.68 minutes (method A) Example 113 N-(3-Chloromethylphenyl)({[2-chloro(trifluoromethy l)phenyl]carbonyl}amino)(methoxymethyl)-1H-benzimidazole carboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 103, using 2-chloro(trifluoromethyl)benzoic acid instead of 2-bromofluorobenzoic acid.

MS(ESI+) m/z 551 (M+H) , Rt= 2.76 minutes (method A) Example 114 N-(3-Chloromethylphenyl)[({2-chloro[2-(propanyl oxy)ethoxy]phenyl}carbonyl)amino](methoxymethyl)-1H-benz imidazolecarboxamide hydrochloride Under argon atmosphere, potassium tert-butoxide (168 mg) was added to a solution of 2-isopropoxyethanol (172 μL) in NMP (1.5 mL). The mixture was stirred at room temperature for 10 minutes, added with 2-chlorofluorobenzoic acid (87 mg), and then stirred at 130°C for 4 hours. The reaction mixture was cooled on ice bath, and added with water, and then acidified with 1N hydrochloric acid and extracted with ethyl acetate.

The organic layer was separated, washed with brine, and dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to obtain crude 2-chloro[2-(propanyloxy)ethoxy]benzoic acid. This was dissolved in DMF (2 mL), added with HATU (61 mg), N,N-diisopropylethylamine (29 μL) and 6-amino-N-(3-chloromethylphenyl)(methoxymethyl)-1H-be nzimidazolecarboxamide (50 mg) in this order, and stirred at room temperature for 12 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate, and extracted with ethyl acetate. The organic layer was separated, washed sequentially with water and brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.

The residue was purified on column chromatography to obtain N-(3-chloromethylphenyl)[({2-chloro[2-(propanyl oxy)ethoxy]phenyl}carbonyl)amino](methoxymethyl)-1H-benz imidazolecarboxamide (41 mg) as white powder. This was dissolved in ethyl acetate (2 mL), and treated with 4N hydrogen chloride/ethyl acetate (1.2 Eq). The precipitate was collected by filtration, and dried to obtain the titled compound (28 mg) as white powder.

MS(ESI+) m/z 585 (M+H) , Rt= 3.14 minutes (method A) Example 115 6-({[2-Chloro(2-ethoxyethoxy)phenyl]carbonyl}amino)-N-(3 -chloromethylphenyl)(methoxymethyl)-1H-benzimidazole- 4-carboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 114, using 2-ethoxyethanol instead of 2-isopropoxy ethanol.

MS(ESI+) m/z 571 (M+H) , Rt= 2.71 minutes (method A) Example 116 6-({[2-Chloro(3-methoxypropyl)phenyl]carbonyl}amino)-N-( 3-chloromethylphenyl)(methoxymethyl)-1H-benzimidazole carboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 103, using 2-chloro(3-methoxypropyl)benzoic acid (prepared as described in Bioorg. Med. Chem. Lett., 2010, 20, 2204) instead of 2-bromofluorobenzoic acid.

MS(ESI+) m/z 555 (M+H) , Rt= 2.73 minutes (method A) Example 117 6-({[5-(3-tert-Butoxypropynyl)chlorophenyl]carbonyl}a mino)-N-(3-chloromethylphenyl)(methoxymethyl)-1H-benz imidazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 103, using -(3-tert-butoxypropynyl)chlorobenzoic acid (Reference Example 6) instead of 2-bromofluorobenzoic acid.

MS(ESI+) m/z 593 (M+H) , Rt= 3.17 minutes (method A) Example 118 6-({[5-(3-tert-Butoxypropyl)chlorophenyl]carbonyl}amino) -N-(3-chloromethylphenyl)(methoxymethyl)-1H-benzimida zolecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 103, using -(3-tert-butoxypropyl)chlorobenzoic acid (Reference Example 7) instead of 2-bromofluorobenzoic acid.

MS(ESI+) m/z 597 (M+H) , Rt= 3.28 minutes (method A) Example 119 6-({[2-Chloro(3-hydroxymethylbutyl)phenyl]carbonyl}am ino)-N-(3-chloromethylphenyl)(methoxymethyl)-1H-benzi midazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 103, using 2-chloro(3-hydroxymethylbutyl)benzoic acid (Reference Example 8) instead of 2-bromofluorobenzoic acid.

MS(ESI+) m/z 569 (M+H) , Rt= 2.64 minutes (method A) Example 120 6-({[2-Chloro(ethoxymethyl)phenyl]carbonyl}amino)-N-(3-c hloromethylphenyl)(methoxymethyl)-1H-benzimidazole carboxamide The titled compound was obtained as white powder according to the procedure as described in Example 103, using 2-chloro(ethoxymethyl)benzoic acid (Reference Example 1) instead of 2-bromofluorobenzoic acid.

MS(ESI+) m/z 541 (M+H) , Rt= 2.52 minutes (method A) Example 121 6-[({2-Chloro[(2-ethoxyethoxy)methyl]phenyl}carbonyl)ami no]-N-(3-chloromethylphenyl)(methoxymethyl)-1H-benzim idazolecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 103, using 2-chloro[(2-ethoxyethoxy)methyl]benzoic acid (Reference Example 2) instead of 2-bromofluorobenzoic acid.

MS(ESI+) m/z 585 (M+H) , Rt= 2.51 minutes (method A) Example 122 6-({[2-Chloro(2-cyclopropylethyl)phenyl]carbonyl}amino)- N-(3-chloromethylphenyl)(methoxymethyl)-1H-benzimidaz olecarboxamide The titled compound was obtained as white powder according to the procedure as described in Example 103, using 2-chloro(2-cyclopropylethyl)benzoic acid (Reference Example 4) instead of 2-bromofluorobenzoic acid.

MS(ESI+) m/z 551 (M+H) , Rt= 2.92 minutes (method A) Example 123 N-(3-Chloromethylphenyl)({[2-chloro(2-phenylethyl) phenyl]carbonyl}amino)(methoxymethyl)-1H-benzimidazole-4 -carboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 103, using 2-chloro(2-phenylethyl)benzoic acid (Reference Example 5) instead of 2-bromofluorobenzoic acid.

MS(ESI+) m/z 587 (M+H) , Rt= 2.98 minutes (method A) Example 124 N-(3-Chloromethylphenyl)cyclopentyl({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamid e hydrochloride [Step 1] Methyl 2-cyclopentylnitro-1H-benzimidazolecarboxylate The titled compound was obtained as pale yellow powder according to the procedure as described in Steps 1 to 3 of Example 11, using cyclopentanecarbonyl chloride instead of methoxyacetyl chloride.

[Step 2] 6-Amino-N-(3-chloromethylphenyl)cyclopentyl-1H-benzim idazolecarboxamide The titled compound was obtained as yellow powder according to the procedure as described in Step 1 of Example 92, using methyl 2-cyclopentylnitro-1H-benzimidazolecarboxylate instead of methyl 2-(methoxymethyl)nitro-1H-benzimidazolecarboxylate.

[Step 3] N-(3-Chloromethylphenyl)cyclopentyl({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamid e hydrochloride The titled compound was obtained as white powder according to the procedure as described in Step 2 of Example 92, using 6-amino-N-(3-chloromethylphenyl)cyclopentyl-1H-benzim idazolecarboxamide instead of 6-amino-N-(3-chloromethylphenyl)(methoxymethyl)-1H-be nzimidazolecarboxamide, and 2-(trifluoromethyl)benzoyl chloride instead of 2-chlorofluorobenzoyl chloride.

MS(ESI+) m/z 541 (M+H) , Rt= 3.21 minutes (method A) Example 125 N-(3-Chloromethylphenyl)cyclopentyl{[(2,5-dichloro phenyl)carbonyl]amino}-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Step 2 of Example 92, using 6-amino-N-(3-chloromethylphenyl)cyclopentyl-1H-benzim idazolecarboxamide instead of 6-amino-N-(3-chloromethylphenyl)(methoxymethyl)-1H-be nzimidazolecarboxamide, and 2,5-dichlorobenzoyl chloride instead of 2-chlorofluorobenzoyl chloride.

MS(ESI+) m/z 543 (M+H) , Rt= 3.32 minutes (method A) Example 126 6-{[(2-Chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)cyclopentyl-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Step 2 of Example 92, using 6-amino-N-(3-chloromethylphenyl)cyclopentyl-1H-benzim idazolecarboxamide instead of 6-amino-N-(3-chloromethylphenyl)(methoxymethyl)-1H-be nzimidazolecarboxamide.

MS(ESI+) m/z 525 (M+H) , Rt= 3.24 minutes (method A) Example 127 6-{[(2-Chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)[(2R)-tetrahydrofuranyl]-1H-benzimidazol ecarboxamide hydrochloride [Step 1] Methyl 6-nitro[(2R)-tetrahydrofuranyl]-1H-benzimidazoleca rboxylate The titled compound was obtained as pale yellow powder according to the procedure as described in Steps 1 to 3 of Example 11, using (2R)-tetrahydrofurancarbonyl chloride (prepared as described in WO2006/79642) instead of methoxyacetyl chloride.

[Step 2] 6-Amino-N-(3-chloromethylphenyl)[(2R)-tetrahydrofuran yl]-1H-benzimidazolecarboxamide The titled compound was obtained as yellow powder according to the procedure as described in Step 1 of Example 92, using methyl 6-nitro[(2R)-tetrahydrofuranyl]-1H-benzimidazoleca rboxylate instead of methyl 2-(methoxymethyl)nitro-1H-benzimidazolecarboxylate.

[Step 3] 6-{[(2-Chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)[(2R)-tetrahydrofuranyl]-1H-benzimidazol ecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Step 2 of Example 92, using 6-amino-N-(3-chloromethylphenyl)[(2R)-tetrahydrofuran yl]-1H-benzimidazolecarboxamide instead of 6-amino-N-(3-chloromethylphenyl)(methoxymethyl)-1H-be nzimidazolecarboxamide.

MS(ESI+) m/z 527 (M+H) , Rt= 2.75 minutes (method A) Example 128 N-(3-Chloromethylphenyl){[(2,6-dichlorophenyl)carbony l]amino}[(2R)-tetrahydrofuranyl]-1H-benzimidazolec arboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Step 2 of Example 92, using 6-amino-N-(3-chloromethylphenyl)[(2R)-tetrahydrofuran yl]-1H-benzimidazolecarboxamide instead of 6-amino-N-(3-chloromethylphenyl)(methoxymethyl)-1H-be nzimidazolecarboxamide, and 2,6-dichlorobenzoyl chloride instead of 2-chlorofluorobenzoyl chloride.

MS(ESI+) m/z 543 (M+H) , Rt= 2.80 minutes (method A) Example 129 N-(3-Chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}[(2R)-tetrahydrofuranyl]-1H-benzimidazolec arboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Step 2 of Example 92, using 6-amino-N-(3-chloromethylphenyl)[(2R)-tetrahydrofuran yl]-1H-benzimidazolecarboxamide instead of 6-amino-N-(3-chloromethylphenyl)(methoxymethyl)-1H-be nzimidazolecarboxamide, and 2,5-dichlorobenzoyl chloride instead of 2-chlorofluorobenzoyl chloride.

MS(ESI+) m/z 543 (M+H) , Rt= 2.86 minutes (method A) Example 130 N-(3-Chloromethylphenyl)[(2S)oxopyrrolidinyl]-6 -({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidaz olecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 11, using (S)-(-)pyrrolidone 5-carbonyl chloride (prepared as described in Tetrahedron Lett., 1997, 38, 2259) instead of methoxyacetyl chloride.

MS(ESI+) m/z 556 (M+H) , Rt= 2.03 minutes (method A) Example 131 N-(3-Chloromethylphenyl)[(2R)oxopyrrolidinyl]-6 -({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidaz olecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 11, using (R)-(+)pyrrolidonecarbonyl chloride (prepared as described in Tetrahedron Lett., 1997, 38, 2259) instead of methoxyacetyl chloride.

MS(ESI+) m/z 556 (M+H) , Rt= 2.03 minutes (method A) Example 132 N-(3-Chloromethylphenyl)[2-oxo(pyrrolidinyl)eth yl]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzi midazolecarboxamide hydrochloride [Step 1] Methyl 2-(2-ethoxyoxoethyl)-1H-benzimidazolecarboxylate A solution of methyl 2,3-diaminobenzoate(680 mg) and ethyl 3-aminoethoxyacrylate hydrochloride (880 mg) in EtOH (12 mL) was stirred at 60°C for 2 hours. EtOH was removed under reduced pressure, and the residue was purified on column chromatography to obtain the titled compound (1.14g) as a pale yellow solid.

[Step 2] Methyl 2-(2-ethoxyoxoethyl)({[2-(trifluoromethyl)phenyl]carb onyl}amino)-1H-benzimidazolecarboxylate The titled compound was obtained as pale yellow powder according to the procedures as described in Steps 3 to 5 of Example 11, using methyl 2-(2-ethoxyoxoethyl)-1H-benzimidazolecarboxylate instead of methyl 1H-benzimidazolecarboxylate as a starting material.

[Step 3] Methyl 2-[2-oxo(pyrrolidinyl)ethyl]({[2-(trifluoromethyl) phenyl]carbonyl}amino)-1H-benzimidazolecarboxylate Pyrrolidine (1 mL) was added to methyl 2-(2-ethoxyoxoethyl)({[2-(trifluoromethyl)phenyl]carb onyl}amino)-1H-benzimidazolecarboxylate (80 mg), and the solution was stirred at 70°C for 30 minutes. The reaction mixture was diluted with ethyl acetate, and washed with brine.

The ethyl acetate layer was concentrated under reduced pressure.

The residue was purified on column chromatography to obtain the titled compound (74 mg) as white powder.

[Step 4] 2-[2-Oxo(pyrrolidinyl)ethyl]({[2-(trifluoromethyl) phenyl]carbonyl}amino)-1H-benzimidazolecarboxylic acid A solution of methyl 2-[2-oxo(pyrrolidinyl)ethyl]({[2-(trifluoromethyl) phenyl]carbonyl}amino)-1H-benzimidazolecarboxylate (74 mg), lithium hydroxide hydrate (66 mg) in MeOH-water (1:1, 2 mL) was stirred at 50°C for 30 minutes. The reaction mixture was removed the solvent under reduced pressure, added with water, and to neutralize by 1N hydrochloric acid under ice-cooling.

The precipitate was collected by filtration, washed with diethyl ether, and dried under reduced pressure to obtain the titled compound (60 mg) as pale yellow powder.

[Step 5] N-(3-Chloromethylphenyl)[2-oxo(pyrrolidinyl)eth yl]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzi midazolecarboxamide hydrochloride To a solution of 2-[2-oxo(pyrrolidinyl)ethyl]({[2-(trifluoromethyl) phenyl]carbonyl}amino)-1H-benzimidazolecarboxylic acid (30 mg) and HATU (30 mg) in DMF (0.5 mL), were added N,N-diisopropylethylamine (28 μL) and 3-chloromethylaniline (10 μL), and the mixture was stirred at room temperature for 15 minutes. The reaction mixture was diluted with ethyl acetate, washed with brine, and the organic layer was concentrated under reduced pressure. The residue was purified on column chromatography to obtain pale yellow powder (28 mg). This was suspended in MeOH (1 mL), and 2N hydrogen chloride/EtOH solution (1 Eq) was added to obtain a homogeneous solution, which was then concentrated under reduced pressure.

The residue was triturated in diethyl ether and washed. The precipitate was collected by filtration and dried under reduced pressure to obtain the titled compound (20 mg) as white powder.

MS(ESI+) m/z 584 (M+H) , Rt= 2.24 minutes (method A) Example 133 N-(3-Chloromethylphenyl)[2-(dimethylamino)oxoethyl ]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimi dazolecarboxamide hydrochloride [Step 1] Methyl 2-[2-(dimethylamino)oxoethyl]({[2-(trifluoromethyl)ph enyl]carbonyl}amino)-1H-benzimidazolecarboxylate The titled compound was obtained as pale yellow powder according to the procedure as described in Step 3 of Example 132, using 40% aqueous dimethylamine solution and THF instead of pyrrolidine.

[Step 2] 2-[2-(Dimethylamino)oxoethyl]({[2-(trifluoromethyl)ph enyl]carbonyl}amino)-1H-benzimidazolecarboxylic acid The titled compound was obtained as gray powder according to the procedure as described in Step 4 of Example 132, using methyl 2-[2-(dimethylamino)oxoethyl]({[2-(trifluoromethyl)ph enyl]carbonyl}amino)-1H-benzimidazolecarboxylate instead of methyl 2-[2-oxo(pyrrolidinyl)ethyl]({[2-(trifluoromethyl) phenyl]carbonyl}amino)-1H-benzimidazolecarboxylate.

[Step 3] N-(3-Chloromethylphenyl)[2-(dimethylamino)oxoethyl ]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimi dazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Step 5 of Example 132, using 2-[2-(dimethylamino)oxoethyl]({[2-(trifluoromethyl)ph enyl]carbonyl}amino)-1H-benzimidazolecarboxylic acid instead of 2-[2-oxo(pyrrolidinyl)ethyl]({[2-(trifluoromethyl) phenyl]carbonyl}amino)-1H-benzimidazolecarboxylic acid.

MS(ESI+) m/z 558 (M+H) , Rt= 2.12 minutes (method A) Example 134 N-(3-Chloromethylphenyl)[2-(methylamino)oxoethyl]- 6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimida zolecarboxamide hydrochloride [Step 1] Methyl 2-[2-(methylamino)oxoethyl]({[2-(trifluoromethyl)phen yl]carbonyl}amino)-1H-benzimidazolecarboxylate The titled compound was obtained as white powder according to the procedure as described in Step 3 of Example 132, using 40% aqueous methylamine solution and THF instead of pyrrolidine.

[Step 2] 2-[2-(Methylamino)oxoethyl]({[2-(trifluoromethyl)phen yl]carbonyl}amino)-1H-benzimidazolecarboxylic acid The titled compound was obtained as brown powder according to the procedure as described in Step 4 of Example 132, using methyl 2-[2-(methylamino)oxoethyl]({[2-(trifluoromethyl)phen yl]carbonyl}amino)-1H-benzimidazolecarboxylate instead of methyl 2-[2-oxo(pyrrolidinyl)ethyl]({[2-(trifluoromethyl) phenyl]carbonyl}amino)-1H-benzimidazolecarboxylate.

[Step 3] N-(3-Chloromethylphenyl)[2-(methylamino)oxoethyl]- 6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimida zolecarboxamide hydrochloride The titled compound was obtained as pale red powder according to the procedure as described in Step 5 of Example 132, using 2-[2-(methylamino)oxoethyl]({[2-(trifluoromethyl)phen yl]carbonyl}amino)-1H-benzimidazolecarboxylic acid instead of 2-[2-oxo(pyrrolidinyl)ethyl]({[2-(trifluoromethyl) phenyl]carbonyl}amino)-1H-benzimidazolecarboxylic acid.

MS(ESI+) m/z 544 (M+H) , Rt= 1.98 minutes (method A) Example 135 2-Chloro-N-(3-chloromethylphenyl)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide [Step 1] Methyl 2-chloro-1H-benzimidazolecarboxylate A solution of methyl 2-oxo 2,3-dihydro-1H-benzimidazolecarboxylate (prepared as described in US2009/186879) (2.0g) in phosphoryl chloride (18 mL) was stirred at 120°C for 2.5 hours. Excessive phosphoryl chloride was removed under reduced pressure. The residue was added with saturated aqueous sodium bicarbonate under ice-cooling, and extracted with ethyl acetate. The ethyl acetate layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified on column chromatography to obtain the titled compound (1.5g) as white powder.

[Step 2] Methyl 2-chloronitro-1H-benzimidazolecarboxylate The titled compound (0.98g) was obtained as pale yellow powder according to the procedure as described in Step 2 of Example 1, using methyl 2-chloro-1H-benzimidazolecarboxylate (1.46g) instead of methyl-1H-benzimidazolecarboxylate.

[Step 3] Methyl 6-aminochloro-1H-benzimidazolecarboxylate To a solution of methyl 2-chloronitro-1H-benzimidazolecarboxylate (0.87g) in MeOH (100 mL), was added 1% platinum + 0.1% copper-activated carbon (Degussa type CF105 R/W) (0.19g), and the mixture was stirred under hydrogen atmosphere (0.2 MPa) for 4 hours. The reaction mixture was filtered off through celite and washed with MeOH. The mother liquid was concentrated to obtain the titled compound (0.78g) as yellow powder.

[Step 4] Methyl 2-chloro({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H- benzimidazolecarboxylate The titled compound (0.69g) was obtained as colorless powder according to the procedure as described in Step 4 of Example 1, using methyl 6-aminochloro-1H-benzimidazolecarboxylate (0.78g) instead of methyl 6-amino-1H-benzimidazolecarboxylate.

[Step 5] 2-Chloro({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H- benzimidazolecarboxylic acid The titled compound (620 mg) was obtained as white powder according to the procedure as described in Step 5 of Example 1, using methyl 2-chloro({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H- benzimidazolecarboxylate (688 mg) instead of methyl 6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimida zolecarboxylate.

[Step 6] 2-Chloro-N-(3-chloromethylphenyl)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide Oxalyl chloride (1.42 mL) was added dropwise to a stirring solution of 2-chloro({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H- benzimidazolecarboxylic acid (1.27g) in THF (13 mL) under ice-cooling. The mixture was added with DMF (five drops), and stirred at room temperature for 2 hours. From the reaction mixture was removed the solvent and excessive oxalyl chloride under reduced pressure. The residue was added with toluene, and concentrated under reduced pressure, dried, and then dissolved in THF (10 mL). The solution was dropped slowly to a solution of 3-chloromethylaniline (0.42 mL) and N,N-diisopropylethylamine (2.3 mL) in THF (10 mL) under ice-cooling for 1 hour. The reaction mixture was diluted with ethyl acetate, washed with brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.

The residue was purified on column chromatography to obtain the titled compound (0.58g) as white powder.

MS(ESI+) m/z 507 (M+H) , Rt= 2.56 minutes (method A) Example 136 N-(3-Chloromethylphenyl)[(2-methoxyethyl)amino]({[ 2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole- 4-carboxamide hydrochloride 2-Methoxyethylamine (2 mL) was added to 2-chloro-N-(3-chloromethylphenyl)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide (40 mg, Example 135). The mixture was stirred at 150°C in a sealed pressure-proof stainless steel container for 17 hours. The reaction mixture was washed with brine and concentrated under reduced pressure. The residue was purified on column chromatography to obtain N-(3-chloromethylphenyl)[(2-methoxyethyl)amino]({[ 2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole- 4-carboxamide (35 mg) as white powder. This was dissolved in MeOH (1 mL), was added with 2N hydrogen chloride/EtOH solution (1 Eq), stirred and concentrated. The residue was triturated in diethyl ether, and the precipitate was collected by filtration and dried to obtain the titled compound (28 mg) as white powder.

MS(ESI+) m/z 546 (M+H) , Rt= 1.80 minutes (method A) Example 137 N-(3-Chloromethylphenyl)[(2-hydroxyethyl)amino]({[ 2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole- 4-carboxamide hydrochloride The titled compound was obtained as brown powder according to the procedure as described in Example 136, using 2-aminoethanol instead of 2-methoxyethylamine.

MS(ESI+) m/z 532 (M+H) , Rt= 1.58 minutes (method A) Example 138 N-(3-Chloromethylphenyl)(methylamino)({[2-(trifluo romethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxam ide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 136, using 40% aqueous methylamine solution instead of 2-methoxyethylamine.

MS(ESI+) m/z 502 (M+H) , Rt= 1.69 minutes (method A) Example 139 N-(3-Chloromethylphenyl)(ethylamino)({[2-(trifluor omethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxami de hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 136, using 70% aqueous ethylamine solution instead of 2-methoxyethylamine.

MS(ESI+) m/z 516 (M+H) , Rt= 1.80 minutes (method A) Example 140 N-(3-Chloromethylphenyl)[(2,2-dimethylpropyl)amino]-6 -({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidaz olecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 136, using neopentylamine instead of 2-methoxyethylamine.

MS(ESI+) m/z 558 (M+H) , Rt= 2.22 minutes (method A) Elemental Analysis for C H Cl N O •HCl+0.5H O 28 27 3 5 2 2 Calcd.(%) C:55.73 H:4.84 N:11.61 Found.(%) C:55.99 H:4.75 N:11.69 Example 141 N-(3-Chloromethylphenyl)(cyclopentylamino)({[2-(tr ifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecar boxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 136, using cyclopentylamine instead of 2-methoxyethylamine.

MS(ESI+) m/z 556 (M+H) , Rt= 2.10 minutes (method A) Example 142 N-(3-Chloromethylphenyl)(piperidinyl)({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 136, using piperidine instead of 2-methoxyethylamine.

MS(ESI+) m/z 556 (M+H) , Rt= 2.54 minutes (method A) Example 143 N-(3-Chloromethylphenyl)(4-methylpiperazinyl)({ [2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide dihydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 136, using 1-methylpiperazine instead of 2-methoxyethylamine.

MS(ESI+) m/z 571 (M+H) , Rt= 1.63 minutes (method A) Example 144 2-[Bis(2-hydroxyethyl)amino]-N-(3-chloromethylphenyl) ({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazo lecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 136, using diethanolamine instead of 2-methoxyethylamine.

MS(ESI+) m/z 576 (M+H) , Rt= 1.66 minutes (method A) Example 145 N-(3-Chloromethylphenyl)(dimethylamino)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 136, using 50% aqueous dimethylamine solution instead of 2-methoxyethylamine.

MS(ESI+) m/z 516 (M+H) , Rt= 2.13 minutes (method A) Elemental Analysis for C H ClF N O •HCl+0.5H O 21 3 5 2 2 Calcd.(%) C:53.49 H:4.13 N:12.48 Found.(%) C:53.44 H:4.17 N:12.39 Example 146 N-(3-Chloromethylphenyl){[2-(morpholinyl)ethyl]ami no}({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzi midazolecarboxamide hydrochloride The titled compound was obtained as pink powder according to the procedure as described in Example 136, using 4-(2-aminoethyl)morpholine instead of 2-methoxyethylamine.

MS(ESI+) m/z 601 (M+H) , Rt= 1.53 minutes (method A) Example 147 N-(3-Chloromethylphenyl){[2-(dimethylamino)ethyl]amin o}({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzim idazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 136, using N,N-dimethylethylenediamine instead of 2-methoxyethylamine.

MS(ESI+) m/z 559 (M+H) , Rt= 1.51 minutes (method A) Example 148 N-(3-Chloromethylphenyl)(3-hydroxyazetidinyl)({ [2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 136, using 3-hydroxyazetidine hydrochloride, N,N-diisopropylethylamine and EtOH instead of 2-methoxyethylamine.

MS(ESI+) m/z 544 (M+H) , Rt= 1.77 minutes (method A) Example 149 N-(3-Chloromethylphenyl)[(3S)(dimethylamino)pyrrol idinyl]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1 H-benzimidazolecarboxamide dihydrochloride The titled compound was obtained as brown powder according to the procedure as described in Example 136, using (S)-(-)dimethylaminopyrrolidine, N,N-diisopropylethylamine and EtOH instead of 2-methoxyethylamine.

MS(ESI+) m/z 585 (M+H) , Rt= 1.53 minutes (method A) Example 150 N-(3-Chloromethylphenyl)[(3S)hydroxypyrrolidiny l]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzim idazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 136, using (S)hydroxypyrrolidine, N,N-diisopropylethylamine and EtOH instead of 2-methoxyethylamine.

MS(ESI+) m/z 558 (M+H) , Rt= 1.75 minutes (method A) Example 151 N-(3-Chloromethylphenyl){[2-(diethylamino)ethyl]amino }({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimi dazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 136, using N,N-diethylethylenediamine instead of 2-methoxyethylamine.

MS(ESI+) m/z 587 (M+H) , Rt= 1.57 minutes (method A) Example 152 N-(3-Chloromethylphenyl){[2-(pyrrolidinyl)ethyl]am ino}({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benz imidazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 136, using 1-(2-aminoethyl)pyrrolidine instead of 2-methoxyethylamine.

MS(ESI+) m/z 585 (M+H) , Rt= 1.59 minutes (method A) Example 153 N-(3-Chloromethylphenyl){[3-(dimethylamino)propyl]ami no}({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzi midazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 136, using N,N-dimethyl-1,3-propanediamine instead of 2-methoxyethylamine.

MS(ESI+) m/z 573 (M+H) , Rt= 1.43 minutes (method A) Example 154 N-(3-Chloromethylphenyl){[3-(dimethylamino)-2,2-dimet hylpropyl]amino}({[2-(trifluoromethyl)phenyl]carbonyl}am ino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 136, using N,N,2,2-tetramethyl-1,3-propanediamine instead of 2-methoxyethylamine.

MS(ESI+) m/z 601 (M+H) , Rt= 1.56 minutes (method A) Example 155 N-(3-Chloromethylphenyl){[2-(dipropanylamino)ethyl ]amino}({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-b enzimidazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 136, using N,N-diisopropylethylenediamine instead of 2-methoxyethylamine.

MS(ESI+) m/z 615 (M+H) , Rt= 1.69 minutes (method A) Example 156 N-(3-Chloromethylphenyl)(morpholinyl)({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xamide The titled compound was obtained as pale yellow powder according to the procedure as described in Example 136 using morpholine instead of 2-methoxyethylamine.

MS(ESI+) m/z 558 (M+H) , Rt= 2.25 minutes (method A) Example 157 2-Amino-N-(3-chloromethylphenyl)({[2-(trifluoromethyl )phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide hydrochloride According to the procedure as described in Example 136, N-(3-chloromethylphenyl)[(4-methoxybenzyl)amino]({ [2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide (97 mg) was obtained as yellow powder, using 4-methoxybenzylamine instead of 2-methoxyethylamine. This was dissolved in TFA (2 mL), and the solution was stirred at 70°C for 2 hours, and removed TFA under reduced pressure. The residue was added with saturated aqueous sodium bicarbonate, and extracted with ethyl acetate. The ethyl acetate layer was washed with brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified on column chromatography to obtain 2-amino-N-(3-chloromethylphenyl)({[2-(trifluoromethyl )phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide (35 mg). This was suspended in MeOH (3 mL), added with 2N hydrogen chloride/MeOH solution (0.3 mL), and removed MeOH under reduced pressure. The residue was triturated in 2-propanol/diethyl ether, and the precipitate was collected by filtration and dried to obtain the titled compound (21 mg) as yellow powder.

MS(ESI+) m/z 488 (M+H) , Rt= 1.62 minutes (method A) Example 158 N-(3-Chloromethylphenyl)[(3-hydroxy-2,2-dimethylpropy l)amino]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H- benzimidazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 136, using 3-amino-2,2-dimethylpropanol instead of 2-methoxyethylamine.

MS(ESI+) m/z 574 (M+H) , Rt= 1.81 minutes (method A) Example 159 N-(3-Chloromethylphenyl){[(3-methyloxetanyl)methyl ]amino}({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-b enzimidazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 136, using 1-(3-methyloxetanyl)methanamine (prepared as described in US2009/76062) instead of 2-methoxyethylamine.

MS(ESI+) m/z 572 (M+H) , Rt= 1.66 minutes (method A) Example 160 tert-Butyl N-{4-[(3-chloromethylphenyl)carbamoyl]({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolyl}glycinat e hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 136, using glycine tert-butyl ester instead of 2-methoxyethylamine.

MS(ESI+) m/z 602 (M+H) , Rt= 2.42 minutes (method A) Example 161 N-{4-[(3-Chloromethylphenyl)carbamoyl]({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolyl} glycine hydrochloride TFA (1 mL) was added to a solution of tert-butyl N-{4-[(3-chloromethylphenyl)carbamoyl]({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolyl}glycinat e (95 mg) in methylene chloride (2 mL), and the mixture was stirred for 1 hour at room temperature, and concentrated. The residue was neutralized with 1N aqueous NaOH under ice-cooling and extracted with EtOAc. The ethyl acetate layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified on column chromatography to obtain N-{4-[(3-chloromethylphenyl)carbamoyl]({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolyl}glycine (50 mg) as white powder.

N-{4-[(3-chloromethylphenyl)carbamoyl]({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolyl}glycine (16 mg) was suspended in MeOH. The suspension was added with 2N hydrogen chloride/EtOH solution (1 Eq) to obtain a homogeneous solution. The reaction mixture was removed the solvent under reduced pressure. The residue was triturated in diethyl ether, and the precipitate was collected by filtration and dried to obtain the titled compound (12 mg) as white powder.

MS(ESI+) m/z 546 (M+H) , Rt= 1.74 minutes (method A) Example 162 N-(3-Chloromethylphenyl)[(3-hydroxy-2,2-dimethylpropy l)amino]methyl({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxamide hydrochloride Sodium hydroxide powder (6.2 mg) was added to a solution N-(3-chloromethylphenyl)[(3-hydroxy-2,2-dimethylpropy l)amino]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H- benzimidazolecarboxamide (80 mg) in DMF (2 mL), and the solution was stirred at room temperature for 30 minutes, added with methyl iodide (8.7 μL), and stirred for 17 hours. The reaction mixture was diluted with ethyl acetate, washed with brine, and concentrated under reduced pressure. The residue was purified on column chromatography to obtain N-(3-chloromethylphenyl)[(3-hydroxy-2,2-dimethylpropy l)amino]methyl({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxamide (20 mg) as white powder.

This was suspended in MeOH, and added with 2N hydrogen chloride/EtOH (1 Eq) and stirred to obtain the solution and removed the solvent under reduced pressure. The residue was washed with diethyl ether, and the precipitate was collected by filtration and dried to obtain the titled compound (15 mg) as white powder.

MS(ESI+) m/z 588 (M+H) , Rt= 2.06 minutes (method A) Example 163 N-(3-Chloromethylphenyl)[(3-methoxy-2,2-dimethylpropy l)amino]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H- benzimidazolecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 136, using 3-methoxy-2,2-dimethyl propylamine (prepared as described in WO2007/28051) instead of 2-methoxyethylamine.

MS(ESI+) m/z 588 (M+H) , Rt= 2.11 minutes (method A) Elemental Analysis for C H ClF N O •HCl+0.5H O 29 29 3 5 3 2 Calcd.(%) C:54.98 H:4.93 N:11.06 Found.(%) C:54.94 H:4.63 N:11.09 Example 164 N-(3-Chloromethylphenyl)(pyrrolidinyl)({[2-(tri fluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarb oxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 136, using pyrrolidine instead of 2-methoxyethylamine.

MS(ESI+) m/z 542 (M+H) , Rt= 2.15 minutes (method A) Elemental Analysis for C H ClF N O •HCl+1.0H O 27 23 3 5 2 2 Calcd.(%) C:54.37 H:4.39 N:11.74 Found.(%) C:54.34 H:4.66 N:12.26 Example 165 2-(Azetidinyl)-N-(3-chloromethylphenyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide hydrochloride A solution of 2-chloro-N-(3-chloromethylphenyl)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide (80 mg, Example 135), azetidine hydrochloride (60 mg) and N,N-diisopropylethylamine (208μL) in EtOH (1.8 mL) was reacted at 120°C for 20 minutes in a microwaves reactor (Biotage, Initiator). The reaction mixture was concentrated under reduced pressure, and the residue was purified on column chromatography to obtain 2-(azetidinyl)-N-(3-chloromethylphenyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide (27 mg). This was dissolved in MeOH (1 mL), and added with 2N hydrogen chloride/MeOH solution (1 Eq), and stirred and concentrated. The residue was triturated in diethyl ether, and the precipitate was collected by filtration and dried to obtain the titled compound (21 mg) as white powder.

MS(ESI+) m/z 528 (M+H) , Rt= 2.09 minutes (method A) Example 166 N-(3-Chloromethylphenyl)(3-methoxyazetidinyl)({ [2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 136, using 3-methoxy azetidine hydrochloride, N,N-diisopropylethylamine and EtOH instead of 2-methoxyethylamine.

MS(ESI+) m/z 558 (M+H) , Rt= 2.20 minutes (method A) Example 167 N-(3-Chloromethylphenyl)[(2-hydroxymethylpropyl)am ino]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benz imidazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 136, using 1-aminomethylpropanol (prepared as described in WO2009/57827) and THF instead of 2-methoxyethylamine.

MS(ESI+) m/z 560 (M+H) , Rt= 1.87 minutes (method A) Example 168 N-(3-Chloromethylphenyl){[(2S)-tetrahydrofuranylme thyl]amino}({[2-(trifluoromethyl)phenyl]carbonyl}amino)- 1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 136, using (S)-(+)-tetrahydrofurfurylamine and THF instead of 2-methoxyethylamine.

MS(ESI+) m/z 572 (M+H) , Rt= 2.04 minutes (method A) Example 169 N-(3-Chloromethylphenyl){[(2R)-tetrahydrofuranylme thyl]amino}({[2-(trifluoromethyl)phenyl]carbonyl}amino)- 1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 136, using (R)-(-)-tetrahydrofurfurylamine and THF instead of 2-methoxyethylamine.

MS(ESI+) m/z 572 (M+H) , Rt= 2.04 minutes (method A) Elemental Analysis for C H Cl N O •HCl+0.7H O. 28 25 3 5 3 2 Calcd.(%) C:54.15 H:4.45 N:11.28 Found.(%) C:54.16 H:4.57 N:11.19 Example 170 N-(3-Chloromethylphenyl){[(2S)hydroxymethylbuta nyl]amino}({[2-(trifluoromethyl)phenyl]carbonyl}amino )-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 136, using (S)-(+)aminomethylbutanol and THF instead of 2-methoxyethylamine.

MS(ESI+) m/z 574 (M+H) , Rt= 1.98 minutes (method A) Example 171 N-(3-Chloromethylphenyl){[(2R)hydroxymethylbuta nyl]amino}({[2-(trifluoromethyl)phenyl]carbonyl}amino )-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 136, using (R)-(-)aminomethylbutanol and THF instead of 2-methoxyethylamine.

MS(ESI+) m/z 574 (M+H) , Rt= 1.98 minutes (method A) Example 172 N-(3-Chloromethylphenyl){[(2S)hydroxy-3,3-dimethyl butanyl]amino}({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 136, using (S)-tert-leucinol and THF instead of 2-methoxyethylamine.

MS(ESI+) m/z 588 (M+H) , Rt= 2.20 minutes (method A) Example 173 N-(3-Chloromethylphenyl)[(3-methoxy-2,2-dimethylpropy l)(methyl)amino]({[2-(trifluoromethyl)phenyl]carbonyl}am ino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 136, using 3-methoxy-N,2,2-trimethylpropanamine (Reference Example 9) and THF instead of 2-methoxyethylamine.

MS(ESI+) m/z 602 (M+H) , Rt= 2.71 minutes (method A) Example 174 N-(3-Chloromethylphenyl)[(3-methoxypropyl)amino]({ [2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 136, using 3-methoxypropylamine and THF instead of 2-methoxyethylamine.

MS(ESI+) m/z 560 (M+H) , Rt= 2.10 minutes (method A) Example 175 N-(3-Chloromethylphenyl){[2-(propanyloxy)ethyl]ami no}({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzi midazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 136, using 2-aminoethyl isopropyl ether and THF instead of 2-methoxyethylamine.

MS(ESI+) m/z 574 (M+H) , Rt= 2.29 minutes (method A) Example 176 2-[(2-tert-Butoxyethyl)amino]-N-(3-chloromethylphenyl)-6 -({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidaz olecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 136, using O-tert-butylaminoethanol and THF instead of 2-methoxyethylamine.

MS(ESI+) m/z 588 (M+H) , Rt= 2.42 minutes (method A) Example 177 N-(3-Chloromethylphenyl)[(2-methoxymethylpropyl)am ino]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benz imidazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 136, using 2-methoxymethylpropylamine and THF instead of 2-methoxyethylamine.

MS(ESI+) m/z 574 (M+H) , Rt= 2.30 minutes (method A) Example 178 N-(3-Chloromethylphenyl){[2-(methylsulfanyl)ethyl]ami no}({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzi midazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 136, using 2-(methylthio)ethylamine and THF instead of 2-methoxyethylamine.

MS(ESI+) m/z 562 (M+H) , Rt= 2.51 minutes (method A) Example 179 N-(3-Chloromethylphenyl)(methylsulfanyl)({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xamide [Step 1] Methyl 2-(methylsulfanyl)-1H-benzimidazolecarboxylate To a solution of methyl 2-sulfanyl-1H-benzimidazolecarboxylate (prepared as described in WO2003/106430) (1.0g) in DMF (15 mL), were added potassium carbonate (700 mg) and methyl iodide (0.32 mL), and the mixture was stirred at room temperature for 3 days. The reaction mixture was diluted with ethyl acetate, washed with brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified on column chromatography to obtain the titled compound (860 mg) as white powder.

[Step 2] Methyl 2-(methylsulfanyl)nitro-1H-benzimidazolecarboxylate The titled compound (840 mg) was obtained as pale yellow powder according to the procedure as described in Step 2 of Example 1, using methyl 2-(methylsulfanyl)-1H-benzimidazolecarboxylate (860 mg) instead of methyl-1H-benzimidazolecarboxylate.

[Step 3] Methyl 6-amino(methylsulfanyl)-1H-benzimidazolecarboxylate The titled compound (380 mg) was obtained as pale yellow powder according to the procedure as described in Step 3 of Example 1, using methyl 2-(methylsulfanyl)nitro-1H-benzimidazolecarboxylate (840 mg) instead of methyl 6-nitro-1H-benzimidazolecarboxylate.

[Step 4] Methyl 2-(methylsulfanyl)({[2-(trifluoromethyl)phenyl]carbonyl} amino)-1H-benzimidazolecarboxylate The titled compound (250 mg) was obtained as white powder according to the procedure as described in Step 4 of Example 1, using methyl 6-amino(methylsulfanyl)-1H-benzimidazolecarboxylate (150 mg) instead of methyl 6-amino-1H-benzimidazolecarboxylate.

[Step 5] 2-(Methylsulfanyl)({[2-(trifluoromethyl)phenyl]carbonyl} amino)-1H-benzimidazolecarboxylic acid The titled compound (240 mg) was obtained as pale yellow powder according to the procedure as described in Step 5 of Example 1,, using methyl 2-(methylsulfanyl)({[2-(trifluoromethyl)phenyl]carbonyl} amino)-1H-benzimidazolecarboxylate (250 mg) instead of methyl 6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimida zolecarboxylate.

[Step 6] N-(3-Chloromethylphenyl)(methylsulfanyl)({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xamide The titled compound (35 mg) was obtained as white powder according to the procedure as described in Step 6 of Example 135, using 2-(methylsulfanyl)({[2-(trifluoromethyl)phenyl]carbonyl} amino)-1H-benzimidazolecarboxylic acid (45 mg) instead of 2-chloro({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H- benzimidazolecarboxylic acid.

MS(ESI+) m/z 519 (M+H) , Rt= 2.79 minutes (method A) Example 180 N-(3-Chloromethylphenyl)(methylsulfonyl)({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xamide To a solution of N-(3-chloromethylphenyl)(methylsulfanyl)({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xamide (33 mg) in MeOH (5 mL), was added an aqueous solution (0.5 mL) of Oxone monpoersulfate compound (75 mg), and the mixture was stirred at room temperature for 17 hours.

Additionally the mixture was added with an aqueous solution (0.5 mL) of Oxone monopersulfate compound (50 mg), and stirred for 3 hours. The reaction mixture was diluted with ethyl acetate and washed with saturated aqueous sodium bicarbonate. The organic layer was separated, and concentrated under reduced pressure. The residue was purified on column chromatography to obtain titled compound (11 mg) as white powder.

MS(ESI+) m/z 551 (M+H) , Rt= 2.54 minutes (method A) Example 181 N-(3-Chloromethylphenyl)(methylsulfinyl)({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xamide To a solution of N-(3-chloromethylphenyl)(methylsulfanyl)({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xamide (26 mg) in THF (3 mL), was added an aqueous solution of m-chloroperbenzoic acid (75%, 12 mg) (1 mL), and the mixture was stirred at room temperature for 3 hours. The reaction mixture was diluted with ethyl acetate, washed sequentially with saturated aqueous sodium bicarbonate and brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified on column chromatography to yield the titled compound (10 mg) as pale yellow powder.

MS(ESI+) m/z 535 (M+H) , Rt= 2.42 minutes (method A) Example 182 6-{[(2-Chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)(dimethylamino)-1H-benzimidazolecarboxam ide hydrochloride [Step 1] Methyl 2-(dimethylamino)-1H-benzimidazolecarboxylate (Dichloromethylene)dimethyliminium chloride (4.93g) was added to a solution of methyl 2,3-diaminobenzoate(4.2g) in methylene chloride (75 mL), and the solution was stirred on oil bath at 50°C for 1 hour. The reaction mixture was added with saturated aqueous sodium bicarbonate was added, and extracted with ethyl acetate. The organic layer was separated, washed with brine and concentrated under reduced pressure. The residue was purified on column chromatography to obtain the titled compound (4.7g) as a pale yellow solid.

[Step 2] Methyl 2-(dimethylamino)nitro-1H-benzimidazolecarboxylate The titled compound (1.8g) was obtained as orange powder according to the procedure as described in Step 2 of Example 1, using methyl 2-(dimethylamino)-1H-benzimidazolecarboxylate (4.57g) instead of methyl 1H-benzimidazolecarboxylate.

[Step 3] 2-(Dimethylamino)nitro-1H-benzimidazolecarboxylic acid A solution of methyl 2-(dimethylamino)nitro-1H-benzimidazolecarboxylate (1.5g) and lithium hydroxide hydrate (2.4g) in THF-H O (1:1, 100 mL) was stirred at 50°C for 2 hours. THF was removed under reduced pressure, and 1N hydrochloric acid was added to the residue with stirring under ice-cooling to adjust the pH to 5.

The precipitate was collected by filtration and dried under reduced pressure to obtain the titled compound (1.38g) as yellow solid.

[Step 4] N-(3-Chloromethylphenyl)(dimethylamino)nitro-1H-be nzimidazolecarboxamide To a solution of 2-(dimethylamino)nitro-1H-benzimidazolecarboxylic acid (520 mg) and HBTU (1.03g) in DMF (6 mL), were added N,N-diisopropylethylamine (942 μL) and 3-chloromethylaniline (323 μL), and the mixture was stirred at room temperature for 15 hours. The reaction mixture was diluted with the ethyl acetate-THF (1:1), washed with brine, and the organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was washed with MeOH to obtain the titled compound (650 mg) as a yellow solid.

[Step 5] 6-Amino-N-(3-chloromethylphenyl)(dimethylamino)-1H-be nzimidazolecarboxamide To a suspension of N-(3-chloromethylphenyl)(dimethylamino)nitro-1H-be nzimidazolecarboxamide (580 mg) in MeOH-THF (1:1, 60 mL), was added 2N hydrogen chloride/EtOH (1 mL). The mixture was added with 1% platinum + 0.1% copper-activated carbon (Degussa type CF105 R/W) (150 mg) and stirred vigorously under hydrogen atmosphere (0.2MPa) for 3 hours. The reaction mixture was filtered off through celite, and the mother mixture was concentrated. The residue was added with saturated aqueous sodium bicarbonate, and extracted with ethyl acetate. The ethyl acetate layer was washed with brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.

The residue was purified on column chromatography to obtain the titled compound (265 mg) as brown powder.

[Step 6] 6-{[(2-Chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)(dimethylamino)-1H-benzimidazolecarboxam ide hydrochloride To a solution of 6-amino-N-(3-chloromethylphenyl)(dimethylamino)-1H-be nzimidazolecarboxamide (30 mg) in THF (1 mL), was added N,N-diisopropylethylamine (22 μL). The mixture was stirred under ice-cooling, and added slowly with 2-chlorofluorobenzoyl chloride (13 μL), and stirred for 2 hours. The reaction mixture was diluted with ethyl acetate, washed sequentially with saturated aqueous sodium bicarbonate and brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified on column chromatography to obtain 6-{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)(dimethylamino)-1H-benzimidazolecarboxam ide (30 mg) as pale yellow powder. This was suspended in MeOH (1 mL), and was added with 1N hydrogen chloride/MeOH (1 Eq) to obtain a homogeneous solution, and removed MeOH under reduced pressure. The residue was triturated in n-hexane/ethyl acetate (1:1), and the precipitate was collected by filtration and dried under reduced pressure to obtain the titled compound (23 mg) as pale yellow powder.

MS(ESI+) m/z 500 (M+H) , Rt= 2.13 minutes (method A) Example 183 N-(3-Chloromethylphenyl){[(2,6-dichlorophenyl)carbony l]amino}(dimethylamino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Step 6 of Example 182, using 2,6-dichlorobenzoyl chloride instead of 2-chlorofluorobenzoyl chloride.

MS(ESI+) m/z 516 (M+H) , Rt= 2.19 minutes (method A) Example 184 N-(3-Chloromethylphenyl){[(2,4-dichlorophenyl)carbony l]amino}(dimethylamino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Step 6 of Example 182, using 2,4-dichlorobenzoyl chloride instead of 2-chlorofluorobenzoyl chloride.

MS(ESI+) m/z 516 (M+H) , Rt= 2.31 minutes (method A) Example 185 N-(3-Chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}(dimethylamino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Step 6 of Example 182, using 2,5-dichlorobenzoyl chloride instead of 2-chlorofluorobenzoyl chloride.

MS(ESI+) m/z 516 (M+H) , Rt= 2.31 minutes (method A) Elemental Analysis for C H Cl N O •HCl+0.5H O 24 20 3 5 2 2 Calcd.(%) C:51.27 H:3.94 N:12.46 Found.(%) C:51.10 H:4.02 N:12.45 Example 186 6-{[(2-Bromofluorophenyl)carbonyl]amino}-N-(3-chlorom ethylphenyl)(dimethylamino)-1H-benzimidazolecarboxami de hydrochloride The titled compound was obtained as gray powder according to the procedure as described in Step 6 of Example 182, using 2-bromofluorobenzoyl chloride (prepared as described in WO2007/144327) instead of 2-chlorofluorobenzoyl chloride.

MS(ESI+) m/z 544 (M+H) , Rt= 2.23 minutes (method A) Example 187 6-{[(2-Bromochlorophenyl)carbonyl]amino}-N-(3-chlorom ethylphenyl)(dimethylamino)-1H-benzimidazolecarboxami de hydrochloride The titled compound was obtained as light brown powder according to the procedure as described in Step 6 of Example 182, using 2-bromochlorobenzoyl chloride instead of 2-chlorofluorobenzoyl chloride.

MS(ESI+) m/z 560 (M+H) , Rt= 2.29 minutes (method A) Example 188 6-({[2-Chloro(cyclopropylethynyl)phenyl]carbonyl}amino)- N-(3-chloromethylphenyl)(dimethylamino)-1H-benzimidaz olecarboxamide hydrochloride To a solution of 2-chloro(cyclopropylethynyl)benzoic acid (33 mg, Reference Example 3), 6-amino-N-(3-chloromethylphenyl)(dimethylamino)-1H-be nzimidazolecarboxamide (50 mg) and HATU (72 mg) in DMF (1 mL), was added N,N-diisopropylethylamine (66 μL), and the mixture was stirred at room temperature for 17 hours. The reaction mixture was diluted with ethyl acetate, and washed sequentially with saturated aqueous sodium bicarbonate and brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified on column chromatography to obtain 6-({[2-chloro(cyclopropylethynyl)phenyl]carbonyl}amino)- N-(3-chloromethylphenyl)(dimethylamino)-1H-benzimidaz olecarboxamide (74 mg). This was suspended in MeOH (1 mL), and was added with 2N hydrogen chloride/EtOH solution (1 Eq) to obtain a homogeneous solution, and removed the solvent under reduced pressure. The residue was triturated in ethyl acetate, and the precipitated was collected by filtration and dried under reduced pressure to obtain the titled compound (58 mg) as pale yellow powder.

MS(ESI+) m/z 546 (M+H) , Rt= 2.60 minutes (method A) Example 189 N-(3-Chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}[(3-hydroxy-2,2-dimethylpropyl)amino]-1H-benzimi dazolecarboxamide hydrochloride [Step 1] Methyl 2-chloro{[(2,5-dichlorophenyl)carbonyl]amino}-1H-benzimi dazolecarboxylate The titled compound (1.68g) was obtained as colorless amorphous according to the procedure as described in Step 4 of Example 1, using methyl 6-aminochloro-1H-benzimidazolecarboxylate instead of methyl 6-amino-1H-benzimidazolecarboxylate, and 2,5-dichlorobenzoyl chloride instead of 2-(trifluoromethyl)benzoyl chloride.

[Step 2] 2-Chloro{[(2,5-dichlorophenyl)carbonyl]amino}-1H-benzimi dazolecarboxylic acid The titled compound (1.41g) was obtained as white powder according to the procedure as described in Step 5 of Example 1, using methyl 2-chloro{[(2,5-dichlorophenyl)carbonyl]amino}-1H-benzimi dazolecarboxylate (1.68g) instead of methyl 6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimida zolecarboxylate.

[Step 3] 2-Chloro-N-(3-chloromethylphenyl){[(2,5-dichloropheny l)carbonyl]amino}-1H-benzimidazolecarboxamide The titled compound was obtained as a white solid according to the procedure as described in Step 6 of Example 135, using 2-chloro{[(2,5-dichlorophenyl)carbonyl]amino}-1H-benzimi dazolecarboxylic acid instead of 2-chloro({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H- benzimidazolecarboxylic acid.

[Step 4] N-(3-Chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}[(3-hydroxy-2,2-dimethylpropyl)amino]-1H-benzimi dazolecarboxamide hydrochloride THF (1 mL) was added to 2-chloro-N-(3-chloromethylphenyl){[(2,5-dichloropheny l)carbonyl]amino}-1H-benzimidazolecarboxamide (50 mg) and 3-amino-2,2-dimethylpropanol (400 mg). The mixture was stirred at 150°C in a sealed pressure-proof stainless steel container for 8 hours. The reaction mixture was diluted with ethyl acetate, washed with brine and concentrated under reduced pressure. The residue was purified on column chromatography to obtain N-(3-chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}[(3-hydroxy-2,2-dimethylpropyl)amino]-1H-benzimi dazolecarboxamide (50 mg) as pale yellow powder. This was dissolved in MeOH (1 mL), and added with 2N Hydrogen chloride/EtOH solution (1 Eq), and stirred and concentrated.

The residue was triturated in diethyl ether, and the precipitate was collected by filtration and dried to obtain the titled compound (40 mg) as white powder.

MS(ESI+) m/z 574 (M+H) , Rt= 2.06 minutes (method A) Example 190 N-(3-Chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}[(3-methoxy-2,2-dimethylpropyl)amino]-1H-benzimi dazolecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 189, using 3-methoxy-2,2-dimethylpropylamine instead of 3-amino-2,2-dimethylpropanol.

MS(ESI+) m/z 588 (M+H) , Rt= 2.41 minutes (method A) Example 191 N-(3-Chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}[(2-hydroxymethylpropyl)amino]-1H-benzimidazo lecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 189, using 2-hydroxymethylpropylamine instead of 3-amino-2,2-dimethylpropanol.

MS(ESI+) m/z 560 (M+H) , Rt= 2.12 minutes (method A) Example 192 N-(3-Chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}[(2-methoxymethylpropyl)amino]-1H-benzimidazo lecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 189, using 2-methoxymethylpropylamine instead of 3-amino-2,2-dimethylpropanol.

MS(ESI+) m/z 574 (M+H) , Rt= 2.48 minutes (method A) Example 193 N-(3-Chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}{[2-(propanyloxy)ethyl]amino}-1H-benzimidazol ecarboxamide hydrochloride The titled compound was obtained as milky white powder according to the procedure as described in Example 189, using 2-aminoethyl isopropyl ether instead of 3-amino-2,2-dimethylpropanol.

MS(ESI+) m/z 574 (M+H) , Rt= 2.60 minutes (method A) Elemental Analysis for C H Cl N O •HCl+0.1H O 27 26 3 5 3 2 Calcd.(%) C:52.89 H:4.47 N:11.42 Found.(%) C:52.55 H:4.10 N:11.36 Example 194 6-{[(2-Chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl){[2-(propanyloxy)ethyl]amino}-1H-benzimi dazolecarboxamide hydrochloride [Step 1] 2-Chloro{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3- chloromethylphenyl)-1H-benzimidazolecarboxamide The titled compound was obtained as a white solid according to the procedures as described in Steps 1 to 3 of Example 189, using 2-chlorofluorobenzoyl chloride instead of 2,5-dichlorobenzoyl chloride in Step 1.

[Step 2] 6-{[(2-Chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl){[2-(propanyloxy)-ethyl]amino}-1H-benzim idazolecarboxamide hydrochloride THF (1 mL) was added to 2-chloro{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3- chloromethylphenyl)-1H-benzimidazolecarboxamide (50 mg) and 2-aminoethyl isopropyl ether (32 mg). The mixture was stirred at 150°C in a sealed pressure-proof stainless steel container for 17 hours. The reaction mixture was diluted with ethyl acetate and washed with brine and concentrated under reduced pressure. The residue was purified on column chromatography to obtain 6-[{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro-2 -methylphenyl){[2-(propanyloxy)ethyl]amino}-1H-benzim idazolecarboxamide (41 mg) as pale yellow powder. This was dissolved in MeOH (1 mL), and added with 2N hydrogen chloride/EtOH solution (1 Eq), and stirred and concentrated.

The residue was triturated in diethyl ether, and the precipitate was collected by filtration and dried to obtain the titled compound (35 mg) as white powder.

MS(ESI+) m/z 558 (M+H) , Rt= 2.41 minutes (method A) Example 195 2-[(2-tert-Butoxyethyl)amino]{[(2-chlorofluorophenyl) carbonyl]amino}-N-(3-chloromethylphenyl)-1H-benzimidazol ecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Step 2 of Example 194, using O-tert-butyl 2-aminoethanol instead of 2-aminoethyl isopropyl ether.

MS(ESI+) m/z 572 (M+H) , Rt= 2.49 minutes (method A) Example 196 6-[{[(2-Chlorofluorophenyl)carbonyl]amino}-N-(3-chloro-2 -methylphenyl)[(3-methoxy-2,2-dimethylpropyl)amino]-1H-b enzimidazolecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Step 2 of Example 194, using 3-methoxy-2,2-dimethylpropylamine instead of 2-aminoethyl isopropyl ether.

MS(ESI+) m/z 572 (M+H) , Rt= 2.51 minutes (method A) Example 197 6-[{[(2-Chlorofluorophenyl)carbonyl]amino}-N-(3-chloro-2 -methylphenyl)[(2-methoxymethylpropyl)amino]-1H-benzi midazolecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Step 2 of Example 194, using 2-methoxymethylpropylamine instead of 2-aminoethyl isopropyl ether.

MS(ESI+) m/z 558 (M+H) , Rt= 2.34 minutes (method A) Example 198 6-{[(2-Chlorofluorophenyl)-carbonyl]amino}-N-(3-chloro-2 -methylphenyl){[(2S)-tetrahydrofuranylmethyl]amino}-1 H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as pale pink powder according to the procedure as described in Step 2 of Example 194, using (S)-(+)-tetrahydrofurfurylamine instead of 2-aminoethyl isopropyl ether.

MS(ESI+) m/z 556 (M+H) , Rt= 2.28 minutes (method A) Example 199 6-{[(2-Chlorofluorophenyl)-carbonyl]amino}-N-(3-chloro-2 -methylphenyl){[(2R)-tetrahydrofuranylmethyl]amino}-1 H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as pale pink powder according to the procedure as described in Step 2 of Example 194, using (R)-(-)-tetrahydrofurfurylamine instead of 2-aminoethyl isopropyl ether.

MS(ESI+) m/z 556 (M+H) , Rt= 2.28 minutes (method A) Example 200 6-[{[(2-Chlorofluorophenyl)carbonyl]amino}-N-(3-chloro-2 -methylphenyl)[(3-hydroxy-2,2-dimethylpropyl)amino]-1H-b enzimidazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Step 2 of Example 194, using 3-amino-2,2-dimethylpropanol instead of 2-aminoethyl isopropyl ether.

MS(ESI+) m/z 558 (M+H) , Rt= 2.22 minutes (method A) Example 201 6-{[(2-Chlorofluorophenyl)-carbonyl]amino}-N-(3-chloro-2 -methylphenyl){[(2S)hydroxymethylbutanyl]amino} -1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Step 2 of Example 194, using (S)-(+)aminomethylbutanol instead of 2-aminoethyl isopropyl ether.

MS(ESI+) m/z 558 (M+H) , Rt= 2.31 minutes (method A) Example 202 N-(3-Chloromethylphenyl)(dimethylamino)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide hydrochloride [Step 1] 2-(dimethylamino)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxylic acid To a stirring solution of methyl 6-aminochloro-1H-benzimidazolecarboxylate (400 mg, Example 135, Step 3) and triethylamine (209 μL) in THF (18 mL), 2-(trifluoromethyl)benzoyl chloride (316 μL) was dropped slowly under ice-cooling. After 1 hour, the reaction mixture was diluted with ethyl acetate, washed sequentially with water and brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to obtain crude methyl 2-chloro({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H- benzimidazolecarboxylate. This was dissolved in THF (15 mL) and MeOH (7 mL), and added with 1N aqueous lithium hydroxide solution (9 mL), and stirred at room temperature overnight. The reaction mixture was removing THF and MeOH under reduced pressure. The residue was added with water, and neutralized with 1N hydrochloric acid under ice-cooling. The precipitation was collected by filtration to obtain crude 2-chloro({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H- benzimidazolecarboxylic acid. This was dissolved in THF (10 mL), and added with 40% aqueous dimethylamine solution (7 mL), and stirred at 120°C for 14 hours. The reaction mixture was cooled to room temperature, removed THF under reduced pressure. The residue was added with water, and adjusted to PH 3-4 with 1N hydrochloric acid under ice-cooling. The precipitate was collected by filtration, washed with diethyl ether, and dried under reduced pressure to obtain the titled compound (589 mg) as slightly yellow solid.

[Step 2] N-(3-Chloromethylphenyl)(dimethylamino)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide hydrochloride To a solution of 2-(dimethylamino)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxylic acid (50 mg) and HATU (82 mg) in DMF (1 mL), were added N,N-diisopropylethylamine (88 μL) and 3-chloromethylaniline (26 μL), and the mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with ethyl acetate, washed sequentially with saturated aqueous sodium bicarbonate and brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified on column chromatography to obtain N-(3-chloromethylphenyl)(dimethylamino)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide (65 mg) as white powder. This was suspended in MeOH (1.5 mL), and added with 2N hydrogen chloride/MeOH (1 Eq), stirred and concentrated. The residue was triturated in diethyl ether, and the precipitate was collected by filtration and dried to obtain the titled compound (40 mg) as white powder.

MS(ESI+) m/z 516 (M+H) , Rt= 2.20 minutes (method A) Example 203 N-(4-tert-Buthylphenyl)(dimethylamino)({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamid e hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Step 2 of Example 202, using 4-tert-butylaniline instead of 3-chloromethylaniline.

MS(ESI+) m/z 524 (M+H) , Rt= 2.30 minutes (method A) Example 204 N-(2,3-Dihydro-1H-indenyl)(dimethylamino)({[2-(tri fluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarb oxamide hydrochloride The titled compound was obtained as gray powder according to the procedure as described in Step 2 of Example 202, using -aminoindan instead of 3-chloromethylaniline.

MS(ESI+) m/z 508 (M+H) , Rt= 2.11 minutes (method A) Example 205 6-{[(2-Chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)(dimethylamino)-1H-benzimidazolecarboxam ide hydrochloride [Step 1] 6-Amino-N-(3-chloromethylphenyl)(dimethylamino)-1H-be nzimidazolecarboxamide N-(3-chloromethylphenyl)(dimethylamino)nitro -1H-benzimidazolecarboxamide (520 mg) was obtained as yellow powder according to the procedure as described in Step 4 of Example 182, using 3-chloromethylaniline instead of 3-chloromethylaniline. This was then reacted according to the procedure as described in Step 5 of Example 182, to obtain the titled compound (358 mg) as yellow powder.

[Step 2] 6-{[(2-Chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)(dimethylamino)-1H-benzimidazolecarboxam ide hydrochloride To a solution of 6-amino-N-(3-chloromethylphenyl)(dimethylamino)-1H-be nzimidazolecarboxamide (50 mg) in THF (1.5 mL), was added N,N-diisopropylethylamine (37 μL) and the mixture was stirred under ice-cooling. The mixture was added slowly with 2-chlorofluorobenzoyl chloride (24 μL), and stirred for 2 hours. The reaction mixture was diluted with ethyl acetate, washed sequentially with saturated aqueous sodium bicarbonate and brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified on column chromatography to obtain 6-{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)(dimethylamino)-1H-benzimidazolecarboxam ide (30 mg) as pale yellow powder. This was then suspended in MeOH (1 mL), and added with 2N hydrogen chloride/MeOH (1 Eq) to obtain a homogeneous solution, and MeOH was removed under reduced pressure. The residue was triturated in n-hexane/ethyl acetate (1:1), and the precipitate was collected by filtration and dried to obtain the titled compound (24 mg) as pale purple powder.

MS(ESI+) m/z 500 (M+H) , Rt= 2.20 minutes (method A) Example 206 N-(3-Chloromethylphenyl){[(2,6-dichlorophenyl)carbony l]amino}(dimethylamino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as pale purple powder according to the procedure as described in Step 2 of Example 205, using 2,6-dichlorobenzoyl chloride instead of 2-chlorofluorobenzoyl chloride.

MS(ESI+) m/z 516 (M+H) , Rt= 2.26 minutes (method A) Example 207 N-(3-Chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}(dimethylamino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Step 2 of Example 205, using 2,5-dichlorobenzoyl chloride instead of 2-chlorofluorobenzoyl chloride.

MS(ESI+) m/z 516 (M+H) , Rt= 2.39 minutes (method A) Elemental Analysis for C H Cl N O •HCl 24 20 3 5 2 Calcd.(%) C:52.10 H:3.83 N:12.66 Found.(%) C:51.96 H:3.61 N:12.76 Example 208 N-(3-Chloromethylphenyl)cyclopropyl{[(2,5-dichloro phenyl)carbonyl]amino}-1H-benzimidazolecarboxamide hydrochloride [Step 1] Methyl 6-aminocyclopropyl-1H-benzimidazolecarboxylate The title compound was obtained as white powder according to the procedures as described in step 1 to step 4 of Example 11, using cyclopropanecarbonyl chloride instead of methoxyacetyl chloride in Step 1.

[Step 2] 2-Cyclopropyl{[2,5-dichlorophenyl]carbonyl]amino}-1H-ben zimidazolecarboxylic acid The title compound was obtained according to the procedures as described in step 4 and step 5 of Example 1, using methyl 6-aminocyclopropyl-1H-benzimidazolecarboxylate instead of methyl 6-amino-1H-benzimidazolecarboxylate, and 2,5-dichlorobenzoyl chloride instead of 2-(trifluoromethyl)benzoyl chloride.

[Step 3] N-(3-Chloromethylphenyl)cyclopropyl{[(2,5-dichloro phenyl)carbonyl]amino}-1H-benzimidazolecarboxamide hydrochloride The title compound was obtained according to the procedures as described in step 7 and step 8 of Example 11, using 2-cyclopropyl{[2,5-dichlorophenyl]carbonyl]amino}-1H-ben zimidazolecarboxylic acid instead of 2-(methoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxylic acid.

MS(ESI+) m/z 513 (M+H) , Rt= 1.88 minutes (method A) Example 209 N-(3-Chloromethylphenyl)cyclopropyl{[(2,5-dichloro phenyl)carbonyl]amino}-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedures as described in step 7 and step 8 of Example 11, using 2-cyclopropyl{[2,5-dichlorophenyl]carbonyl]amino}-1H-ben zimidazolecarboxylic acid instead of 2-(methoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxylic acid, and 3-chloromethylaniline instead of 3-chloromethylaniline.

MS(ESI+) m/z 513 (M+H) , Rt= 1.85 minutes (method A) Example 210 N-(3-Chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}(1-methylcyclopropyl)-1H-benzimidazolecarboxa mide hydrochloride [Step 1] Methyl 6-amino(1-methylcyclopropyl)-1H-benzimidazolecarboxyl The title compound was obtained as white powder according to the procedures as described in step 1 to step 4 of Example 11, using 1-methyl-cyclopropanecarbonyl chloride (prepared as described in WO2009/68512) instead of methoxyacetyl chloride in Step 1.

[Step 2] 2-(1-Methylcyclopropyl){[2,5-dichlorophenyl]carbonyl]ami no}-1H-benzimidazolecarboxylic acid The title compound was obtained according to the procedures as described in step 4 and step 5 of Example 1, using methyl 6-amino(1-methylcyclopropyl)-1H-benzimidazolecarboxyl ate instead of methyl 6-amino-1H-benzimidazolecarboxylate, and 2,5-dichlorobenzoyl chloride instead of 2-(trifluoromethyl)benzoyl chloride.

[Step 3] N-(3-Chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}(1-methylcyclopropyl)-1H-benzimidazolecarboxa mide hydrochloride The title compound was obtained according to the procedures as described in step 7 and step 8 of Example 11, using 2-(1-methylcyclopropyl){[2,5-dichlorophenyl]carbonyl]ami no}-1H-benzimidazolecarboxylic acid instead of 2-(methoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxylic acid.

MS(ESI+) m/z 527 (M+H) , Rt= 2.12 minutes (method A) Example 211 N-(3-Chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}(1-methylcyclopropyl)-1H-benzimidazolecarboxa mide hydrochloride The titled compound was obtained as white powder according to the procedures as described in step 7 and step 8 of Example 11, using 2-(1-methylcyclopropyl){[2,5-dichlorophenyl]carbonyl]ami no}-1H-benzimidazolecarboxylic acid instead of 2-(methoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxylic acid, and 3-chloromethylaniline instead of 3-chloromethylaniline.

MS(ESI+) m/z 527 (M+H) , Rt= 2.18 minutes (method A) Example 212 N-(3-Chloromethylphenyl)(methoxymethyl)({[2-(methy lsulfonyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxa mide The titled compound was obtained as pale yellow powder according to the procedure as described in Example 103, using 2-(methylsulfonyl)benzoic acid instead of 2-bromofluorobenzoic acid.

MS(ESI+) m/z 527 (M+H) , Rt= 2.08 minutes (method A) Example 213 N-(3-Chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}(2-methoxyethyl)-1H-benzimidazolecarboxamide hydrochloride [Step 1] Methyl 6-amino(2-methoxyethyl)-1H-benzimidazolecarboxylate The title compound was obtained as white powder according to the procedures as described in step 1 to step 4 of Example 11, using methoxypropionyl chloride instead of methoxyacetyl chloride in Step 1.

[Step 2] 2-(2-Methoxyethyl){[2,5-dichlorophenyl]carbonyl]amino}-1 H-benzimidazolecarboxylic acid The title compound was obtained according to the procedures as described in step 4 and step 5 of Example 1, using methyl 6-amino(2-methoxyethyl)-1H-benzimidazolecarboxylate instead of methyl 6-amino-1H-benzimidazolecarboxylate, and 2,5-dichlorobenzoyl chloride instead of 2-(trifluoromethyl)benzoyl chloride.

[Step 3] N-(3-Chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}(2-methoxyethyl)-1H-benzimidazolecarboxamide hydrochloride The title compound was obtained according to the procedures as described in step 7 and step 8 of Example 11, using 2-(2-methoxyethyl){[2,5-dichlorophenyl]carbonyl]amino}-1 H-benzimidazolecarboxylic acid instead of 2-(methoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxylic acid.

MS(ESI+) m/z 531 (M+H) , Rt= 2.43 minutes (method A) Example 214 2-(Methoxymethyl)-N-phenyl({[2-(trifluoromethyl)phenyl]c arbonyl}amino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using aniline instead of 3-chloromethylaniline.

MS(ESI+) m/z 469 (M+H) , Rt= 2.01 minutes (method A) Example 215 2-(Methoxymethyl)-N-propyl({[2-(trifluoromethyl)phenyl]c arbonyl}amino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using n-propylamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 435 (M+H) , Rt= 1.61 minutes (method A) Example 216 2-(Methoxymethyl)-N-(pyridinyl)({[2-(trifluoromethyl) phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using 3-aminopyridine instead of 3-chloromethylaniline.

MS(ESI+) m/z 470 (M+H) , Rt= 1.25 minutes (method A) Example 217 N-Benzyl(methoxymethyl)({[2-(trifluoromethyl)phenyl]c arbonyl}amino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using benzylamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 483 (M+H) , Rt= 1.83 minutes (method A) Example 218 N-(Cyclohexylmethyl)(methoxymethyl)({[2-(trifluoromet hyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using cyclohexanemethylamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 489 (M+H) , Rt= 2.11 minutes (method A) Example 219 2-(Methoxymethyl)-N-(naphthalenyl)({[2-(trifluorometh yl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using 1-naphthylamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 519 (M+H) , Rt= 2.29 minutes (method A) Example 220 2-(Methoxymethyl)-N-(thiophenyl)({[2-(trifluoromethyl )phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using 3-aminothiophene instead of 3-chloromethylaniline.

MS(ESI+) m/z 475 (M+H) , Rt= 1.92 minutes (method A) Example 221 N-(2,1,3-Benzothiadiazolyl)(methoxymethyl)({[2-(tr ifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecar boxamide hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using 4-amino-2,1,3-benzothiadiazole instead of 3-chloromethylaniline.

MS(ESI+) m/z 527 (M+H) , Rt= 2.16 minutes (method A) Example 222 N-(1,1-Dioxidebenzothiophenyl)(methoxymethyl)({ [2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using 6-aminobenzo[b]thiophene 1,1-dioxide instead of 3-chloromethylaniline.

MS(ESI+) m/z 557 (M+H) , Rt= 1.82 minutes (method A) Example 223 2-(Methoxymethyl)-N-(thiophenylmethyl)({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamid e hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using 2-thiophene methylamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 489 (M+H) , Rt= 1.77 minutes (method A) Example 224 N-(1H-Indolyl)(methoxymethyl)({[2-(trifluoromethyl )phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using -aminoindole instead of 3-chloromethylaniline.

MS(ESI+) m/z 508 (M+H) , Rt= 1.75 minutes (method A) Example 225 N-(1,3-Benzothiazolyl)(methoxymethyl)({[2-(trifluo romethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxam ide hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using 2-aminobenzothiazole instead of 3-chloromethylaniline.

MS(ESI+) m/z 526 (M+H) , Rt= 2.20 minutes (method A) Example 226 N-(2,2-Dimethylpropyl)(methoxymethyl)({[2-(trifluorom ethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using neopentyl amine instead of 3-chloromethylaniline.

MS(ESI+) m/z 463 (M+H) , Rt= 1.95 minutes (method A) Example 227 2-(Methoxymethyl)-N-(thiophenyl)({[2-(trifluoromethyl )phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained was obtained as colorless powder according to the procedure as described in Example 11, using 2-aminothiophene instead of 3-chloromethylaniline.

MS(ESI+) m/z 475 (M+H) , Rt= 1.94 minutes (method A) Example 228 N-(5-Chloro-1,3-benzoxazolyl)(methoxymethyl)({[2-( trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolec arboxamide hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using 2-aminochlorobenzoxazole instead of 3-chloromethylaniline.

MS(ESI+) m/z 544 (M+H) , Rt= 2.09 minutes (method A) Example 229 N-(2-Benzylphenyl)(methoxymethyl)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using 2-benzylaniline instead of 3-chloromethylaniline.

MS(ESI+) m/z 559 (M+H) , Rt= 2.34 minutes (method A) Example 230 2-(Methoxymethyl)-N-(quinolinyl)({[2-(trifluoromethyl )phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 11, using 8-aminoquinoline instead of 3-chloromethylaniline.

MS(ESI+) m/z 520 (M+H) , Rt= 2.03 minutes (method A) Example 231 N-(Cycloheptylmethyl)(methoxymethyl)({[2-(trifluorome thyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 11, using cycloheptanemethyleneamine instead of 3-chloromethylaniline.

MS(ESI+) m/z 503 (M+H) , Rt= 2.23 minutes (method A) Example 232 N-(1,3-Benzoxazolyl)(methoxymethyl)({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamid e hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using 2-aminobenzoxazole instead of 3-chloromethylaniline.

MS(ESI+) m/z 510 (M+H) , Rt= 1.80 minutes (method A) Example 233 N-(6-Chloro-1,3-benzoxazolyl)(methoxymethyl)({[2-( trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolec arboxamide hydrochloride The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using 2-aminochlorobenzoxazole instead of 3-chloromethylaniline.

MS(ESI+) m/z 544 (M+H) , Rt= 2.09 minutes (method A) Example 234 NChloro(hydroxymethyl)phenyl](methoxymethyl)({[ 2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole- 4-carboxamide The titled compound was obtained as colorless powder according to the procedure as described in Example 11, using (2-aminochlorophenyl)methanol (prepared as described in J.

Med. Chem., 2005, 48, 2080) instead of 3-chloromethylaniline.

MS(ESI+) m/z 533 (M+H) , Rt= 2.08 minutes (method A) Example 235 N-(3-Chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}(dimethylamino)-1H-benzimidazolecarboxamide methanesulfonate To a suspension of N-(3-chloromethylphenyl) {[(2,5-dichlorophenyl)carbonyl]amino}(dimethylamino)- 1H-benzimidazolecarboxamide (200 mg)(obtained in Example 207) in MeOH (2 ml), was added methanesulfonic acid (1 Eq). The mixture was stirred at room temperature for 30 minutes, and filtered off through glass filter to collect crystals, which were dried under reduced pressure to obtain the titled compound (180 mg) as white powder.

Elemental Analysis for C H Cl N O •CH SO H+1.5H O 24 20 3 5 2 3 3 2 Calcd.(%) C:46.92 H:4.25 N:10.94 Found.(%) C:46.85 H:4.04 N:10.89 Example 236 N-(3-Chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}(dimethylamino)-1H-benzimidazolecarboxamide 4-methylbenzenesulfonate The titled compound was obtained as white powder according to the procedure as described in Example 235, using p-toluenesulfonic acid monohydrate (1 Eq) instead of methanesulfonic acid.

Elemental Analysis for C H Cl N O •C H O S+1.2H O 24 20 3 5 2 7 8 3 2 Calcd.(%) C:52.40 H:4.31 N:9.86 Found.(%) C:52.24 H:4.28 N:9.95 Example 237 N-(3-Chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}(dimethylamino)-1H-benzimidazolecarboxamide sulfate The titled compound was obtained as white powder according to the procedure as described in Example 235, using sulfuric acid (1 Eq) instead of methanesulfonic acid.

Elemental Analysis for C H Cl N O •H SO +1.5H O 24 20 3 5 2 2 4 2 Calcd.(%) C:44.91 H:3.93 N:10.91 Found.(%) C:44.71 H:3.81 N:10.85 Example 238 N-(3-Chloromethylphenyl)(methoxymethyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide methanesulfonate Methanesulfonic acid (1 Eq) was added to a suspension of N-(3-chloromethylphenyl)(methoxymethyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide (250 mg)(obtained in Example 11) in MeOH (2 ml). After stirring for 30 minutes at room temperature, MeOH was removed under reduced pressure to obtain the titled compound as white powder.

Elemental Analysis for C H ClF N O •CH SO H+1.0H O 20 3 4 3 3 3 2 Calcd.(%) C:49.49 H:4.15 N:8.88 Found.(%) C:49.20 H:4.14 N:8.78 Example 239 N-(3-Chloromethylphenyl)(methoxymethyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide 4-methylbenzenesulfonate The titled compound was obtained as white powder according to the procedure as described in Example 238, using p-toluenesulfonic acid monohydrate (1 Eq) instead of methanesulfonic acid.

Elemental Analysis for C H ClF N O •C H O S 20 3 4 3 7 8 3 Calcd.(%) C:55.78 H:4.10 N:8.13 Found.(%) C:55.62 H:4.12 N:8.16 Example 240 N-(3-Chloromethylphenyl)(methoxymethyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide sulfate The titled compound was obtained as white powder according to the procedure as described in Example 238, using sulfuric acid (1 Eq) instead of methanesulfonic acid.

Elemental Analysis for C H ClF N O •H SO +0.5H O 20 3 4 3 2 4 2 Calcd.(%) C:48.12 H:3.72 N:8.98 Found.(%) C:48.34 H:3.57 N:8.99 Example 241 N-(3-Chloromethylphenyl)(1-methylcyclopropyl)({[2- (trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide methanesulfonate Methanesulfonic acid (1 Eq) was added to a suspension of N-(3-chloromethylphenyl)(1-methylcyclopropyl)({[2- (trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide (250 mg)(obtained in Example 85) in MeOH (2 ml).

After stirring at room temperature for 30 minutes, MeOH was removed under reduced pressure to obtain the titled compound as white powder.

Elemental Analysis for C H ClF N O •CH SO H+0.5H O 27 22 3 4 2 3 3 2 Calcd.(%) C:53.21 H:4.31 N:8.86 Found.(%) C:52.97 H:4.14 N:8.90 Example 242 N-(3-Chloromethylphenyl)(1-methylcyclopropyl)({[2- (trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide 4-methylbenzenesulfonate The titled compound was obtained as white powder according to the procedure as described in Example 241, using p-toluenesulfonic acid monohydrate (1 Eq) instead of methanesulfonic acid.

Elemental Analysis for C H ClF N O •C H O S 27 22 3 4 2 7 8 3 Calcd.(%) C:58.41 H:4.32 N:8.01 Found.(%) C:58.13 H:4.50 N:8.00 Example 243 N-(3-Chloromethylphenyl)(1-methylcyclopropyl)({[2- (trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide sulfate The titled compound was obtained as white powder according to the procedure as described in Example 241, using sulfuric acid (1 Eq) instead of methanesulfonic acid.

Elemental Analysis for C H ClF N O •H SO +0.6H O 27 22 3 4 2 2 4 2 Calcd.(%) C:51.00 H:3.99 N:8.81 Found.(%) C:51.35 H:4.39 N:8.85 Example 244 N-(3-Chloromethylphenyl){[(3-fluoropyridinyl)carbo nyl]amino}(methoxymethyl)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 103, using 3-fluoropyridinecarboxylic acid instead of 2-bromofluorobenzoic acid.

MS(ESI+) m/z 468 (M+H) , Rt= 2.17 minutes (method A) Example 245 N-(3-Chloromethylphenyl){[(3-chloropyridinyl)carbo nyl]amino}(methoxymethyl)-1H-benzimidazolecarboxamide hydrochloride The titled compound was obtained as pale yellow powder according to the procedure as described in Example 103, using 3-chloropicolinic acid instead of 2-bromofluorobenzoic acid.

MS(ESI+) m/z 484 (M+H) , Rt= 2.08 minutes (method A) Example 246 N-(3-Chloromethylphenyl){[(3,5-dichloropyridinyl)c arbonyl]amino}(methoxymethyl)-1H-benzimidazolecarboxa mide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 103, using 3,5-dichloroisonicotinic acid instead of 2-bromofluorobenzoic acid.

MS(ESI+) m/z 518 (M+H) , Rt= 2.24 minutes (method A) Example 247 6-{[(5-Butoxychlorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)(methoxymethyl)-1H-benzimidazolecarboxam ide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 103, using -butoxychlorobenzoic acid (prepared in Reference Example ) instead of 2-bromofluorobenzoic acid.

MS(ESI+) m/z 555 (M+H) , Rt= 2.67 minutes (method A) Example 248 6-({[2-Chloro(2,2-difluoroethoxy)phenyl]carbonyl}amino)- N-(3-chloromethylphenyl)(methoxymethyl)-1H-benzimidaz olecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 103, using 2-chloro(2,2-difluoroethoxy)benzoic acid (prepared in Reference Example 11) instead of 2-bromofluorobenzoic acid.

MS(ESI+) m/z 563 (M+H) , Rt= 1.66 minutes (method A) Example 249 N-(3-Chloromethylphenyl)({[2-chloro(4,4,4-trifluor obutoxy)phenyl]carbonyl}amino)(methoxymethyl)-1H-benzimi dazolecarboxamide hydrochloride The titled compound was obtained as white powder according to the procedure as described in Example 103, using 2-chloro(4,4,4-trifluorobutoxy)benzoic acid (prepared in Reference Example 12) instead of 2-bromofluorobenzoic acid.

MS(ESI+) m/z 609 (M+H) , Rt= 1.99 minutes (method A) The chemical structures of the compounds of Examples 1 to 249 are shown in the following Tables 1 to 14.

[Table 1] Example Structure Example Structure Example Structure 1 7 13 2 8 14 3 9 15 16 11 17 6 12 18 [Table 2] Example Structure Example Structure Example Structure 19 25 31 26 32 21 27 33 22 28 34 23 29 35 24 30 36 [Table 3] Example Structure Example Structure Example Structure 37 43 49 38 44 50 39 45 51 40 46 52 41 47 53 42 48 54 [Table 4] Example Structure Example Structure Example Structure 55 61 67 56 62 68 57 63 69 58 64 70 59 65 71 60 66 72 [Table 5] Example Structure Example Structure Example Structure 73 79 85 74 80 86 75 81 87 76 82 88 77 83 89 78 84 90 [Table 6] Example Structure Example Structure Example Structure 91 97 103 92 98 104 93 99 105 94 100 106 95 101 107 96 102 108 [Table 7] Example Structure Example Structure Example Structure 109 115 121 110 116 122 111 117 123 112 118 124 113 119 125 114 120 126 [Table 8] Example Structure Example Structure Example Structure 127 133 139 128 134 140 129 135 141 130 136 142 131 137 143 132 138 144 [Table 9] Examp Exam Exam Structure Structure Structure le ple ple 145 151 157 146 152 158 147 153 159 148 154 160 149 155 161 150 156 162 [Table 10] Example Structure Example Structure Example Structure 163 169 175 164 170 176 165 171 177 166 172 178 167 173 179 168 174 180 [Table 11] Example Structure Example Structure Example Structure 181 187 193 182 188 194 183 189 195 184 190 196 185 191 197 186 192 198 [Table 12] Example Structure Example Structure Example Structure 199 205 211 200 206 212 201 207 213 202 208 214 203 209 215 204 210 216 [Table 13] Example Structure Example Structure Example Structure 217 223 229 218 224 230 219 225 231 220 226 232 221 227 233 222 228 234 [Table 14] Example Structure Example Structure Example Structure 235 241 247 236 242 248 237 243 249 238 244 239 245 240 246 Test Example 1: mPGES-1 inhibiting activity mPGES-1 microsome fractions were prepared from CHO-K1 cells transiently transfected with plasmid encoding the human mPGES-1cDNA. Microsomes were diluted with potassium phosphate buffer containing reduced glutathione (pH7.4), and DMSO containing test compound or DMSO alone, which was each 1% of DMSO final concentration, was added and incubated at 4°C for minutes. Then, the enzymatic reactions were initiated by the addition of PGH2 substrate (final concentration 1 μM) and incubated at 4°C for 60 seconds. The reaction was terminated by addition of the citrate solution (final citrate concentration 50mM) containing ferric chloride (final concentration 1 mg/mL). PGE2 production in the enzyme reaction aliquot was measured using HTRF kit (Cisbio International, catalogue #62P2APEC). The solution free of test compound was used as positive control, and the solution free of test compound and microsome sample was used as negative control. 100% activity was defined as PGE2 production in the positive control minus PGE2 production in negative control. IC50 value was calculated by standard method.

Test Example 2: Inhibition of PGE2 and PGF2α production in A549 cell Human A549 cells were seeded on to a 96-well plate at 2x10 cells/100 μL per well and allowed to incubate overnight. After removing the culture medium and washed with phosphate buffered saline, the culture medium was replaced by RPMI culture medium with 3%FBS containing a DMSO solution containing test compound or DMSO alone, which was each 0.1% of DMSO final concentration.

After incubation for 60 minutes, IL-1β (5 ng/well) was added and incubated at 37°C for 24 hours. Then, PGE2 in the culture medium was measured using HTRF kit (Cisbio International, catalogue #62P2APEC), and PGF2α in the culture medium was measured using EIA kit (Cayman Chemical Company, catalogue #516011). The solution free of test compound was used as positive control, and the solution free of test compound and IL-1β was used as negative control. 100% activity was defined as PGE2 and PGF2α production in the positive control minus PGE2 and PGF2α production in the negative control. IC50 value was calculated by standard method.

The results of Test Example 1 and Test Example 2 are shown in Tables 15-18 ("-" means unadministered test).

[Table 15] A549 Cell A549 Cell mPGES-1 PGE2 mPGES-1 PGE2 Example Inhibition Production Example Inhibition Production IC50 (nM) Inhibition IC50 (nM) Inhibition IC50 (nM) IC50 (nM) 1 12.7 88.9 39 10.4 236.9 2 7.6 240.5 40 194.5 300.2 3 1.5 24.6 41 52.5 145.0 42 28.5 1857.9 453.4 - 43 70.7 438.3 6 27.4 - 44 4.1 1101.2 7 105.1 341.6 45 4.9 2084.5 8 160.3 105.8 46 26.0 230.8 9 452.2 - 47 269.6 - 332.8 - 48 49.9 146.3 11 6.6 12.9 49 100.3 375.3 12 7.1 41 50 140.3 810.2 13 35.1 75.6 51 120.2 330.4 14 3.8 15.2 52 40.2 280.7 37.4 465.0 53 179.3 279.9 16 63.9 1303.5 54 23.2 225.3 17 9.8 21.6 55 2.7 64.3 18 21.6 110.1 56 7.5 85.0 19 9.4 47.8 57 0.5 16.8 5.6 98 58 5.4 157.0 21 8.3 69.4 59 2.1 12.9 22 4.8 104.2 60 19.8 8.0 23 7.2 115.7 61 3.2 66.7 24 10.5 750.6 62 11.0 51.6 89.0 849.6 63 5.6 54.8 26 171.5 871.5 64 2.3 20.1 27 2.4 16.0 65 9.6 72.2 28 3.3 114.4 66 9.9 57.3 29 3.5 85.5 67 11.0 56.4 1.8 210.1 68 63.4 10000< 31 4.1 69.0 69 10.0 21.6 32 5.2 71.7 70 4.6 146.9 33 3.0 33.6 71 33.1 227.2 34 4.9 27.6 72 9.8 60.0 20.3 204.6 73 18.6 76.4 36 147.2 234.2 74 71.3 10.4 37 23.3 265.1 75 31.7 19.7 38 6.6 17.4 76 0.2 5.5 [Table 16] A549 Cell A549 Cell mPGES-1 PGE2 mPGES-1 PGE2 Example Inhibition Production Example Inhibition Production IC50 (nM) Inhibition IC50 (nM) Inhibition IC50 (nM) IC50 (nM) 77 1.7 32.9 115 11.5 37.0 78 96.8 176.8 116 9.7 251.5 79 15.0 284.6 117 583.8 - 80 29.4 1251.4 118 7.3 5.3 81 5.0 404.5 119 207.6 - 82 0.4 6.3 120 57.5 513.2 83 9.8 16.5 121 6.3 432.4 84 0.8 6.5 122 9.7 1000< 85 0.5 3.7 123 8.7 99.8 86 1.0 5.1 124 2.2 3.2 87 5.7 6.9 125 25.6 56.9 88 15.1 9.2 126 5.6 13.1 89 1.2 2.1 127 6.3 144.1 90 117.7 348.4 128 1 253.3 91 327.3 - 129 59.4 177.6 92 6.7 32.2 130 3.9 10000< 93 4.2 153.5 131 32.8 10000< 94 9.1 182.1 132 2.2 590.4 95 5.1 105.3 133 7.0 487.5 96 34.0 125.7 134 10.3 921.3 97 6.1 43.1 135 0.3 87.3 98 6.0 11.9 136 2.4 61.9 99 3.7 18.9 137 3.3 1106.7 100 33.3 122.2 138 2.2 87.4 101 77.8 117.9 139 1.9 72.8 102 1.6 49.1 140 0.2 33.0 103 2.8 59.6 141 0.4 36.5 104 2.9 71.1 142 0.4 82.7 105 8.9 324.6 143 5.3 87.5 106 4.5 63.8 144 9.7 2992.1 107 1.5 42.0 145 1.6 13.0 108 11.5 87.9 146 3.1 128.9 109 7.8 8.7 147 15.8 185.9 110 2.6 35.5 148 1.9 324.4 111 764.8 - 149 1.0 43.3 112 2.6 186.7 150 2.1 375.8 113 約 0.1 1.2 151 11.6 327.5 114 3.5 8.8 152 31.6 854.4 [Table 17] A549 Cell A549 Cell mPGES-1 PGE2 mPGES-1 PGE2 Example Inhibition Production Example Inhibition Production IC50 (nM) Inhibition IC50 (nM) Inhibition IC50 (nM) IC50 (nM) 153 22.3 617.8 191 3.9 49.5 154 20.0 64.4 192 9.9 18.1 155 100.6 208.7 193 0.4 18.9 156 1.6 24.6 194 0.4 33.8 157 3.9 10856.6 195 2.3 17.2 158 8.5 82.2 196 6.5 35.9 159 403.3 - 197 5.2 34.4 160 7.6 71.6 198 6.0 34.1 161 3.8 10000< 199 9.7 43.2 162 23.8 52.2 200 4.6 107.6 163 5.9 23.2 201 0.5 253.0 164 0.3 13.3 202 4.9 5.9 165 1.3 7.4 203 1.4 5.2 166 3.2 29.0 204 1.0 12.2 167 1.0 217.3 205 3.7 25.6 168 3.2 23.9 206 3.2 74.5 169 2.4 88.6 207 3.6 6.2 170 3.2 17.8 208 0.7 13.0 171 4.7 97.8 209 1.0 10.3 172 4.5 134.4 210 4.7 13.8 173 1.1 60.8 211 2.5 8.5 174 2.0 117.2 212 42.3 305.4 175 3.6 143.9 213 0.9 141.6 176 0.3 138.4 214 5.2 60.7 177 8.3 45.2 215 140.4 772.5 178 1.2 12.8 216 203.6 - 179 3.6 20.2 217 26.9 316.7 180 1.1 773.6 218 5.3 42.8 181 1.1 705.0 219 2.0 26.0 182 1.6 38.4 220 8.6 - 183 1.9 6.1 221 2.2 - 184 1.0 138.2 222 661.1 - 185 4.5 5.6 223 68.2 - 186 6.1 13.9 224 26.5 - 187 3.6 12.7 225 15.6 - 188 456.9 1019.5 226 26.9 - 189 1.4 24.5 227 0.1 - 190 0.1 7.0 228 1.7 - [Table 18] A549 Cell A549 Cell mPGES-1 PGE2 mPGES-1 PGE2 Example Inhibition Production Example Inhibition Production IC50 (nM) Inhibition IC50 (nM) Inhibition IC50 (nM) IC50 (nM) 229 2.3 39 244 56.2 104 230 1.9 100 245 25.7 166 231 1.9 150 246 35.9 132 232 7.7 125 247 68.4 55 233 2.5 195 248 201 - 234 97.4 198 249 404 - Test Example 3: Inhibition of PGE2 production in human whole blood Human whole blood assay was carried out according to Brideau et al. (Inflamm. Res., vol.45, p.68, 1996). Venous bloods from volunteers were collected into each tube (containing heparin). These volunteers did not have clinical appearance of inflammation and not take NSAID at least seven days before the blood collection. DMSO solution containing test compound or DMSO alone, which was each 0.25% of DMSO final concentration, was added to the blood, and incubated at 37°C for 20 minutes. LPS from E. coli (E. coli serotype 0111:B4 diluted with phosphate-buffered saline) was added at the final concentration of 100μg/mL and incubated at 37°C for 24 hours.

After the incubation, the blood was centrifuged at 2000 rpm for minutes at 4°C, and PGE2 in the supernatant was measured using HTRF kit (Cisbio International, catalogue #62P2APEC). The solution free of test compound was used as positive control, and the solution free of test compound and LPS was used as negative control. 100% activity was defined as PGE2 production in the positive control minus PGE2 production in the negative control. IC50 value was calculated by standard method.

Test Example 4: Inhibition of PGE2 production in mouse air pouch model Air pouch was established in BALB/c mose by the subcutaneous injection (twice at intervals of 3 days) of sterilized air into the back. 3 days after the second air injection, 0.5% zymosan was injected into the air pouch. 5 hours later, 1 mL of phosphate-buffered saline containing 10μM indomethacin was injected into the air pouch to wash the interior thereof, and the white blood cells and PGE2 in the pouch fluid were measured. PGE2 was quantified using HTRF kit (Cisbio International, catalogue #62P2APEC). The test compound was suspended in 0.5% methylcellulose solution and administered orally 1 hour before the zymosan injection. The group which was administered only methylcellulose solution was used as control for comparison.

Test Example 5: Pharmacokinetic assay in rat A 10mg/5mL liquid of a test compound was prepared by suspending the compound in 0.5% methylcellulose solution. The liquid was administered orally to female SD rats at fasting state at a dose of 10 mg/kg, and bloods were collected from the jugular vein 1, 2, 4 and 6 hours after the administration. The Blood samples were centrifuged to separate plasma. After deproteinization of the plasma, the concentration of the test compound in plasma was measured by HPLC.

Test Example 6: Evaluation of analgesic effect using mouse writhing test Analgesic effect was evaluated from pain-related behavior induced by the intraperitoneal injection of 0.6% acetic acid solution (10mL/kg) into ddY mouse. The number of times of writhing in 20 minutes after the acetic acid injection was counted as pain-related behavior. The test compound was suspended in 0.5% methylcellulose solution and administered orally 1 hour before the acetic acid injection. The group which was administered only methylcellulose solution was used as control for comparison.

Test Example 7: Evaluation of analgesic effect using mouse formalin test Analgesic effect was evaluated from pain-related behavior induced by the injection of 5% formalin solution (0.02 mL/mouse) into the right hind-foot pad of ICR mouse. The sum of the duration of licking in 30 minutes after the formalin injection was measured as pain-related behavior. The test compound was suspended in 0.5% methylcellulose solution and administered orally 1 hour before the formalin injection. The group which was administered only methylcellulose solution was used as control for comparison.

Test Example 8: Evaluation of antiinflamatory effect in rat carrageenan edema model Antiinflamatory effect was evaluated from paw edema induced by the injection of 0.5% carrageenan solution (0.1 mL/rat) into the right hind-foot pad of SD rat. The volume of the paw was measured before and 3 hours later the carrageenan injection using a plethysmometer (Unicom Inc., catalogue #TK-105). Swelling volume was determined from the increase in the volume from the volume before the injection. The inhibiting rate was determined as the ratio of the average swelling volume in the group given the test compound to the average swelling in the controll group. The test compound was suspended in 0.5% methylcellulose solution and administered orally 1 hour before the carrageenan injection. The group which was administered only methylcellulose solution was used as control for comparison.

The compound of the invention or a pharmaceutically acceptable salt thereof showed potent mPGES-1 inhibiting activity and inhibited PGE2 production, as shown in Test Example 1 and Test Example 2. Thus, it is particularly useful as an agent for the treatment or prevention of inflammatory bowel disease, irritable bowel syndrome, migraine, headache, low back pain, spinal stenosis, herniated disk, temporomandibular joint disorder, cervical syndrome, cervical spondylosis, endometriosis, adenomyosis, preterm labour and delivery, threatened premature delivery, dysmenorrhea, overactive bladder, nocturia, interstitial cystitis, neurodegenerative disease, psoriasis, rheumatoid arthritis, rheumatic fever, fibromyalgia, neuralgia, complex regional pain syndrome, fascial dysfunction, viral infections, bacterial infection, mycosis, burn, inflammation and pain after operation, injury and dental extraction, malignant tumors, atherosclerosis, stroke, gout, arthritis, osteoarthritis, juvenile arthritis, ankylosing spondylitis, tenosynovitis, ligament ossification, systemic lupus erythematosus, vasculitis, pancreatitis, nephritis, conjunctivitis, iritis, scleritis, uveitis, wound therapy, dermatitis, eczema, osteoporosis, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, allergic disease, familial adenomatous polyposis, scleroderma, bursitis, leiomyoma of uterus, prostatitis, and a pain from cancer.

Formulation 1: 80 mg Tablets for oral administration Ingredient Quantity (mg/teblet) Compound of Example 1 5.0 Corn starch 46.6 Cellulose, crystalline 24.0 Methylcellulose 4.0 Magnesium stearate 0.4 The components are blended and compressed to form tablets.

[Industrial applicability] The compound of the invention or a pharmaceutically acceptable salt thereof has mPGES-1 inhibiting activity and is particularly useful as an agent for the treatment or prevention of inflammatory bowel disease, irritable bowel syndrome, migraine, headache, low back pain, spinal stenosis, herniated disk, temporomandibular joint disorder, cervical syndrome, cervical spondylosis, endometriosis, adenomyosis, preterm labour and delivery, threatened premature delivery, dysmenorrhea, overactive bladder, nocturia, interstitial cystitis, neurodegenerative disease, psoriasis, rheumatoid arthritis, rheumatic fever, fibromyalgia, neuralgia, complex regional pain syndrome, fascial dysfunction, viral infections, bacterial infection, mycosis, burn, inflammation and pain after operation, injury and dental extraction, malignant tumors, atherosclerosis, stroke, gout, arthritis, osteoarthritis, juvenile arthritis, ankylosing spondylitis, tenosynovitis, ligament ossification, systemic lupus erythematosus, vasculitis, pancreatitis, nephritis, conjunctivitis, iritis, scleritis, uveitis, wound therapy, dermatitis, eczema, osteoporosis, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, allergic disease, familial adenomatous polyposis, scleroderma, bursitis, leiomyoma of uterus, prostatitis, and a pain from cancer.

Claims (13)

Claims:

1. A heterocyclic derivative represented by the general formula [1]: or its tautomer or a pharmaceutically acceptable salt thereof, wherein ring A is a group represented by the general formulae [4]: wherein X is NH or N-alkyl; A is i) hydrogen; ii) halogen; iii) alkyl optionally substituted with one to three groups selected from the group consisting of halogen, amino, monoalkylamino, dialkylamino, carbamoyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, a saturated cyclic aminocarbonyl, alkoxy, alkoxyalkoxy and alkylcarbonyloxy; iv) cycloalkyl optionally substituted with alkyl optionally substituted with one to three halogens; v) alkoxy; vi) a saturated heterocycle group optionally substituted with alkyl, alkyloxycarbonyl, alkylcarbonyl or oxo; vii) alkylthio; viii) alkylsulfonyl; ix) alkylsulfinyl; x) a group of the general formula [5]: wherein R and R are the same or different group selected from a) hydrogen, b) alkyl optionally substituted with a group selected from the group consisting of monoalkylamino, dialkylamino, a saturated cyclic amino optionally substituted with alkyl, a saturated heterocycle group optionally substituted with alkyl, alkoxy, hydroxycarbonyl, hydroxyl, alkyloxycarbonyl and alkylthio, or c) cycloalkyl; or xi) a saturated cyclic amino optionally substituted with alkyl, amino, monoalkylamino, dialkylamino, alkoxy or hydroxyl; R is phenyl, benzyl, naphthyl, cycloalkyl, cycloalkylmethyl, heteroaryl, heteroarylmethyl, 1,2,3,4-tetrahydronaphthalenyl, 1,2,3,4-tetrahydronaphthalenyl, 2,3-dihydro-1H-indenyl, 2,3-dihydro-1H-indenyl, 1,2-dihydrocyclobutabenzenyl, 1,2-dihydrocyclobutabenzenyl or alkyl, wherein said phenyl, benzyl, cycloalkyl, cycloalkylmethyl, heteroaryl and heteroarylmethyl is optionally substituted with one to three groups selected from the group consisting of i) halogen, ii) alkyl optionally substituted with one to three groups selected from the group consisting of halogen, hydroxy and phenyl, iii) alkoxy, iv) hydroxy, and v) cyano; R is phenyl or pyridyl, wherein said phenyl and pyridyl is optionally substituted with one to three groups selected from the group consisting of i) halogen, ii) alkylsulfonyl, iii) alkoxy optionally substituted with one to three halogens or alkoxy; iv) alkynyl optionally substituted with alkoxyalkyl or cycloalkyl, and v) alkyl optionally substituted with one to three groups selected from the group consisting of alkoxy, alkoxyalkoxy, cycloalkyl, phenyl and halogen.

2. The heterocyclic derivative according to claim 1, wherein X is NH, or its tautomer or a pharmaceutically acceptable salt thereof.

3. The heterocyclic derivative according to claim 1, wherein R is phenyl, 1,2,3,4-tetrahydronaphthalenyl, 1,2,3,4-tetrahydronaphthalenyl, 2,3-dihydro-1H-indenyl, 2,3-dihydro-1H-indenyl, 1,2-dihydrocyclobutabenzenyl, or 1,2-dihydrocyclobutabenzenyl, and said phenyl is optionally substituted with one to three groups selected from the group consisting of i) halogen, ii) alkyl optionally substituted with one to three halogens, iii) alkoxy, and iv) cyano, or its tautomer or a pharmaceutically acceptable salt thereof.

4. The heterocyclic derivative according to claim 1, wherein R is phenyl and said phenyl is optionally substituted with one to three groups selected from the group consisting of i) halogen ii) alkylsulfonyl, iii) alkoxy optionally substituted with alkoxy, iv) alkynyl optionally substituted with alkoxyalkyl or cycloalkyl, and v) alkyl optionally substituted with one to three groups selected from the group consisting of halogen, alkoxy, alkoxyalkoxy, cycloalkyl and phenyl, or its tautomer or a pharmaceutically acceptable salt thereof.

5. The heterocyclic derivative according to claim 1, wherein X is NH, A is i) hydrogen, ii) alkyl optionally substituted with a group selected from the group consisting of halogen, monoalkylamino, dialkylamino, monoalkylaminocarbonyl, dialkylaminocarbonyl, a saturated cyclic aminocarbonyl, alkoxy, alkoxyalkoxy and alkylcarbonyloxy, iii) cycloalkyl optionally substituted with alkyl optionally substituted with one to three halogens, iv) alkoxy, v) a saturated heterocyclic group optionally substituted with alkyl or alkyloxycarbonyl, vi) alkylthio, vii) alkylsulfonyl, viii) alkylsulfinyl, ix) amino substituted with alkyl wherein said alkyl is optionally substituted with a group selected from the group consisting of monoalkylamino, dialkylamino, a saturated cyclic amino optionally substituted with alkyl, tetrahydrofuryl, morpholino, alkoxy, hydroxycarbonyl, hydroxyl and alkylthio, x) amino substituted with cycloalkyl or xi) a saturated cyclic amino optionally substituted with alkyl, dialkylamino, alkoxy or hydroxyl, and R is i) phenyl optionally substituted with one to three groups selected from the group consisting of halogen, alkyl optionally substituted with one to three halogens, alkoxy and cyano, ii) 1,2,3,4-tetrahydronaphthalenyl, iii) 2,3-dihydro-1H-indenyl, iv) benzyl optionally substituted with halogen or alkyl optionally substituted with one to three halogens, v) cycloalkyl, vi) cycloalkylmethyl, vii) naphthyl, viii) pyridylmethyl optionally substituted with alkyl optionally substituted one to three halogens, ix) thienyl, x) thienylmethyl, xi) benzothiazolyl, xii) benzothiadiazolyl, xiii) indolyl or xiv) alkyl, and R is phenyl or pyridyl wherein said phenyl is optionally substituted with one to three groups selected from the group consisting of i) halogen, ii) alkylsulfonyl, iii) alkoxy optionally substituted with alkoxy, iv) alkynyl optionally substituted with alkoxyalkyl or cycloalkyl, and v) alkyl optionally substituted with one to three groups selected from the group consisting of halogen, alkoxy, alkoxyalkoxy, cycloalkyl and phenyl, and said pyridyl is optionally substituted with halogen, or its tautomer or a pharmaceutically acceptable salt thereof.

6. The heterocyclic derivative according to claim 1, wherein X is NH, A is alkyl substituted with alkoxy, dialkylamino, tetrahydrofuryl, tetrahydrofurylmethyl, alkoxyalkylamino, or cycloalkyl optionally substituted with alkyl optionally substituted with one to three halogens, R is phenyl substituted with one halogen and one methyl, and R is phenyl optionally substituted with one trifluoromethyl or two halogens, or its tautomer or a pharmaceutically acceptable salt thereof.

7. The heterocyclic derivative according to claim 1 selected from: N-[2-(trifluoromethyl)benzyl]({[2-(trifluoromethyl)pheny l]carbonyl}amino)-1H-benzimidazolecarboxamide, N-cyclohexyl({[2-(trifluoromethyl)phenyl]carbonyl}amino) -1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl)({[2-(trifluoromethyl)phenyl] carbonyl}amino)-1H-benzimidazolecarboxamide, N-[(1-hydroxycyclohexyl)methyl]({[2-(trifluoromethyl)phe nyl]carbonyl}amino)-1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl)(methoxymethyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide, 2-methyl-N-[2-(trifluoromethyl)benzyl]({[2-(trifluoromet hyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, N-cyclohexylmethyl({[2-(trifluoromethyl)phenyl]carbon yl}amino)-1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl)methyl({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, N-cyclopentylmethyl({[2-(trifluoromethyl)phenyl]carbo nyl}amino)-1H-benzimidazolecarboxamide, N-cyclobutylmethyl({[2-(trifluoromethyl)phenyl]carbon yl}amino)-1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl)ethyl({[2-(trifluoromethyl )phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, N-cyclohexylethyl({[2-(trifluoromethyl)phenyl]carbony l}amino)-1H-benzimidazolecarboxamide, 2-ethyl-N-[2-(trifluoromethyl)benzyl]({[2-(trifluorometh yl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, N-cyclohexyl(methoxymethyl)({[2-(trifluoromethyl)phen yl]carbonyl}amino)-1H-benzimidazolecarboxamide, 2-(methoxymethyl)-N-[2-(trifluoromethyl)benzyl]({[2-(tri fluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarb oxamide, 2-(methoxymethyl)-N-(2-methylphenyl)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, 2-(methoxymethyl)-N-(4-methylphenyl)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, N-(2-chlorobenzyl)(methoxymethyl)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, 2-(methoxymethyl)-N-(4-methylbenzyl)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, N-(4,4-difluorocyclohexyl)(methoxymethyl)({[2-(triflu oromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxa mide, N-(4-tert-buthylphenyl)(methoxymethyl)({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamid 2-(methoxymethyl)-N-[4-(trifluoromethyl)phenyl]({[2-(tri fluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarb oxamide, N-(2,4-dimethylphenyl)(methoxymethyl)({[2-(trifluorom ethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide N-(2-chloromethylphenyl)(methoxymethyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide, N-(3,4-dimethylphenyl)(methoxymethyl)({[2-(trifluorom ethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide N-(3-chloromethylphenyl)(methoxymethyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide, N-(2,3-dihydro-1H-indenyl)(methoxymethyl)({[2-(tri fluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarb oxamide, 2-(methoxymethyl)-N-(5,6,7,8-tetrahydronaphthalenyl)( {[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazol ecarboxamide, N-(2-fluorophenyl)(methoxymethyl)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, 2-(methoxymethyl)-N-(2-methoxypheny)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, 2-(methoxymethyl)-N-(4-methoxypheny)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, N-(3-bromomethylphenyl)(methoxymethyl)({[2-(triflu oromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxa mide, N-(3-chloromethylbenzyl)(methoxymethyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide, N-(2,6-difluorophenyl)(methoxymethyl)({[2-(trifluorom ethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide N-(3-cyanomethylphenyl)(methoxymethyl)({[2-(triflu oromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxa mide, 2-(methoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-N-{[3-(trifluoromethyl)pyridinyl]methyl}-1H-benzim idazolecarboxamide, N-(2-chloromethylphenyl)(methoxymethyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide, 2-(2-aminooxoethyl)-N-(3-chloromethylphenyl)({[2-( trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolec arboxamide, 2-(2-aminooxoethyl)-N-[2-(trifluoromethyl)benzyl]({[2 -(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4 -carboxamide, N-(3-chloromethylphenyl)methyl({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, N-cyclohexylmethyl({[2-(trifluoromethyl)phenyl]carbon yl}amino)-1H-benzimidazolecarboxamide, 1-methyl-N-[2-(trifluoromethyl)benzyl]({[2-(trifluoromet hyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl)ethyl({[2-(trifluoromethyl )phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, N-cyclohexylethyl({[2-(trifluoromethyl)phenyl]carbony l}amino)-1H-benzimidazolecarboxamide, 1-ethyl-N-[2-(trifluoromethyl)benzyl]({[2-(trifluorometh yl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl)ethoxy({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, 2-ethoxy-N-[2-(trifluoromethyl)benzyl]({[2-(trifluoromet hyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl)(1-chloromethylpropanyl )({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimi dazolecarboxamide, N-(3-chloromethylphenyl)[(dimethylamino)methyl]({[ 2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole- 4-carboxamide, N-(3-chloromethylphenyl)(2-methylpropyl)({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xamide, 2-(2-methylpropyl)-N-[2-(trifluoromethyl)benzyl]({[2-(tr ifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecar boxamide, tert-butyl 3-{4-[(3-chloromethylphenyl)carbamoyl]({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolyl}azetidin ecarboxylate, N-(3-chloromethylphenyl)[(methylamino)methyl]({[2- (trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide, {4-[(3-chloromethylphenyl)carbamoyl]({[2-(trifluorome thyl)phenyl]carbonyl}amino)-1H-benzimidazolyl}methyl acetate, N-(3-chloromethylphenyl)[(2R)-tetrahydrofuranyl]-6 -({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidaz olecarboxamide, 2-[[(2R)-tetrahydrofuranyl]-N-[2-(trifluoromethyl)benzyl ]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimi dazolecarboxamide, N-(3-chloromethylphenyl)[(2S)-tetrahydrofuranyl]-6 -({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidaz olecarboxamide, 2-[[(2S)-tetrahydrofuranyl]-N-[2-(trifluoromethyl)benzyl ]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimi dazolecarboxamide, 2-(1-acetylazetidinyl)-N-(3-chloromethylphenyl)({[ 2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole- 4-carboxamide, tert-butyl (2S){4-[(3-chloromethylphenyl)carbamoyl]({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolyl}pyr rolidinecarboxylate, tert-butyl (2R){4-[(3-chloromethylphenyl)carbamoyl]({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolyl}pyr rolidinecarboxylate, N-(3-chloromethylphenyl)[(2S)-pyrrolidinyl]({[2 -(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4 -carboxamide, N-(3-chloromethylphenyl)[(2S)methylpyrrolidinyl ]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimi dazolecarboxamide, 2-[(2S)acetylpyrrolidinyl]-N-(3-chloromethylphenyl )({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimi dazolecarboxamide, N-(3-chloromethylphenyl)[(2-methoxyethoxy)methyl]( {[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazol ecarboxamide, N-(3-chloromethylphenyl)(1-methoxymethylpropany l)({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzim idazolecarboxamide, 2-tert-butyl-N-(3-chloromethylphenyl)({[2-(trifluorom ethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide 2-tert-butyl({[2-(trifluoromethyl)phenyl]carbonyl}amino) -N-{[3-(trifluoromethyl)pyridinyl]methyl}-1H-benzimidazo lecarboxamide, N-(3-chloromethylphenyl)(2-ethoxyethyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide, N-(3-chloromethylphenyl)(ethoxymethyl)({[2-(triflu oromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxa mide, 2-(ethoxymethyl)({[2-(trifluoromethyl)phenyl]carbonyl}am ino)-N-{[3-(trifluoromethyl)pyridinyl]methyl}-1H-benzimi dazolecarboxamide, N-(3-chloromethylphenyl)(2-methoxyethyl)({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xamide, N-(3-chloromethylphenyl)(2,2-dimethylpropyl)({[2-( trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolec arboxamide, N-(3-chloromethylphenyl)cyclopropyl({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamid N-(3-chloromethylphenyl)(2-methylpentanyl)({[2- (trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide, N-(3-chloromethylphenyl)(1-methylcyclopropyl)({[2- (trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide, 2-tert-butyl-N-(3-chloromethylphenyl)({[2-(trifluorom ethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide 2-tert-butyl-N-(3-chloromethylphenyl){[(2,5-dichlorop henyl)carbonyl]amino}-1H-benzimidazolecarboxamide, 2-tert-butyl-N-(3-chloromethylphenyl){[(2,5-dichlorop henyl)carbonyl]amino}-1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl)[1-(trifluoromethyl)cycloprop yl]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzi midazolecarboxamide, N-(3-chloromethylphenyl)(methoxymethyl)methyl({ [2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide, N-(2-chlorobenzyl)(methoxymethyl)methyl({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide, 6-{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)(methoxymethyl)-1H-benzimidazolecarboxam ide, 6-{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)methoxymethyl-1H-benzimidazolecarboxamid 6-{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)(methoxymethyl)-1H-benzimidazolecarboxam ide, N-(3-chloromethylphenyl){[(2-chlorophenyl)carbonyl]am ino}(methoxymethyl)-1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl){[(2-chloropyridinyl)carbo nyl]amino}(methoxymethyl)-1H-benzimidazolecarboxamide 6-{[(2-bromophenyl)carbonyl]amino}-N-(3-chloromethylphen yl)(methoxymethyl)-1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl){[(2,6-dichlorophenyl)carbony l]amino}(methoxymethyl)-1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}(methoxymethyl)-1H-benzimidazolecarboxamide, 6-{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)(methoxymethyl)-1H-benzimidazolecarboxam ide, 6-{[(2-chloro-3,6-difluorophenyl)carbonyl]amino}-N-(3-chlor omethylphenyl)(methoxymethyl)-1H-benzimidazolecarb oxamide, 6-{[(2-bromochlorophenyl)carbonyl]amino}-N-(3-chlorom ethylphenyl)(methoxymethyl)-1H-benzimidazolecarboxami 6-{[(2-bromofluorophenyl)carbonyl]amino}-N-(3-chlorom ethylphenyl)(methoxymethyl)-1H-benzimidazolecarboxami N-(3-chloromethylphenyl){[(2-chloromethylphenyl)ca rbonyl]amino}(methoxymethyl)-1H-benzimidazolecarboxam ide, N-(3-chloromethylphenyl){[(2-chloromethylphenyl)ca rbonyl]amino}(methoxymethyl)-1H-benzimidazolecarboxam ide, 6-{[(5-bromochlorophenyl)carbonyl]amino}-N-(3-chlorom ethylphenyl)(methoxymethyl)-1H-benzimidazolecarboxami 6-{[(2-bromochlorophenyl)carbonyl]amino}-N-(3-chlorom ethylphenyl)(methoxymethyl)-1H-benzimidazolecarboxami N-(3-chloromethylphenyl){[(2-chloromethylphenyl)ca rbonyl]amino}(methoxymethyl)-1H-benzimidazolecarboxam ide, N-(3-chloromethylphenyl)(methoxymethyl)({[5-methyl (trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide, 6-({[2,5-bis(trifluoromethyl)phenyl]carbonyl}amino)-N-(3-ch loromethylphenyl)(methoxymethyl)-1H-benzimidazolec arboxamide, 6-({[2,4-bis(trifluoromethyl)phenyl]carbonyl}amino)-N-(3-ch loromethylphenyl)(methoxymethyl)-1H-benzimidazolec arboxamide, N-(3-chloromethylphenyl)({[5-fluoro(trifluoromethy l)phenyl]carbonyl}amino)(methoxymethyl)-1H-benzimidazole carboxamide, N-(3-chloromethylphenyl)({[2-chloro(trifluoromethy l)phenyl]carbonyl}amino)(methoxymethyl)-1H-benzimidazole carboxamide, N-(3-chloromethylphenyl)[({2-chloro[2-(propanyl oxy)ethoxy]phenyl}carbonyl)amino](methoxymethyl)-1H-benz imidazolecarboxamide, 6-({[2-chloro(2-ethoxyethoxy)phenyl]carbonyl}amino)-N-(3 -chloromethylphenyl)(methoxymethyl)-1H-benzimidazole- 4-carboxamide, 6-({[2-chloro(3-methoxypropyl)phenyl]carbonyl}amino)-N-( 3-chloromethylphenyl)(methoxymethyl)-1H-benzimidazole carboxamide, 6-({[5-(3-tert-butoxypropynyl)chlorophenyl]carbony l}amino)-N-(3-chloromethylphenyl)(methoxymethyl)-1H-b enzimidazolecarboxamide, 6-({[5-(3-tert-butoxypropyl)chlorophenyl]carbonyl}amino) -N-(3-chloromethylphenyl)(methoxymethyl)-1H-benzimida zolecarboxamide, 6-({[2-chloro(3-hydroxymethylbutyl)phenyl]carbonyl}am ino)-N-(3-chloromethylphenyl)(methoxymethyl)-1H-benzi midazolecarboxamide, 6-({[2-chloro(ethoxymethyl)phenyl]carbonyl}amino)-N-(3-c hloromethylphenyl)(methoxymethyl)-1H-benzimidazole carboxamide, 6-[({2-chloro[(2-ethoxyethoxy)methyl]phenyl}carbonyl)ami no]-N-(3-chloromethylphenyl)(methoxymethyl)-1H-benzim idazolecarboxamide, 6-({[2-chloro(2-cyclopropylethyl)phenyl]carbonyl}amino)- N-(3-chloromethylphenyl)(methoxymethyl)-1H-benzimidaz olecarboxamide, N-(3-chloromethylphenyl)({[2-chloro(2-phenylethyl) phenyl]carbonyl}amino)(methoxymethyl)-1H-benzimidazole-4 -carboxamide, N-(3-chloromethylphenyl)cyclopentyl({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamid N-(3-chloromethylphenyl)cyclopentyl{[(2,5-dichloro phenyl)carbonyl]amino}-1H-benzimidazolecarboxamide, 6-{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)cyclopentyl-1H-benzimidazolecarboxamide, 6-[{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro-2 -methylphenyl)[(2R)-tetrahydrofuranyl]-1H-benzimidazo lecarboxamide, N-(3-chloromethylphenyl){[(2,6-dichlorophenyl)carbony l]amino}[(2R)-tetrahydrofuranyl]-1H-benzimidazolec arboxamide, N-(3-chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}[(2R)-tetrahydrofuranyl]-1H-benzimidazolec arboxamide, N-(3-chloromethylphenyl)[(2S)oxopyrrolidinyl]-6 -({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidaz olecarboxamide, N-(3-chloromethylphenyl)[(2R)oxopyrrolidinyl]-6 -({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidaz olecarboxamide, N-(3-chloromethylphenyl)[2-oxo(pyrrolizinyl)eth yl]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzi midazolecarboxamide, N-(3-chloromethylphenyl)[2-(dimethylamino)oxoethyl ]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimi dazolecarboxamide, N-(3-chloromethylphenyl)[2-(methylamino)oxoethyl]- 6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimida zolecarboxamide, 2-chloro-N-(3-chloromethylphenyl)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl)[(2-methoxyethyl)amino]({[ 2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole- 4-carboxamide, N-(3-chloromethylphenyl)[(2-hydroxyethyl)amino]({[ 2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole- 4-carboxamide, N-(3-chloromethylphenyl)(methylamino)({[2-(trifluo romethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxam ide, N-(3-chloromethylphenyl)(ethylamino)({[2-(trifluor omethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxami N-(3-chloromethylphenyl)[(2,2-dimethylpropyl)amino]-6 -({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidaz olecarboxamide, N-(3-chloromethylphenyl)(cyclopentylamino)({[2-(tr ifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecar boxamide, N-(3-chloromethylphenyl)(piperidinyl)({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xamide, N-(3-chloromethylphenyl)(4-methylpiperazinyl)({ [2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide, 2-[bis(2-hydroxyethyl)amino]-N-(3-chloromethylphenyl) ({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazo lecarboxamide, N-(3-chloromethylphenyl)(dimethylamino)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide, N-(3-chloromethylphenyl){[2-(morpholinyl)ethyl]ami no}({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzi midazolecarboxamide, N-(3-chloromethylphenyl){[2-(dimethylamino)ethyl]amin o}({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzim idazolecarboxamide, N-(3-chloromethylphenyl)(3-hydroxyazetidinyl)({ [2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide, N-(3-chloromethylphenyl)[(3S)(dimethylamino)pyrrol izinyl]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1 H-benzimidazolecarboxamide, N-(3-chloromethylphenyl)[(3S)hydroxypyrroliziny l]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzim idazolecarboxamide, N-(3-chloromethylphenyl){[2-(diethylamino)ethyl]amino }({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimi dazolecarboxamide, N-(3-chloromethylphenyl){[2-(pyrrolizinyl)ethyl]am ino}({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benz imidazolecarboxamide, N-(3-chloromethylphenyl){[3-(dimethylamino)propyl]ami no}({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzi midazolecarboxamide, N-(3-chloromethylphenyl){[3-(dimethylamino)-2,2-dimet hylpropyl]amino}({[2-(trifluoromethyl)phenyl]carbonyl}am ino)-1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl){[2-(dipropanylamino)ethyl ]amino}({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-b enzimidazolecarboxamide, N-(3-chloromethylphenyl)(morpholinyl)({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xamide, 2-amino-N-(3-chloromethylphenyl)({[2-(trifluoromethyl )phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl)[(3-hydroxy-2,2-dimethylpropy l)amino]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H- benzimidazolecarboxamide, N-(3-chloromethylphenyl){[(3-methyloxetanyl)methyl ]amino}({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-b enzimidazolecarboxamide, tert-butyl N-{4-[(3-chloromethylphenyl)carbamoyl]({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolyl}glycinat N-{4-[(3-chloromethylphenyl)carbamoyl]({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolyl}glycine, N-(3-chloromethylphenyl)[(3-hydroxy-2,2-dimethylpropy l)amino]methyl({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl)[(3-methoxy-2,2-dimethylpropy l)amino]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H- benzimidazolecarboxamide, N-(3-chloromethylphenyl)(pyrrolizinyl)({[2-(tri fluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarb oxamide, 2-(azetidinyl)-N-(3-chloromethylphenyl)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide, N-(3-chloromethylphenyl)(3-methoxyazetidinyl)({ [2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide, N-(3-chloromethylphenyl)[(2-hydroxymethylpropyl)am ino]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benz imidazolecarboxamide, N-(3-chloromethylphenyl){[(2S)-tetrahydrofuranylme thyl]amino}({[2-(trifluoromethyl)phenyl]carbonyl}amino)- 1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl){[(2R)-tetrahydrofuranylme thyl]amino}({[2-(trifluoromethyl)phenyl]carbonyl}amino)- 1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl){[(2S)hydroxymethylbuta nyl]amino}({[2-(trifluoromethyl)phenyl]carbonyl}amino )-1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl){[(2R)hydroxymethylbuta nyl]amino}({[2-(trifluoromethyl)phenyl]carbonyl}amino )-1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl){[(2S)hydroxy-3,3-dimethyl butanyl]amino}({[2-(trifluoromethyl)phenyl]carbonyl}a mino)-1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl)[(3-methoxy-2,2-dimethylpropy l)(methyl)amino]({[2-(trifluoromethyl)phenyl]carbonyl}am ino)-1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl)[(3-methoxypropyl)amino]({ [2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide, N-(3-chloromethylphenyl){[2-(propanyloxy)ethyl]ami no}({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzi midazolecarboxamide, 2-[(2-tert-butoxyethyl)amino]-N-(3-chloromethylphenyl)-6 -({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidaz olecarboxamide, N-(3-chloromethylphenyl)[(2-methoxymethylpropyl)am ino]({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benz imidazolecarboxamide, N-(3-chloromethylphenyl){[2-(methylsulfanyl)ethyl]ami no}({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzi midazolecarboxamide, N-(3-chloromethylphenyl)(methylsulfanyl)({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xamide, N-(3-chloromethylphenyl)(methylsulfonyl)({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xamide, N-(3-chloromethylphenyl)(methylsulfinyl)({[2-(trif luoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbo xamide, 6-{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)(dimethylamino)-1H-benzimidazolecarboxam ide, N-(3-chloromethylphenyl){[(2,6-dichlorophenyl)carbony l]amino}(dimethylamino)-1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl){[(2,4-dichlorophenyl)carbony l]amino}(dimethylamino)-1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}(dimethylamino)-1H-benzimidazolecarboxamide, 6-{[(2-bromofluorophenyl)carbonyl]amino}-N-(3-chlorom ethylphenyl)(dimethylamino)-1H-benzimidazolecarboxami 6-{[(2-bromochlorophenyl)carbonyl]amino}-N-(3-chlorom ethylphenyl)(dimethylamino)-1H-benzimidazolecarboxami 6-({[2-chloro(cyclopropylethynyl)phenyl]carbonyl}amino)- N-(3-chloromethylphenyl)(dimethylamino)-1H-benzimidaz olecarboxamide, N-(3-chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}[(3-hydroxy-2,2-dimethylpropyl)amino]-1H-benzimi dazolecarboxamide, N-(3-chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}[(3-methoxy-2,2-dimethylpropyl)amino]-1H-benzimi dazolecarboxamide, N-(3-chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}[(2-hydroxymethylpropyl)amino]-1H-benzimidazo lecarboxamide, N-(3-chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}[(2-methoxymethylpropyl)amino]-1H-benzimidazo lecarboxamide, N-(3-chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}{[2-(propanyloxy)ethyl]amino}-1H-benzimidazol ecarboxamide, 6-[{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro-2 -methylphenyl){[2-(propanyloxy)ethyl]amino}-1H-benzim idazolecarboxamide, 2-[(2-tert-butoxyethyl)amino]{[(2-chlorofluorophenyl) carbonyl]amino}-N-(3-chloromethylphenyl)-1H-benzimidazol ecarboxamide, 6-[{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro-2 -methylphenyl)[(3-methoxy-2,2-dimethylpropyl)amino]-1H-b enzimidazolecarboxamide, 6-[{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro-2 -methylphenyl)[(2-methoxymethylpropyl)amino]-1H-benzi midazolecarboxamide, 6-[{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro-2 -methylphenyl){[(2S)-tetrahydrofuranylmethyl]amino}-1 H-benzimidazolecarboxamide, 6-[{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro-2 -methylphenyl){[(2R)-tetrahydrofuranylmethyl]amino}-1 H-benzimidazolecarboxamide, 6-[{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro-2 -methylphenyl)[(3-hydroxy-2,2-dimethylpropyl)amino]-1H-b enzimidazolecarboxamide, 6-[{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro-2 -methylphenyl){[(2S)hydroxymethylbutanyl]amino} -1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl)(dimethylamino)({[2-(trifl uoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarbox amide, N-(4-tert-buthylphenyl)(dimethylamino)({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamid N-(2,3-dihydro-1H-indenyl)(dimethylamino)({[2-(tri fluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarb oxamide, 6-{[(2-chlorofluorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)(dimethylamino)-1H-benzimidazolecarboxam ide, N-(3-chloromethylphenyl){[(2,6-dichlorophenyl)carbony l]amino}(dimethylamino)-1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}(dimethylamino)-1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl)cyclopropyl{[(2,5-dichloro phenyl)carbonyl]amino}-1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl)cyclopropyl{[(2,5-dichloro phenyl)carbonyl]amino}-1H-benzimidazolecarboxamide, N-(3-chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}(1-methylcyclopropyl)-1H-benzimidazolecarboxa mide, N-(3-chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}(1-methylcyclopropyl)-1H-benzimidazolecarboxa mide, N-(3-chloromethylphenyl)(methoxymethyl)({[2-(methy lsulfonyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxa mide, N-(3-chloromethylphenyl){[(2,5-dichlorophenyl)carbony l]amino}(2-methoxyethyl)-1H-benzimidazolecarboxamide, 2-(methoxymethyl)-N-phenyl({[2-(trifluoromethyl)phenyl]c arbonyl}amino)-1H-benzimidazolecarboxamide, 2-(methoxymethyl)-N-propyl({[2-(trifluoromethyl)phenyl]c arbonyl}amino)-1H-benzimidazolecarboxamide, 2-(methoxymethyl)-N-(pyridinyl)({[2-(trifluoromethyl) phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, N-benzyl(methoxymethyl)({[2-(trifluoromethyl)phenyl]c arbonyl}amino)-1H-benzimidazolecarboxamide, N-(cyclohexylmethyl)(methoxymethyl)({[2-(trifluoromet hyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, 2-(methoxymethyl)-N-(naphthalenyl)({[2-(trifluorometh yl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, 2-(methoxymethyl)-N-(thiophenyl)({[2-(trifluoromethyl )phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, N-(2,1,3-benzothiadiazolyl)(methoxymethyl)({[2-(tr ifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolecar boxamide, N-(1,1-dioxidebenzothiophenyl)(methoxymethyl)({ [2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide, 2-(methoxymethyl)-N-(thiophenylmethyl)({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamid N-(1H-indolyl)(methoxymethyl)({[2-(trifluoromethyl )phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, N-(1,3-benzothiazolyl)(methoxymethyl)({[2-(trifluo romethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxam ide, N-(2,2-dimethylpropyl)(methoxymethyl)({[2-(trifluorom ethyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide 2-(methoxymethyl)-N-(thiophenyl)({[2-(trifluoromethyl )phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, N-(5-chloro-1,3-benzoxazolyl)(methoxymethyl)({[2-( trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolec arboxamide, N-(2-benzylphenyl)(methoxymethyl)({[2-(trifluoromethy l)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, 2-(methoxymethyl)-N-(quinolinyl)({[2-(trifluoromethyl )phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, N-(cycloheptylmethyl)(methoxymethyl)({[2-(trifluorome thyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamide, N-(1,3-benzoxazolyl)(methoxymethyl)({[2-(trifluoro methyl)phenyl]carbonyl}amino)-1H-benzimidazolecarboxamid N-(6-chloro-1,3-benzoxazolyl)(methoxymethyl)({[2-( trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazolec arboxamide, N-[3-chloro(hydroxymethyl)phenyl](methoxymethyl)({ [2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole carboxamide, N-(3-chloromethylphenyl){[(3-fluoropyridinyl)carbo nyl]amino}(methoxymethyl)-1H-benzimidazolecarboxamide N-(3-chloromethylphenyl){[(3-chloropyridinyl)carbo nyl]amino}(methoxymethyl)-1H-benzimidazolecarboxamide N-(3-chloromethylphenyl){[(3,5-dichloropyridinyl)c arbonyl]amino}(methoxymethyl)-1H-benzimidazolecarboxa mide, 6-{[(5-butoxychlorophenyl)carbonyl]amino}-N-(3-chloro methylphenyl)(methoxymethyl)-1H-benzimidazolecarboxam ide, 6-({[2-chloro(2,2-difluoroethoxy)phenyl]carbonyl}amino)- N-(3-chloromethylphenyl)(methoxymethyl)-1H-benzimidaz olecarboxamide, and N-(3-chloromethylphenyl)({[2-chloro(4,4,4-trifluor obutoxy)phenyl]carbonyl}amino)(methoxymethyl)-1H-benzimi dazolecarboxamide, or a tautomer or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition containing a compound selected from the group consisting of the heterocyclic derivative according to any one of claims 1 to 7, its tautomerand a pharmaceutically acceptable salt thereof as an active ingredient.

9. An mPGES-1 inhibiting agent containing a compound selected from the group consisting of the heterocyclic derivative according to any one of claims 1 to 7, its tautomer and a pharmaceutically acceptable salt thereof as an active ingredient.

10. An agent containing a compound selected from the group consisting of the heterocyclic derivative according to any one of claims 1 to 7, its tautomer and a pharmaceutically acceptable salt thereof as an active ingredient, for the prevention or treatment of inflammatory bowel disease, irritable bowel syndrome, migraine, headache, low back pain, spinal stenosis, herniated disk, temporomandibular joint disorders, cervical syndrome, cervical spondylosis, endometriosis, adenomyosis, preterm labour and delivery, threatened premature delivery, dysmenorrhea, overactive bladder, nocturia, interstitial cystitis, neurodegenerative disease, psoriasis, rheumatoid arthritis, rheumatic fever, fibromyalgia, neuralgia, complex regional pain syndrome, fascial dysfunction, viral infections, bacterial infection, mycosis, burn, inflammation and pain after operation, injury and dental extraction, malignant tumors, atherosclerosis, stroke, gout, arthritis, osteoarthritis, juvenile arthritis, ankylosing spondylitis, tenosynovitis, ligament ossification, systemic lupus erythematosus, vasculitis, pancreatitis, nephritis, conjunctivitis, iritis, scleritis, uveitis, wound therapy, dermatitis, eczema, osteoporosis, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, allergic disease, familial adenomatous polyposis, scleroderma, bursitis, leiomyoma of uterus, or a pain from cancer.

11. The agent according to claim 10, wherein the neurodegenerative disease is Alzheimer's disease or multiple sclerosis.

12. The agent according to claim 10, wherein the viral infectious disease is influenza, common cold, zoster or AIDS.

13. The agent according to claim 10, wherein the malignant tumor is colon cancer, breast cancer, lung cancer or prostatic cancer.